René's URL Explorer Experiment


Title: News Onkologie, Hämatologie - Onlineportal für Onkologie und Hämatologie

Description: Berichte über neue Therapien und Fortschritte in der Krebsbehandlung, Reports on new therapies and advances in cancer treatment

Generator: Contao Open Source CMS

direct link

Domain: oncoletter.ch


Hey, it has json ld scripts:
{"@context":{"contao":"https:\/\/schema.contao.org\/"},"@type":"contao:Page","contao:title":"News Onkologie, H\u00e4matologie","contao:pageId":2702,"contao:noSearch":false,"contao:protected":false,"contao:groups":[],"contao:fePreview":false}

None1

Links:

https://oncoletter.ch/
Livehttps://oncoletter.ch/Live.html
Kongressberichtehttps://oncoletter.ch/kongressberichte/id-2024.html
Aktuelle Kongressberichtehttps://oncoletter.ch/kongressberichte/id-2024.html
ASCO 2026 Gastrointestinal (GI) Cancers Symposiumhttps://oncoletter.ch/kongressberichte/id-2026/ascogi-gastrointestinal-cancers-symposium.html
Aktuelle Kongressberichtehttps://oncoletter.ch/kongressberichte/id-2024.html
48th SAN ANTONIO BREAST CANCER SYMPOSIUM - December 9 - 12, 2025, San Antonio Texashttps://oncoletter.ch/kongressberichte/2025/48th-san-antonio-breast-cancer-symposium-san-antonio.html
67th ASH Annual Meeting and Exposition - December 6-9, 2025, Orlando, Floridahttps://oncoletter.ch/kongressberichte/2025/67th-ash-annual-meeting.html
ESMO Congress 2025 - 17. - 21. OKTOBER - BERLIN, DEUTSCHLANDhttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025.html
 IASLC 2025 World Conference on Lung Cancerhttps://oncoletter.ch/kongressberichte/2025/iaslc-2025-world-conference-on-lung-cancer.html
ESMO Gastrointestinal Cancers Congress 2025https://oncoletter.ch/kongressberichte/2025/esmo-gastrointestinal-cancers-congress-2025.html
EHA2025 Congress - Milano, June 12-15, 2025https://oncoletter.ch/kongressberichte/2025/eha2025.html
ASCO Annual Meeting 2025 May 30 - June 3, 2025 - McCormick Place, Chicagohttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025.html
European Lung Cancer Congress 2025https://oncoletter.ch/kongressberichte/2025/european-lung-cancer-congress-2025-elcc.html
St.Gallen International Breast Cancer Conference 2025https://oncoletter.ch/kongressberichte/2025/sgbcc-2025.html
ASCO Genitourinary Cancers Symposiumhttps://oncoletter.ch/kongressberichte/2025/ascogenitourinary-cancers-symposium.html
ASCO 2025 Gastrointestinal (GI) Cancers Symposiumhttps://oncoletter.ch/kongressberichte/2025/ascogi2025-gastrointestinal-gi-cancers-symposium.html
Aktuelle Kongressberichtehttps://oncoletter.ch/kongressberichte/id-2024.html
47th SAN ANTONIO BREAST CANCER SYMPOSIUM - December 10 - 13, 2024, San Antonio Texashttps://oncoletter.ch/kongressberichte/id-2024/47th-san-antonio-breast-cancer-symposium.html
66th ASH Annual Meeting and Exposition - December 7-10, 2024https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024.html
ESMO Congress 2024 - 13. - 17. SEPTEMBER - BARCELONA, SPANIENhttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024.html
 IASLC 2024 World Conference on Lung Cancerhttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer.html
ESMO Gastrointestinal Cancers Congress 2024https://oncoletter.ch/kongressberichte/id-2024/esmo-gastrointestinal-cancers-congress-2024.html
EHA2024 Hybrid Congress - Madrid, June 13-16, 2024.https://oncoletter.ch/kongressberichte/id-2024/eha2024.html
ASCO Annual Meeting 2024 May 31 - June 4, 2024 - McCormick Place, Chicagohttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024.html
ESGO - 25th European Congress on Gynaecological Oncologyhttps://oncoletter.ch/kongressberichte/id-2024/esgo-25th-european-congress-on-gynaecological-oncology.html
EBMT-EHA 6th European CAR T-cell Meetinghttps://oncoletter.ch/kongressberichte/id-2024/ebmt-eha-6th-european-car-t-cell-meeting.html
ASCO Genitourinary Cancers Symposiumhttps://oncoletter.ch/kongressberichte/id-2024/ascogenitourinary-cancers-symposium.html
ASCO 2024 Gastrointestinal (GI) Cancers Symposiumhttps://oncoletter.ch/kongressberichte/id-2024/asco2024-gastrointestinal-gi-cancers-symposium.html
Kongressberichte 2023https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023.html
65th ASH Annual Meeting and Exposition - December 09-12, 2023https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023.html
46th SAN ANTONIO BREAST CANCER SYMPOSIUM - December 5 - 9, 2023, San Antonio Texashttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium.html
ESMO Congress 2023 - 20. - 24. OKTOBER - MADRID, SPANIENhttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien.html
 IASLC 2023 World Conference on Lung Cancerhttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer.html
ESMO World Congress on Gastrointestinal Cancer (ESMO World GI 2023)https://oncoletter.ch/kongressberichte/id-2023/esmo-world-congress-on-gastrointestinal-cancer-2023.html
EHA2023 Congresshttps://oncoletter.ch/kongressberichte/id-2023/eha2023-congress.html
ASCO Annual Meeting, June 2-6, 2023 - McCormick Place, Chicagohttps://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023.html
Comprehensive Cancer Center Zürich: Patientenakademie – Brustkrebshttps://oncoletter.ch/kongressberichte/patientenakademie-brustkrebs.html
18th St.Gallen International Breast Cancer Conference 2023 (SGBCC)https://oncoletter.ch/kongressberichte/id-2023/sgbcc-18th-st-gallen-international-breast-cancer-conference-2023.html
ASCO Genitourinary Cancers Symposium 2023https://oncoletter.ch/kongressberichte/id-2023/ascogenitourinary-cancers-symposium-2023.html
ASCO 2023 Gastrointestinal (GI) Cancers Symposiumhttps://oncoletter.ch/kongressberichte/id-2023/asco2023-gastrointestinal-gi-cancers-symposium.html
Archiv Kongressberichtehttps://oncoletter.ch/Kongressberichte/2021/63rd-ASH-Annual-Meeting-and-Exposition_December-11-14-2021.html
63rd ASH Annual Meeting and Exposition - December 11-14, 2021https://oncoletter.ch/Kongressberichte/2021/63rd-ASH-Annual-Meeting-and-Exposition_December-11-14-2021.html
SAN ANTONIO BREAST CANCER SYMPOSIUM - December 7 - 11, 2021, San Antonio Texashttps://oncoletter.ch/Kongressberichte/2021/san-antonio-breast-cancer-symposium-december-7-11-2021-san-antonio-texas.html
9. Interdisziplinäres Prostatakarzinom-Symposium, St. Gallen, 2. Dezember 2021https://oncoletter.ch/Kongressberichte/2021/9-interdisziplinaeres-prostatakarzinom-symposium-st-gallen-2-dezember-2021.html
Kongressberichte Archiv 2021https://archiv.oncoletter.ch/kongressberichte-2020.html
Kongressberichte Archiv 2020https://archiv.oncoletter.ch/kongressberichte-2020.html
Kongressberichte Archiv 2019https://archiv.oncoletter.ch/kongressberichte-2019.html
Kongressberichte Archiv 2018https://archiv.oncoletter.ch/kongressberichte-2018.html
Kongressberichte Archiv 2017https://archiv.oncoletter.ch/kongressberichte-2017.html
Kalenderhttps://oncoletter.ch/kalender.html
Organisationenhttps://oncoletter.ch/Netzwerke.html
Netzwerkehttps://oncoletter.ch/Netzwerke.html
Fachgesellschaftenhttps://oncoletter.ch/Fachgesellschaften.html
Info für PatientINNenhttps://oncoletter.ch/Organisationen/info-fuer-patientinnen-patienten-angehoerige.html
Science Boardhttps://oncoletter.ch/science-board.html
Datenschutzbestimmungenhttps://oncoletter.ch/startseite/datenschutzbestimmungen.html
Impressumhttps://oncoletter.ch/impressum.html
Zustimmenhttps://oncoletter.ch/
Nicht zustimmenhttps://oncoletter.ch/
Oncoletterhttps://oncoletter.ch/home.html
ASCO Gastrointestinal Cancers Symposiumhttps://oncoletter.ch/kongressberichte/id-2026/ascogi-gastrointestinal-cancers-symposium.html
67th ASH Annual Meeting and Exposition - December 6-9, 2025, Orlando, Floridahttps://oncoletter.ch/kongressberichte/2025/67th-ash-annual-meeting.html
INFO@ONCO-SUISSEhttps://www.medinfo-verlag.ch/zeitschriften-charakteristika/info-onco-suisse/
Weitere Talks of the Day https://oncoletter.ch/alle-talks-of-the-day.html
https://oncoletter.ch/newsreader-talk-of-the-day/wonderful-news-from-the-st-gallen-international-breast-cancer-conference-the-results-of-the-world-renowned-st-gallen-international-consensus-session-have-now-been-published-in-the-annals-of-oncology.html
Wonderful news from the St.Gallen International Breast Cancer Conference! The results of the world-renowned St.Gallen International Consensus Session have now been published in the Annals of Oncologyhttps://oncoletter.ch/newsreader-talk-of-the-day/wonderful-news-from-the-st-gallen-international-breast-cancer-conference-the-results-of-the-world-renowned-st-gallen-international-consensus-session-have-now-been-published-in-the-annals-of-oncology.html
https://oncoletter.ch/newsreader-talk-of-the-day/basler-forscher-baut-die-weltweit-groesste-forschungsgruppe-fuer-brustkrebschirurgie-deutschr-krebspreis-walter-weber.html
Basler Forscher Prof. Walter Weber baut die weltweit grösste Forschungsgruppe für Brustkrebschirurgie – und holt den Deutschen Krebspreishttps://oncoletter.ch/newsreader-talk-of-the-day/basler-forscher-baut-die-weltweit-groesste-forschungsgruppe-fuer-brustkrebschirurgie-deutschr-krebspreis-walter-weber.html
https://oncoletter.ch/newsreader-talk-of-the-day/efficacy-of-zenocutuzumab-in-nrg1-fusion-positive-cancer.html
Gute Wirksamkeit von Zenocutuzumab bei NRG1 Fusion–positivem Karzinom - besonders NSCLC & Pankreaskarzinomhttps://oncoletter.ch/newsreader-talk-of-the-day/efficacy-of-zenocutuzumab-in-nrg1-fusion-positive-cancer.html
2https://oncoletter.ch/home.html?page_n648=2
3https://oncoletter.ch/home.html?page_n648=3
4https://oncoletter.ch/home.html?page_n648=4
5https://oncoletter.ch/home.html?page_n648=5
Vorwärtshttps://oncoletter.ch/home.html?page_n648=2
Endehttps://oncoletter.ch/home.html?page_n648=5
Weitere Schlagzeilenhttps://oncoletter.ch/newslist-schlagzeilen.html
https://oncoletter.ch/newsreader-schlagzeilen/bundesamt-fuer-gesundheit-nimmt-zwei-neue-brust-und-lungenkrebs-indikationen-fuer-pembrolizumab-in-spezialitaetenliste-zur-rueckverguetung-auf.html
Bundesamt für Gesundheit nimmt zwei neue Brust- und Lungenkrebs Indikationen für Pembrolizumab in Spezialitätenliste zur Rückvergütung aufhttps://oncoletter.ch/newsreader-schlagzeilen/bundesamt-fuer-gesundheit-nimmt-zwei-neue-brust-und-lungenkrebs-indikationen-fuer-pembrolizumab-in-spezialitaetenliste-zur-rueckverguetung-auf.html
https://oncoletter.ch/newsreader-schlagzeilen/zulassungserweiterung-cabozantinib-cabometyx-r-ab-sofort-neue-therapieoption-fuer-vorbehandelte-fortgeschrittene-neuroendokrine-tumore-net.html
Zulassungserweiterung: Cabozantinib (Cabometyx®) ab sofort neue Therapieoption für vorbehandelte, fortgeschrittene neuroendokrine Tumore (NET)https://oncoletter.ch/newsreader-schlagzeilen/zulassungserweiterung-cabozantinib-cabometyx-r-ab-sofort-neue-therapieoption-fuer-vorbehandelte-fortgeschrittene-neuroendokrine-tumore-net.html
https://oncoletter.ch/newsreader-schlagzeilen/tevimbra-r-tislelizumab-ab-dem-1-dezember-2025-neu-auf-der-spezialitaetenliste-jetzt-auch-fuer-speiseroehren-und-gastrooesophagealen-krebs-und-damit-mit-mehr-therapieoptionen-bei-fortgeschrittenen-oder-operablen-erkrankungen.html
Tevimbra® (Tislelizumab) ab dem 1. Dezember 2025 neu auf der Spezialitätenliste– jetzt auch für Speiseröhren- und gastroösophagealen Krebs und damit mit mehr Therapieoptionen bei fortgeschrittenen oder operablen Erkrankungenhttps://oncoletter.ch/newsreader-schlagzeilen/tevimbra-r-tislelizumab-ab-dem-1-dezember-2025-neu-auf-der-spezialitaetenliste-jetzt-auch-fuer-speiseroehren-und-gastrooesophagealen-krebs-und-damit-mit-mehr-therapieoptionen-bei-fortgeschrittenen-oder-operablen-erkrankungen.html
https://oncoletter.ch/newsreader-schlagzeilen/nubeqa-r-darolutamid-jetzt-erweitert-kassenpflichtig-bei-hormonsensitivem-prostatakrebs-mhspc-in-kombination-mit-androgendeprivationstherapie-adt-13.html
NUBEQA® (Darolutamid) jetzt erweitert kassenpflichtig bei hormonsensitivem Prostatakrebs (mHSPC) in Kombination mit Androgendeprivationstherapie (ADT)13https://oncoletter.ch/newsreader-schlagzeilen/nubeqa-r-darolutamid-jetzt-erweitert-kassenpflichtig-bei-hormonsensitivem-prostatakrebs-mhspc-in-kombination-mit-androgendeprivationstherapie-adt-13.html
https://oncoletter.ch/newsreader-schlagzeilen/swissmedic-erteilt-zulassung-fuer-pembrolizumab-zur-perioperativen-behandlung-des-resezierbaren-lokal-fortgeschrittenen-plattenepithelkarzinoms-des-kopf-hals-bereichs-hnscc-mit-pd-l1-cps-1-bei-erwachsenen1.html
Swissmedic erteilt Zulassung für Pembrolizumab zur perioperativen Behandlung des resezierbaren, lokal fortgeschrittenen Plattenepithelkarzinoms des Kopf-Hals-Bereichs (HNSCC) mit PD-L1 CPS ≥ 1 bei Erwachsenen (1)https://oncoletter.ch/newsreader-schlagzeilen/swissmedic-erteilt-zulassung-fuer-pembrolizumab-zur-perioperativen-behandlung-des-resezierbaren-lokal-fortgeschrittenen-plattenepithelkarzinoms-des-kopf-hals-bereichs-hnscc-mit-pd-l1-cps-1-bei-erwachsenen1.html
More Eventshttps://oncoletter.ch/kalender.html
https://oncoletter.ch/kongressberichte/id-2026/ascogi-gastrointestinal-cancers-symposium.html
ASCO Gastrointestinal Cancers Symposiumhttps://oncoletter.ch/kongressberichte/id-2026/ascogi-gastrointestinal-cancers-symposium.html
Kongressberichtehttps://oncoletter.ch/Kongressberichte/2022.html
Kongresskalenderhttps://oncoletter.ch/kalender.html
Aktuelleshttps://oncoletter.ch/oncoletter-2.html
Impressumhttps://oncoletter.ch/impressum.html
Kontakthttps://oncoletter.ch/kontakt.html
https://www.facebook.com/oncoletter
https://www.twitter.com/oncoletter
https://oncoletter.ch/home.html#contentwrapper
Datenschutzbestimmungenhttps://oncoletter.ch/startseite/datenschutzbestimmungen.html
https://oncoletter.ch/
Livehttps://oncoletter.ch/Live.html
Kongressberichtehttps://oncoletter.ch/kongressberichte/id-2024.html
Aktuelle Kongressberichtehttps://oncoletter.ch/kongressberichte/id-2024.html
ASCO 2026 Gastrointestinal (GI) Cancers Symposiumhttps://oncoletter.ch/kongressberichte/id-2026/ascogi-gastrointestinal-cancers-symposium.html
Aktuelle Kongressberichtehttps://oncoletter.ch/kongressberichte/id-2024.html
48th SAN ANTONIO BREAST CANCER SYMPOSIUM - December 9 - 12, 2025, San Antonio Texashttps://oncoletter.ch/kongressberichte/2025/48th-san-antonio-breast-cancer-symposium-san-antonio.html
67th ASH Annual Meeting and Exposition - December 6-9, 2025, Orlando, Floridahttps://oncoletter.ch/kongressberichte/2025/67th-ash-annual-meeting.html
ESMO Congress 2025 - 17. - 21. OKTOBER - BERLIN, DEUTSCHLANDhttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025.html
 IASLC 2025 World Conference on Lung Cancerhttps://oncoletter.ch/kongressberichte/2025/iaslc-2025-world-conference-on-lung-cancer.html
ESMO Gastrointestinal Cancers Congress 2025https://oncoletter.ch/kongressberichte/2025/esmo-gastrointestinal-cancers-congress-2025.html
EHA2025 Congress - Milano, June 12-15, 2025https://oncoletter.ch/kongressberichte/2025/eha2025.html
ASCO Annual Meeting 2025 May 30 - June 3, 2025 - McCormick Place, Chicagohttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025.html
European Lung Cancer Congress 2025https://oncoletter.ch/kongressberichte/2025/european-lung-cancer-congress-2025-elcc.html
St.Gallen International Breast Cancer Conference 2025https://oncoletter.ch/kongressberichte/2025/sgbcc-2025.html
ASCO Genitourinary Cancers Symposiumhttps://oncoletter.ch/kongressberichte/2025/ascogenitourinary-cancers-symposium.html
ASCO 2025 Gastrointestinal (GI) Cancers Symposiumhttps://oncoletter.ch/kongressberichte/2025/ascogi2025-gastrointestinal-gi-cancers-symposium.html
Aktuelle Kongressberichtehttps://oncoletter.ch/kongressberichte/id-2024.html
47th SAN ANTONIO BREAST CANCER SYMPOSIUM - December 10 - 13, 2024, San Antonio Texashttps://oncoletter.ch/kongressberichte/id-2024/47th-san-antonio-breast-cancer-symposium.html
66th ASH Annual Meeting and Exposition - December 7-10, 2024https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024.html
ESMO Congress 2024 - 13. - 17. SEPTEMBER - BARCELONA, SPANIENhttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024.html
 IASLC 2024 World Conference on Lung Cancerhttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer.html
ESMO Gastrointestinal Cancers Congress 2024https://oncoletter.ch/kongressberichte/id-2024/esmo-gastrointestinal-cancers-congress-2024.html
EHA2024 Hybrid Congress - Madrid, June 13-16, 2024.https://oncoletter.ch/kongressberichte/id-2024/eha2024.html
ASCO Annual Meeting 2024 May 31 - June 4, 2024 - McCormick Place, Chicagohttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024.html
ESGO - 25th European Congress on Gynaecological Oncologyhttps://oncoletter.ch/kongressberichte/id-2024/esgo-25th-european-congress-on-gynaecological-oncology.html
EBMT-EHA 6th European CAR T-cell Meetinghttps://oncoletter.ch/kongressberichte/id-2024/ebmt-eha-6th-european-car-t-cell-meeting.html
ASCO Genitourinary Cancers Symposiumhttps://oncoletter.ch/kongressberichte/id-2024/ascogenitourinary-cancers-symposium.html
ASCO 2024 Gastrointestinal (GI) Cancers Symposiumhttps://oncoletter.ch/kongressberichte/id-2024/asco2024-gastrointestinal-gi-cancers-symposium.html
Kongressberichte 2023https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023.html
65th ASH Annual Meeting and Exposition - December 09-12, 2023https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023.html
46th SAN ANTONIO BREAST CANCER SYMPOSIUM - December 5 - 9, 2023, San Antonio Texashttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium.html
ESMO Congress 2023 - 20. - 24. OKTOBER - MADRID, SPANIENhttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien.html
 IASLC 2023 World Conference on Lung Cancerhttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer.html
ESMO World Congress on Gastrointestinal Cancer (ESMO World GI 2023)https://oncoletter.ch/kongressberichte/id-2023/esmo-world-congress-on-gastrointestinal-cancer-2023.html
EHA2023 Congresshttps://oncoletter.ch/kongressberichte/id-2023/eha2023-congress.html
ASCO Annual Meeting, June 2-6, 2023 - McCormick Place, Chicagohttps://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023.html
Comprehensive Cancer Center Zürich: Patientenakademie – Brustkrebshttps://oncoletter.ch/kongressberichte/patientenakademie-brustkrebs.html
18th St.Gallen International Breast Cancer Conference 2023 (SGBCC)https://oncoletter.ch/kongressberichte/id-2023/sgbcc-18th-st-gallen-international-breast-cancer-conference-2023.html
ASCO Genitourinary Cancers Symposium 2023https://oncoletter.ch/kongressberichte/id-2023/ascogenitourinary-cancers-symposium-2023.html
ASCO 2023 Gastrointestinal (GI) Cancers Symposiumhttps://oncoletter.ch/kongressberichte/id-2023/asco2023-gastrointestinal-gi-cancers-symposium.html
Archiv Kongressberichtehttps://oncoletter.ch/Kongressberichte/2021/63rd-ASH-Annual-Meeting-and-Exposition_December-11-14-2021.html
63rd ASH Annual Meeting and Exposition - December 11-14, 2021https://oncoletter.ch/Kongressberichte/2021/63rd-ASH-Annual-Meeting-and-Exposition_December-11-14-2021.html
SAN ANTONIO BREAST CANCER SYMPOSIUM - December 7 - 11, 2021, San Antonio Texashttps://oncoletter.ch/Kongressberichte/2021/san-antonio-breast-cancer-symposium-december-7-11-2021-san-antonio-texas.html
9. Interdisziplinäres Prostatakarzinom-Symposium, St. Gallen, 2. Dezember 2021https://oncoletter.ch/Kongressberichte/2021/9-interdisziplinaeres-prostatakarzinom-symposium-st-gallen-2-dezember-2021.html
Kongressberichte Archiv 2021https://archiv.oncoletter.ch/kongressberichte-2020.html
Kongressberichte Archiv 2020https://archiv.oncoletter.ch/kongressberichte-2020.html
Kongressberichte Archiv 2019https://archiv.oncoletter.ch/kongressberichte-2019.html
Kongressberichte Archiv 2018https://archiv.oncoletter.ch/kongressberichte-2018.html
Kongressberichte Archiv 2017https://archiv.oncoletter.ch/kongressberichte-2017.html
Kalenderhttps://oncoletter.ch/kalender.html
Organisationenhttps://oncoletter.ch/Netzwerke.html
Netzwerkehttps://oncoletter.ch/Netzwerke.html
Fachgesellschaftenhttps://oncoletter.ch/Fachgesellschaften.html
Info für PatientINNenhttps://oncoletter.ch/Organisationen/info-fuer-patientinnen-patienten-angehoerige.html
Science Boardhttps://oncoletter.ch/science-board.html
Datenschutzbestimmungenhttps://oncoletter.ch/startseite/datenschutzbestimmungen.html
Impressumhttps://oncoletter.ch/impressum.html
Zustimmenhttps://oncoletter.ch/
Nicht zustimmenhttps://oncoletter.ch/
Livehttps://oncoletter.ch/Live.html
Kongressberichtehttps://oncoletter.ch/kongressberichte/id-2024.html
2026https://oncoletter.ch/kongressberichte/id-2026.html
ASCO 2026 Gastrointestinal (GI) Cancers Symposiumhttps://oncoletter.ch/kongressberichte/id-2026/ascogi-gastrointestinal-cancers-symposium.html
2025https://oncoletter.ch/kongressberichte/2025.html
48th SAN ANTONIO BREAST CANCER SYMPOSIUM - December 9 - 12, 2025, San Antonio Texashttps://oncoletter.ch/kongressberichte/2025/48th-san-antonio-breast-cancer-symposium-san-antonio.html
67th ASH Annual Meeting and Exposition - December 6-9, 2025, Orlando, Floridahttps://oncoletter.ch/kongressberichte/2025/67th-ash-annual-meeting.html
ESMO Congress 2025 - 17. - 21. OKTOBER - BERLIN, DEUTSCHLANDhttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025.html
 IASLC 2025 World Conference on Lung Cancerhttps://oncoletter.ch/kongressberichte/2025/iaslc-2025-world-conference-on-lung-cancer.html
ESMO Gastrointestinal Cancers Congress 2025https://oncoletter.ch/kongressberichte/2025/esmo-gastrointestinal-cancers-congress-2025.html
EHA2025 Congress - Milano, June 12-15, 2025https://oncoletter.ch/kongressberichte/2025/eha2025.html
ASCO Annual Meeting 2025 May 30 - June 3, 2025 - McCormick Place, Chicagohttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025.html
European Lung Cancer Congress 2025https://oncoletter.ch/kongressberichte/2025/european-lung-cancer-congress-2025-elcc.html
St.Gallen International Breast Cancer Conference 2025https://oncoletter.ch/kongressberichte/2025/sgbcc-2025.html
ASCO Genitourinary Cancers Symposiumhttps://oncoletter.ch/kongressberichte/2025/ascogenitourinary-cancers-symposium.html
ASCO 2025 Gastrointestinal (GI) Cancers Symposiumhttps://oncoletter.ch/kongressberichte/2025/ascogi2025-gastrointestinal-gi-cancers-symposium.html
2024https://oncoletter.ch/kongressberichte/id-2024.html
47th SAN ANTONIO BREAST CANCER SYMPOSIUM - December 10 - 13, 2024, San Antonio Texashttps://oncoletter.ch/kongressberichte/id-2024/47th-san-antonio-breast-cancer-symposium.html
66th ASH Annual Meeting and Exposition - December 7-10, 2024https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024.html
ESMO Congress 2024 - 13. - 17. SEPTEMBER - BARCELONA, SPANIENhttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024.html
 IASLC 2024 World Conference on Lung Cancerhttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer.html
ESMO Gastrointestinal Cancers Congress 2024https://oncoletter.ch/kongressberichte/id-2024/esmo-gastrointestinal-cancers-congress-2024.html
EHA2024 Hybrid Congress - Madrid, June 13-16, 2024.https://oncoletter.ch/kongressberichte/id-2024/eha2024.html
ASCO Annual Meeting 2024 May 31 - June 4, 2024 - McCormick Place, Chicagohttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024.html
ESGO - 25th European Congress on Gynaecological Oncologyhttps://oncoletter.ch/kongressberichte/id-2024/esgo-25th-european-congress-on-gynaecological-oncology.html
EBMT-EHA 6th European CAR T-cell Meetinghttps://oncoletter.ch/kongressberichte/id-2024/ebmt-eha-6th-european-car-t-cell-meeting.html
ASCO Genitourinary Cancers Symposiumhttps://oncoletter.ch/kongressberichte/id-2024/ascogenitourinary-cancers-symposium.html
ASCO 2024 Gastrointestinal (GI) Cancers Symposiumhttps://oncoletter.ch/kongressberichte/id-2024/asco2024-gastrointestinal-gi-cancers-symposium.html
2023https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023.html
65th ASH Annual Meeting and Exposition - December 09-12, 2023https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023.html
46th SAN ANTONIO BREAST CANCER SYMPOSIUM - December 5 - 9, 2023, San Antonio Texashttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium.html
ESMO Congress 2023 - 20. - 24. OKTOBER - MADRID, SPANIENhttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien.html
 IASLC 2023 World Conference on Lung Cancerhttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer.html
ESMO World Congress on Gastrointestinal Cancer (ESMO World GI 2023)https://oncoletter.ch/kongressberichte/id-2023/esmo-world-congress-on-gastrointestinal-cancer-2023.html
EHA2023 Congresshttps://oncoletter.ch/kongressberichte/id-2023/eha2023-congress.html
ASCO Annual Meeting, June 2-6, 2023 - McCormick Place, Chicagohttps://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023.html
Comprehensive Cancer Center Zürich: Patientenakademie – Brustkrebshttps://oncoletter.ch/kongressberichte/patientenakademie-brustkrebs.html
18th St.Gallen International Breast Cancer Conference 2023 (SGBCC)https://oncoletter.ch/kongressberichte/id-2023/sgbcc-18th-st-gallen-international-breast-cancer-conference-2023.html
ASCO Genitourinary Cancers Symposium 2023https://oncoletter.ch/kongressberichte/id-2023/ascogenitourinary-cancers-symposium-2023.html
ASCO 2023 Gastrointestinal (GI) Cancers Symposiumhttps://oncoletter.ch/kongressberichte/id-2023/asco2023-gastrointestinal-gi-cancers-symposium.html
2021https://oncoletter.ch/Kongressberichte/2021/63rd-ASH-Annual-Meeting-and-Exposition_December-11-14-2021.html
63rd ASH Annual Meeting and Exposition - December 11-14, 2021https://oncoletter.ch/Kongressberichte/2021/63rd-ASH-Annual-Meeting-and-Exposition_December-11-14-2021.html
SAN ANTONIO BREAST CANCER SYMPOSIUM - December 7 - 11, 2021, San Antonio Texashttps://oncoletter.ch/Kongressberichte/2021/san-antonio-breast-cancer-symposium-december-7-11-2021-san-antonio-texas.html
9. Interdisziplinäres Prostatakarzinom-Symposium, St. Gallen, 2. Dezember 2021https://oncoletter.ch/Kongressberichte/2021/9-interdisziplinaeres-prostatakarzinom-symposium-st-gallen-2-dezember-2021.html
Kongressberichte Archiv 2021https://archiv.oncoletter.ch/kongressberichte-2020.html
Kongressberichte Archiv 2020https://archiv.oncoletter.ch/kongressberichte-2020.html
Kongressberichte Archiv 2019https://archiv.oncoletter.ch/kongressberichte-2019.html
Kongressberichte Archiv 2018https://archiv.oncoletter.ch/kongressberichte-2018.html
Kongressberichte Archiv 2017https://archiv.oncoletter.ch/kongressberichte-2017.html
Kalenderhttps://oncoletter.ch/kalender.html
Organisationenhttps://oncoletter.ch/Netzwerke.html
Netzwerkehttps://oncoletter.ch/Netzwerke.html
Fachgesellschaftenhttps://oncoletter.ch/Fachgesellschaften.html
Info für PatientINNenhttps://oncoletter.ch/Organisationen/info-fuer-patientinnen-patienten-angehoerige.html
Science Boardhttps://oncoletter.ch/science-board.html
https://oncoletter.ch/home.html#contentwrapper
Livehttps://oncoletter.ch/Live.html
Kongressberichtehttps://oncoletter.ch/kongressberichte/id-2024.html
2026https://oncoletter.ch/kongressberichte/id-2026.html
ASCO 2026 Gastrointestinal (GI) Cancers Symposiumhttps://oncoletter.ch/kongressberichte/id-2026/ascogi-gastrointestinal-cancers-symposium.html
Rapid Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/id-2026/ascogi-rapid-oral-abstract-sessions.html
Rapid Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/id-2026/ascogi-rapid-abstract-session-1-esophagus-stomach.html
Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/id-2026/ascogi-oral-abstract-sessions.html
Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/id-2026/ascogi-oral-abstract-session-1-esophagus-stomach.html
Trials in Progress Poster Sessionshttps://oncoletter.ch/kongressberichte/id-2026/ascogi-trials-in-progress-poster-sessions.html
Trials in Progress Poster Sessionshttps://oncoletter.ch/kongressberichte/id-2026/ascogi-trials-in-progress-poster-sessions-1-stomach-other-gastrointestinal-cancers.html
Links to more Abstractshttps://oncoletter.ch/kongressberichte/id-2026/ascogi-gastrointestinal-cancers-symposium-more-abstracts.html
2025https://oncoletter.ch/kongressberichte/2025.html
48th SAN ANTONIO BREAST CANCER SYMPOSIUM - December 9 - 12, 2025, San Antonio Texashttps://oncoletter.ch/kongressberichte/2025/48th-san-antonio-breast-cancer-symposium-san-antonio.html
Studies presented at the SABCS 2025 Press Briefingshttps://oncoletter.ch/kongressberichte/2025/48th-sabcs-studies-presented-at-the-press-briefings.html
General Sessions 1-3https://oncoletter.ch/kongressberichte/2025/48th-sabcs/general-sessions-1-3.html
General Sessionshttps://oncoletter.ch/kongressberichte/2025/48th-sabcs/general-session-1.html
Rapid Fire Sessions 1-7https://oncoletter.ch/kongressberichte/2025/48th-sabcs-rapid-fire-sessions-1-7.html
Rapid Fire Sessions 1-7https://oncoletter.ch/kongressberichte/2025/48th-sabcs-rapid-fire-session-1.html
POSTER SPOTLIGHT SESSIONS 1-13https://oncoletter.ch/kongressberichte/2025/48th-sabcs-poster-spotlight-sessions-1-12.html
POSTER SPOTLIGHT SESSIONShttps://oncoletter.ch/kongressberichte/2025/48th-sabcs-poster-spotlight-sessions_summaries.html
67th ASH Annual Meeting and Exposition - December 6-9, 2025, Orlando, Floridahttps://oncoletter.ch/kongressberichte/2025/67th-ash-annual-meeting.html
Late-Breaking Abstracts Session - Room OCCC - West Hall D2 - Tuesday, December 9, 07:30 AM - 09:00 AM ESThttps://oncoletter.ch/kongressberichte/2025/ash-2025-late-breaking-abstracts-session.html
ASH 2025 Plenary Scientific Session - Room OCCC - West Hall D2 - Sunday, December 7, 02:00 PM - 04:00 PM ESThttps://oncoletter.ch/kongressberichte/2025/ash-2025-plenary-scientific-session.html
Acute Lymphoblastic Leukemiashttps://oncoletter.ch/kongressberichte/2025/ASH2025-acute-lymphoblastic-leukemias.html
ALL: Clinical and Epidemiological studieshttps://oncoletter.ch/kongressberichte/2025/ASH2025-all-treatment-diagnostics-immunotherapy.html
ALL: Therapies Excluding Allogeneic Transplantationhttps://oncoletter.ch/kongressberichte/2025/ASH2025-all-emerging-treatment-paradigms.html
ALL: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosishttps://oncoletter.ch/kongressberichte/2025/ASH2025-all-critical-biomarkers-classifiers-b-all-and-t-all-ontogeny-outcomes.html
Acute Myeloid Leukemiashttps://oncoletter.ch/kongressberichte/2025/ASH2025-acute-myeloid-leukemias.html
AML: Clinical and Epidemiological Studieshttps://oncoletter.ch/kongressberichte/2025/ASH2025-aml-biological-and-clinical-nuances-in-patient-outcomes.html
AML: Investigational Drug and Cellular Therapieshttps://oncoletter.ch/kongressberichte/2025/ASH2025-aml-immunotherapy-and-chemotherapy-combinations.html
AML: Commercially Available Therapieshttps://oncoletter.ch/kongressberichte/2025/ASH2025-aml-frontline-treatment-with-intensive-or-lower-intensity-regimens.html
AML: Disease Burden and Measurable Residual Disease in Prognosis and Treatmenthttps://oncoletter.ch/kongressberichte/2025/ASH2025-aml-disease-burden-and-measurable-residual-disease-in-prognosis-and-treatment/cml-decoding-the-molecular-drivers-of-response-and-resistance.html
Chronic Myeloid Leukemiahttps://oncoletter.ch/kongressberichte/2025/ASH2025-chronic-myeloid-leukemia.html
CML: Clinical and Epidemiologicalhttps://oncoletter.ch/kongressberichte/2025/ASH2025-cml-decoding-molecular-drivers-response-resistance.html
Myeloproliferative Syndromes: Clinical and Epidemiologicalhttps://oncoletter.ch/kongressberichte/2025/ASH2025-myeloproliferative-syndromes.html
MPS: Clinical and Epidemiologicalhttps://oncoletter.ch/kongressberichte/2025/ASH2025-mps-therapeutic-prognostic-myeloproliferative-neoplasms-mastocytosis-hypereosinophilic-syndrome.html
Lymphomashttps://oncoletter.ch/kongressberichte/2025/ASH2025-lymphomas.html
Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological:https://oncoletter.ch/kongressberichte/2025/ASH2025-lymphomas/mantle-cell-follicular-waldenstrom-s-and-other-indolent-b-cell-lymphomas/mantle-cell-follicular-waldenstrom-s-and-other-indolent-b-cell-lymphomas-fl-and-wm.html
Hodgkin Lymphomas: Clinical and Epidemiologicalhttps://oncoletter.ch/kongressberichte/2025/ASH2025-improving-outcomes-in-hodgkin-lymphoma-utilizing-targeted-therapeutics-prognostic-modeling-predictive-tools.html
T Cell, NK Cell, or NK/T Cell Lymphomashttps://oncoletter.ch/kongressberichte/2025/ASH2025-lymphomas-fresh-insight-for-cutaneous-and-virus-associated-tcls.html
Aggressive Lymphomashttps://oncoletter.ch/kongressberichte/2025/ASH2025-aggressive-lymphomas-targeted-pharmacologic-therapies-front-line-btki-based-combination-therapy-DLBCL-PCNSL.html
Chronic Lymphocytic Leukemiashttps://oncoletter.ch/kongressberichte/2025/ASH2025-chronic-lymphocytic-leukemias.html
Chronic Lymphocytic Leukemia: Clinical and Epidemiologicalhttps://oncoletter.ch/kongressberichte/2025/ASH2025-cll-clinical-epidemiological-treatment-relapse-richter-transformation.html
Myelodysplastic Syndromeshttps://oncoletter.ch/kongressberichte/2025/ASH2025-myelodysplastic-syndromes.html
Myelodysplastic Syndromes: Clinical and Epidemiologicalhttps://oncoletter.ch/kongressberichte/2025/ASH2025-treatment-advances-in-higher-risk-myelodysplastic-syndromes.html
Multiple Myeloma and Plasma Cell Dyscrasiashttps://oncoletter.ch/kongressberichte/2025/ASH2025-multiple-myeloma-and-plasma-cell-dyscrasias.html
MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias:https://oncoletter.ch/kongressberichte/2025/ASH2025-multiple-myeloma-plasma-cell-dyscrasias-mgus-amyloidosis-other-non-myeloma.html
Multiple Myeloma: Clinical and Epidemiologicalhttps://oncoletter.ch/kongressberichte/2025/ASH2025-multiple-myeloma-and-plasma-cell-dyscrasias-clinical-and-epidemiological-clinical-epidemiological-optimizing-immune-based-therapies.html
Multiple Myeloma: Pharmacologic Therapieshttps://oncoletter.ch/kongressberichte/2025/ASH2025-multiple-myeloma-plasma-cell-dyscrasias-pharmacologic-therapies-improving-myeloma-treatment-through-diagnosis-maintenance-and-relapse.html
Multiple Myeloma: Cellular Therapieshttps://oncoletter.ch/kongressberichte/2025/ASH2025-multiple-myeloma-and-plasma-cell-dyscrasias-cellular-therapies-clinical-trial-advances-in-car-t-cell-therapy.html
CAR-T Cell and Cellular Immunotherapieshttps://oncoletter.ch/kongressberichte/2025/67th-ash-annual-meeting/car-t-cell-and-cellular-immunotherapies.html
ESMO Congress 2025 - 17. - 21. OKTOBER - BERLIN, DEUTSCHLANDhttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025.html
ESMO25 - Presidential Symposia I-IIIhttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/esmo25-presidential-symposia-i-iii.html
ESMO25 - Presidential Symposia I-IIIhttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/presidential-symposium-i-practice-changing-trials.html
BREAST CANCERhttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/breast-cancer.html
Interviewshttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/breast-cancer/interviews-renate-haidinger-brustkrebs-deutschland-e-v.html
Breast cancer, early stagehttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/proffered-paper-session-breast-cancer-early-stage.html
Breast cancer, metastatichttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/proffered-paper-session-1-breast-cancer-metastatic.html
LUNG CANCER & OTHER THORACIC MALIGNANCIEShttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/lung-cancer-other-thoracic-malignancies.html
Non-metastatic NSCLC and other thoracic malignancieshttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/non-metastatic-nsclc-proffered-paper-session.html
NSCLC, metastatichttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/nsclc-metastatic/proffered-paper-session.html
Mesotheliomahttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/proffered-paper-session-mesothelioma.html
HEAD & NECK CANCERhttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/head-neck-cancer.html
Head & Neck Sessionshttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/head-neck-sessions/proffered-paper-session-1.html
GYNAECOLOGICAL CANCERShttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/gynaecological-cancers.html
Interview Renate Haidinger, Brustkrebs Deutschland e.V. mit Prof. Sven Mahner - Highlights Gynäkologische Tumoren (Ovarialkarzinom)https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/gynaecological-cancers/interviews-haidinger-mahner/interviews.html
Gynaecological Sessionshttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/gynaecological-cancer-sessions/proffered-paper-session.html
CNS TUMOURS & SARCOMAhttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/cns-tumours-sarcoma.html
CNS & SARCOMA Sessionshttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/proffered-paper-session-sarcoma.html
GENITOURINARY TUMOURShttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/genitourinary-tumours.html
GU tumours, renal-urothelialhttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/renal-urothelial-tumours-proffered-paper-session-1.html
GU tumours, prostate, penile and testishttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/proffered-paper-session-GU-tumours-prostate-penile-testis.html
GASTROINTESTINAL TUMOURShttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/gastrointestinal-tumours.html
GI, upper digestivehttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/proffered-paper-session-2-gi-tumours-upper-digestive.html
GI, lower digestivehttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/proffered-paper-session-1-gi-tumours-lower-digestive.html
NETs and endocrine tumourshttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/nets-and-endocrine-tumours.html
NETs and endocrine tumours Sessionshttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/proffered-paper-session-nets-and-endocrine-tumours.html
MELANOMA AND OTHER SKIN TUMOURShttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/melanoma-and-other-skin-tumours.html
Melanoma Sessionshttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/proffered-paper-session-melanoma.html
HAEMATOLOGICAL MALIGNANCIEShttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/haematological-malignancies.html
Haematological malignancies Sessionshttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/haematological-malignancies-proffered-paper-session.html
INVESTIGATIONAL IMMUNOTHERAPYhttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/investigational-immunotherapy.html
INVESTIGATIONAL IMMUNOTHERAPYhttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/investigational-immunotherapy/proffered-paper-session.html
SUPPORTIVE AND PALLIATIVE CAREhttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/supportive-and-palliative-care.html
Supportive and palliative care sessionshttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/proffered-paper-session-supportive-and-palliative-care.html
 IASLC 2025 World Conference on Lung Cancerhttps://oncoletter.ch/kongressberichte/2025/iaslc-2025-world-conference-on-lung-cancer.html
PL02 Presidential Symposium 1 - Sunday, September 7, 2025 at 8:15 AM CEST / Plenary Hallhttps://oncoletter.ch/kongressberichte/2025/pl02presidential-symposium-1.html
PL03 Presidential Symposium 2 - Monday, September 8, 2025 at 8:15 AM CEST / Plenary Hallhttps://oncoletter.ch/kongressberichte/2025/iaslc-2025-world-conference-on-lung-cancer/pl03-presidential-symposium-2.html
OA02 Latest Diagnostic and Management Options to Improve Survival Outcomes in Early-stage Resectable Non-small Cell Lung Cancer - Sep 7 2025 12:00PM - 1:15PM / Room 06https://oncoletter.ch/kongressberichte/2025/iaslc-2025-latest-diagnostic-and-management-options.html
OA05 Immunotherapy for Special Populations - Sep 7 2025 4:45PM - 6:00PM / Room 06https://oncoletter.ch/kongressberichte/2025/iaslc-2025-immunotherapy-for-special-populations.html
OA06. Novel ADCs in SCLC - Sep 7 2025 4:45PM - 6:00PM / Room 02https://oncoletter.ch/kongressberichte/2025/iaslc-2025-novel-adcs-in-sclc.html
OA07. Expanding Horizons in Advanced NSCLC Integrating Local Therapy - Sep 8 2025 12:00PM - 1:15PM / Room 08https://oncoletter.ch/kongressberichte/2025/iaslc-2025-expanding-horizons-in-advanced-nsclc-integrating-local-therapy.html
OA08. Improving Outcomes in EGFR and KRAS Mutant Tumours, More is Better? - Sep 8 2025 12:00PM - 1:15PM / Room 02https://oncoletter.ch/kongressberichte/2025/iaslc-2025-improving-outcomes-in-egfr-kras-mutant-tumours-more-is-better.html
OA10. Optimizing Systemic Therapy: Bridging New and Old - Sep 8 2025 3:30PM - 4:45PM / Room 07https://oncoletter.ch/kongressberichte/2025/iaslc-2025optimizing-systemic-therapy-bridging-new-and-old.html
OA12. Novel Clinical Approaches and Translational Investigation in Mesothelioma - Sep 8 2025 5:00PM - 6:15PM / Room 01https://oncoletter.ch/kongressberichte/2025/iaslc-2025-novel-clinical-approaches-and-translational-investigation-in-mesothelioma.html
OA13. Optimizing Front-Line Treatment in SCLC - Sep 8 2025 5:00PM - 6:15PM / Room 06https://oncoletter.ch/kongressberichte/2025/iaslc-2025-optimizing-front-line-treatment-in-sclc.html
OA16. Building Bridges Between Resectable and Unresectable Stage III NSCLC - Sep 9 2025 11:30AM - 12:45PM / Room 06https://oncoletter.ch/kongressberichte/2025/iaslc-2025-building-bridges-between-resectable-and-unresectable-stage-iii-nsclc.html
More Links to Oral Sessionshttps://oncoletter.ch/kongressberichte/2025/iaslc-2025-more-links-to-oral-sessions.html
MA01. New Drugs and Strategies in Locally Advanced NSCLC - Sep 7 2025 12:00PM - 1:15PM / Room 01https://oncoletter.ch/kongressberichte/2025/iaslc-2025-new-drugs-and-strategies-in-locally-advanced-nsclc.html
MA02. New Treatment Strategies in Other Than EGFR-Positive Tumors - Sep 7 2025 12:00PM - 1:15PM / Room 02https://oncoletter.ch/kongressberichte/2025/iaslc-2025-new-treatment-strategies-in-other-than-egfr-positive-tumors.html
MA04. Multi-Modal Treatment of Resectable Lung Cancer - Outcomes of Targeted Treatments and Immunotherapies in Early-Stage Lung Cancer - Sep 8 2025 12:00PM - 1:15PM / Room 01https://oncoletter.ch/kongressberichte/2025/iaslc-2025-multi-modal-treatment-of-resectable-lung-cancer-outcomes-of-targeted-treatments-and-immunotherapies-in-early-stage-lung-cancer.html
MA08. Common and Uncommon EGFR Mutations, New Treatments in the Horizon - Sep 9 2025 11:30AM - 12:45PM / Room 01https://oncoletter.ch/kongressberichte/2025/iaslc-2025-common-and-uncommon-egfr-mutations-new-treatments-in-the-horizon.html
MA10. Longer Follow Up and New IO Combinations - Sep 9 2025 1:00PM - 2:15PM / Room 06https://oncoletter.ch/kongressberichte/2025/iaslc-2025-longer-follow-up-and-new-io-combinations.html
MA11. Innovative Therapeutic Strategies and Molecular Insights in SCLC and Neuroendocrine Tumors - Sep 9 2025 1:00PM - 2:15PM Room 01https://oncoletter.ch/kongressberichte/2025/iaslc-2025-innovative-therapeutic-strategies-and-molecular-insights-in-sclc-and-neuroendocrine-tumors.html
More Links to Mini Oral Sessionshttps://oncoletter.ch/kongressberichte/2025/iaslc-2025-world-conference-on-lung-cancer/more-links-to-mini-oral-sessions.html
ESMO Gastrointestinal Cancers Congress 2025https://oncoletter.ch/kongressberichte/2025/esmo-gastrointestinal-cancers-congress-2025.html
Mini Oral session - Innovation in GI cancershttps://oncoletter.ch/kongressberichte/2025/esmo-gastrointestinal-cancers-congress-2025/mini-oral-session-innovation-in-gi-cancers.html
Proffered Paper session 1https://oncoletter.ch/kongressberichte/2025/esmo-gastrointestinal-cancers-congress-2025/proffered-paper-session-1.html
Proffered Paper session 2https://oncoletter.ch/kongressberichte/2025/esmo-gastrointestinal-cancers-congress-2025/proffered-paper-session-2.html
Mini Oral sessionhttps://oncoletter.ch/kongressberichte/2025/esmo-gastrointestinal-cancers-congress-2025/mini-oral-session.html
EHA2025 Congress - Milano, June 12-15, 2025https://oncoletter.ch/kongressberichte/2025/eha2025.html
Plenary and Late Breaking Abstract Sessionshttps://oncoletter.ch/kongressberichte/2025/eha2025-congress-milano-june-12-15-2025/plenary-and-late-breaking-abstract-sessions.html
Plenary and Late Breaking Abstract Sessionshttps://oncoletter.ch/kongressberichte/2025/eha2025/plenary-session.html
Acute Lymphoblastic Leukemiahttps://oncoletter.ch/kongressberichte/2025/eha2025/acute-lymphoblastic-leukemia.html
Acute lymphoblastic leukemiahttps://oncoletter.ch/kongressberichte/2025/eha2025/all-clinical.html
Acute Myeloid Leukemiahttps://oncoletter.ch/kongressberichte/2025/eha2025/acute-myeloid-leukemia.html
Acute myeloid leukemiahttps://oncoletter.ch/kongressberichte/2025/eha2025/acute-myeloid-leukemia/aml-clinical.html
Aggressive, indolente und Mantelzell Non-Hodgkin lymphomahttps://oncoletter.ch/kongressberichte/2025/eha2025/aggressive-indolente-und-mantelzell-non-hodgkin-lymphoma.html
Aggressive Non-Hodgkin lymphoma.https://oncoletter.ch/kongressberichte/2025/eha2025/aggressive-non-hodgkin-lymphoma-clinical.html
Indolente und Mantelzell Non-Hodgkin lymphomahttps://oncoletter.ch/kongressberichte/2025/eha2025/aggressive-indolente-und-mantelzell-non-hodgkin-lymphoma/indolente-und-mantelzell-non-hodgkin-lymphoma/indolente-und-mantelzell-non-hodgkin-lymphoma.html
Chronic Lymphocytic Leukemia and Related disorders - Clinicalhttps://oncoletter.ch/kongressberichte/2025/eha2025/chronic-lymphocytic-leukemia.html
Chronic lymphocytic leukemia and related disordershttps://oncoletter.ch/kongressberichte/2025/eha2025/chronic-lymphocytic-leukemia-clinical.html
Chronic Myeloid Leukemiahttps://oncoletter.ch/kongressberichte/2025/eha2025/chronic-myeloid-leukemia.html
Chronic Myeloid Leukemiahttps://oncoletter.ch/kongressberichte/2025/eha2025/chronic-myeloid-leukemia-clinical/CML.html
Hodgkin Lymphomahttps://oncoletter.ch/kongressberichte/2025/eha2025/hodgkin-lymphoma.html
Hodgkin lymphomahttps://oncoletter.ch/kongressberichte/2025/eha2025/hodgkin-lymphoma/hodgkin.html
Myelodysplastic Syndromeshttps://oncoletter.ch/kongressberichte/2025/eha2025/myelodysplastic-syndromes.html
Myelodysplastic Syndromeshttps://oncoletter.ch/kongressberichte/2025/eha2025/myelodysplastic-syndromes/mds.html
Myeloma and other monoclonal gammopathies - clinicalhttps://oncoletter.ch/kongressberichte/2025/eha2025/myeloma-and-other-monoclonal-gammopathies-clinical.html
Myeloma and other monoclonal gammopathies - clinicalhttps://oncoletter.ch/kongressberichte/2025/eha2025/myeloma-monoclonal-gammopathies.html
Myeloproliferative Neoplasmshttps://oncoletter.ch/kongressberichte/2025/eha2025/myeloproliferative-neoplasms.html
Myeloproliferative Neoplasmshttps://oncoletter.ch/kongressberichte/2025/eha2025/myeloproliferative-neoplasms/mpn.html
Gen Therapie und zelluläre Immuntherapiehttps://oncoletter.ch/kongressberichte/2025/eha2025/gene-therapy.html
Gen Therapie und zelluläre Immuntherapiehttps://oncoletter.ch/kongressberichte/2025/eha2025/gene-therapies/gene-therapy.html
ASCO Annual Meeting 2025 May 30 - June 3, 2025 - McCormick Place, Chicagohttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025.html
Plenary sessionhttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/plenary-session.html
Plenary Session Late breaking abstracts - Sunday, June 1 - 13:00 – 16:00 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/plenary-session-late-breaking-abstracts-sunday-june-1.html
Breast Cancerhttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/breast-cancer.html
Breast Cancer—Local/Regional/Adjuvanthttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/breast-cancer-local-regional-adjuvant/2-juni.html
Breast Cancer—Metastatichttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/breast-cancer-metastatic/31-mai.html
Lung Cancerhttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/lung-cancer.html
Lung Cancer - Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancershttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/lung-cancer-nsclc-sclc-thoracic-cancer/2-juni-2025.html
Lung Cancer—Non-Small Cell Metastatichttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/lung-cancer-non-small-cell-metastatic/1-juni-2025.html
Gastrointestinal Cancerhttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/gastrointestinal-cancer.html
Gastrointestinal Cancer—Colorectal and Analhttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/gastrointestinal-cancer-colorectal-and-anal/30-mai.html
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliaryhttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/gastrointestinal-cancer-gastroesophageal-pancreatic-and-hepatobiliary-31-mai.html
Genitourinary Cancerhttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/genitourinary-cancer.html
Genitourinary Cancer—Kidney and Bladderhttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/genitourinary-cancer-kidney-bladder/1-juni.html
Genitourinary Cancer—Prostate, Testicular, and Penilehttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/genitourinary-cancer-prostate-testicular-and-penile-3-juni.html
Gynecologic Cancerhttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/gynecologic-cancer.html
Gynecologic Cancerhttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/gynecologic-cancer/2-juni.html
Central Nervous System Tumorshttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/central-nervous-system-tumors.html
Central Nervous System Tumorshttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/central-nervous-system-tumors/30-mai.html
Head and Neck Cancerhttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/head-and-neck-cancer-2.html
Head and Neck Cancerhttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/head-and-neck-cancer/31-mai.html
Melanoma/Skin Cancershttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/melanoma-skin-cancers.html
Melanoma/Skin Cancershttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/melanoma-skin-cancers/3-juni.html
Sarcomahttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/sarcoma.html
Sarcoma.https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/sarcomas/1-juni.html
Pediatric Oncologyhttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/pediatric-oncology.html
Pediatric Oncologyhttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/pediatric-oncology/31.html
Hematologic Malignancieshttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/hematologic-malignancies.html
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplanthttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/leukemia-myelodysplastic-syndromes-and-allotransplant/2-juni.html
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemiahttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/lymphoma-and-chronic-lymphocytic-leukemia/30-mai.html
Hematologic Malignancies—Plasma Cell Dyscrasiahttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/plasma-cell-dyscrasia/3-juni.html
Developmental Therapeuticshttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/developmental-therapeutics.html
Developmental Therapeutics—Immunotherapyhttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/developmental-therapeutics-immunotherapy/1-juni-2025.html
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biologyhttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/molecularly-targeted-agents-and-tumor-biology/30-mai.html
European Lung Cancer Congress 2025https://oncoletter.ch/kongressberichte/2025/european-lung-cancer-congress-2025-elcc.html
Proffered Paper Sessionshttps://oncoletter.ch/kongressberichte/2025/elcc-proffered-paper-sessions.html
Proffered Paper Sessionshttps://oncoletter.ch/kongressberichte/2025/proffered-paper-session-1-elcc.html
Mini Oral Sessionshttps://oncoletter.ch/kongressberichte/2025/mini-oral-sessions-elcc.html
Mini Oral Sessionshttps://oncoletter.ch/kongressberichte/2025/mini-oral-session-1-elcc.html
St.Gallen International Breast Cancer Conference 2025https://oncoletter.ch/kongressberichte/2025/sgbcc-2025.html
BREAST CANCERhttps://oncoletter.ch/kongressberichte/2025/sgbcc-2025/breast-cancer.html
Interviews SGBCC 2025https://oncoletter.ch/kongressberichte/2025/sgbcc-2025/interviews/interviews-renate-haidinger-brustkrebs-deutschland.html
ASCO Genitourinary Cancers Symposiumhttps://oncoletter.ch/kongressberichte/2025/ascogenitourinary-cancers-symposium.html
Rapid Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/2025/rapid-oral-abstract-sessions.html
Rapid Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/2025/rapid-oral-abstract-session-a-prostate-cancer.html
Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/2025/oral-abstract-sessions.html
Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/2025/oral-abstract-session-a-prostate-cancer.html
Trials in Progress Poster Sessionshttps://oncoletter.ch/kongressberichte/2025/ascogenitourinary-cancers-symposium/trials-in-progress.html
Trials in Progress Poster Sessionshttps://oncoletter.ch/kongressberichte/2025/trials-in-progress-poster-session-a-prostate-cancer.html
ASCO 2025 Gastrointestinal (GI) Cancers Symposiumhttps://oncoletter.ch/kongressberichte/2025/ascogi2025-gastrointestinal-gi-cancers-symposium.html
Rapid Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/2025/asco-2025-gastrointestinal-gi-cancers-symposium/rapid-oral-abstract-sessions.html
Rapid Abstract Sessionshttps://oncoletter.ch/kongressberichte/2025/ascogi-2025-rapid-oral-abstract-cancers-of-the-colon-rectum-and-anus.html
Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/2025/ascogi-2025/oral-abstracts.html
Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/2025/ascogi-2025/oral-abstracts-cancers-of-the-esophagus-and-stomach.html
Trials in Progress Poster Sessionshttps://oncoletter.ch/kongressberichte/2025/ascogi-2025/trials-in-progress-poster-sessions.html
Trials in Progress Poster Sessionshttps://oncoletter.ch/kongressberichte/2025/ascogi-2025/trials-in-progress-posters-cancers-of-the-esophagus-and-stomach-and-other-gastrointestinal-cancers.html
Links to more Abstractshttps://oncoletter.ch/kongressberichte/2025/ascogi2025-gastrointestinal-gi-cancers-symposium/links-to-more-abstracts.html
2024https://oncoletter.ch/kongressberichte/id-2024.html
47th SAN ANTONIO BREAST CANCER SYMPOSIUM - December 10 - 13, 2024, San Antonio Texashttps://oncoletter.ch/kongressberichte/id-2024/47th-san-antonio-breast-cancer-symposium.html
Studies presented at the SABCS 2024 Press Briefinghttps://oncoletter.ch/kongressberichte/id-2024/studies-presented-at-the-sabcs-2024-press-briefing.html
Interviews von Renate Haidinger, Brustkrebs Deutschland e.V.https://oncoletter.ch/kongressberichte/id-2024/sabcs-interviews-von-renate-haidinger-brustkrebs-deutschland-e-v.html
Kurze Videos mit Expert:innen zu ausgewählten Highlights aus Sitzungen und Vorträgen sowie speziellen Schwerpunktthemenhttps://oncoletter.ch/kongressberichte/id-2024/sabcs-kurze-videos-mit-expert-innen-zu-ausgewaehlten-highlights-aus-sitzungen-und-vortraegen-sowie-speziellen-schwerpunktthemen.html
General Sessions 1-3https://oncoletter.ch/kongressberichte/id-2024/general-sessions-1-3.html
General Sessionshttps://oncoletter.ch/kongressberichte/id-2024/sabcs-general-session-1.html
Rapid Fire Sessions 1&2https://oncoletter.ch/kongressberichte/id-2024/rapid-fire-sessions-1-2.html
Rapid Fire Sessions 1&2https://oncoletter.ch/kongressberichte/id-2024/sabcs-rapid-fire-session-1.html
Late Breaking Abstracts Oral Sessionhttps://oncoletter.ch/kongressberichte/id-2024/sabcs-late-breaking-abstracts-oral-session.html
Late Breaking Abstracts Oral Sessionhttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/late-breaking-abstracts-oral-session/late-breaking-abstracts-oral-session-friday-december-8.html
POSTER SPOTLIGHT SESSIONS 1-18https://oncoletter.ch/kongressberichte/id-2024/poster-spotlight-sessions-1-18.html
POSTER SPOTLIGHT SESSIONShttps://oncoletter.ch/kongressberichte/id-2024/sabcs-poster-spotlight-session-1-new-insights-into-immune-biomarkers.html
66th ASH Annual Meeting and Exposition - December 7-10, 2024https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024.html
ASH 24 Press Briefings on Late Breaking and other important Abstractshttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024-press-briefings.html
ASH Press Briefingshttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024-press-briefings/december-8.html
ASH 2024 Late-Breaking Abstracts Sessionhttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024-late-breaking-abstracts-session.html
ASH 2024 Plenary Scientific Sessionhttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/plenary-scientific-session.html
Acute Lymphoblastic Leukemiashttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/acute-lymphoblastic-leukemias.html
ALL: Clinical and Epidemiological studieshttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/outcome-predictors-in-all.html
ALL: Therapies, Excluding Allogeneic Transplantation:https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/all-risk-stratification-and-car-t-therapies.html
Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosishttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/genomic-determinants-of-outcomes-in-all.html
ALL Links to Poster Sessionshttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/all-links-to-poster-sessions.html
Acute Myeloid Leukemiashttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/acute-myeloid-leukemias.html
AML: Clinical and Epidemiological studieshttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/aml-in-specific-age-groups-blastic-plasmacytoid-dendritic-cell-neoplasms.html
AML: Investigational Drug and Cellular Therapieshttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/aml-investigational-drug-and-cellular-therapies/menin-inhibitors.html
AML: Commercially Available Therapies:https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/impact-of-molecularly-targeted-agents-in-aml.html
AML: Biomarkers and Molecular Markers in Diagnosis and Prognosis:https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/aml-multi-omic-applications-for-disease-evolution-and-response-to-therapy.html
AML: Disease Burden and Minimal Residual Disease in Prognosis and Treatmenthttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/aml-measurable-residual-disease-in-aml-in-2024-and-beyond.html
AML Links to Poster Sessionshttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/aml-links-to-poster-sessions.html
Chronic Myeloid Leukemiahttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/chronic-myeloid-leukemia.html
CML: Clinical and Epidemiological Programmhttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/cml-novel-molecules-in-clinical-practice.html
CML Links to Poster Sessionshttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/chronic-myeloid-leukemia/cml-links-to-poster-sessions.html
Myeloproliferative Syndromes and Chronic Myeloid Leukemiahttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/myeloproliferative-syndromes-and-chronic-myeloid-leukemia.html
Myeloproliferative Syndromes and Chronic Myeloid Leukemiahttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/mps-basic-and-translational-stem-cell-biology-in-myeloproliferative-syndromes.html
MPS: Clinical and Epidemiologicalhttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/mps-risk-stratification-and-therapeutic-implications.html
Myeloproliferative Syndromes: Links to Poster Sessionshttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/myeloproliferative-syndromes-links-to-poster-sessions.html
Lymphomashttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/lymphomas.html
Lymphomas: Translationalhttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/molecular-and-genetic-single-cell-spatial-analyses-aggressive-t-cell-lymphomas.html
Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological:https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/therapies-mantle-cell-lymphoma.html
Hodgkin Lymphomas and T Cell, NK Cell, or NK/T Lymphomashttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/potentially-practice-changing-trials-in-hodgkin-lymphoma.html
Aggressive Lymphomashttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/cars-bispecifics-and-adcs-progress-and-challenges-in-aggressive-b-cell-lymphoma.html
Lymphomas: Links to Poster Sessionshttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/ymphomas-links-to-poster-sessions.html
Chronic Lymphocytic Leukemiashttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/chronic-lymphocytic-leukemias.html
CLL - Clinical and Epidemiological:https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/chronic-lymphocytic-leukemias/cll/frontline-targeted-therapy-combinations.html
Chronic Lymphocytic Leukemia: Link to Postershttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/chronic-lymphocytic-leukemias/chronic-lymphocytic-leukemia-link-to-posters.html
Myelodysplastic Syndromeshttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/myelodysplastic-syndromes.html
MDShttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/mechanisms-and-therapeutic-vulnerabilities-in-molecular-genetic-subtypes-of-mds.html
MDS: Link to Postershttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/myelodysplastic-syndromes/mds-link-to-posters.html
Multiple Myeloma and Plasma Cell Dyscrasiashttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/multiple-myeloma-and-plasma-cell-dyscrasias.html
Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translationalhttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/genomic-and-epigenomic-insights-into-myeloma-outcomes.html
Multiple Myeloma: Clinical and Epidemiologicalhttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/advancing-minimal-residual-disease-mrd-detection-impact-on-prognosis-and-treatment-decisions.html
Multiple Myeloma: Pharmacologic and Cellular Therapieshttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/optimizing-therapy-in-newly-diagnosed-myeloma-and-beyond.html
MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasiashttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/ignored-no-longer-progress-in-al-amyloidosis.html
Multiple Myeloma and Plasma Dyscrasias: Link to Postershttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/multiple-myeloma-and-plasma-cell-dyscrasias-posters.html
CAR-T Cell and Cellular Immunotherapies other than CAR-T Cellshttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/car-t-cell-and-cellular-immunotherapies-other-than-car-t-cells.html
CAR-T Cell and Cellular Immunotherapies other than CAR-T Cellshttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/enhancements-in-car-t-cell-signaling-delivery-Manufacturing.html
Cell Therapieshttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/adoptive-cell-therapies/cell-therapies.html
ESMO Congress 2024 - 13. - 17. SEPTEMBER - BARCELONA, SPANIENhttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024.html
ESMO 2024 Press Conference Recordinghttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024-press-conference-recordings.html
ESMO24 - Presidential Symposia I-IIIhttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/presidential-symposia-i-iii.html
ESMO24 - Presidential Symposia I-IIIhttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/presidential-symposium-i-practice-changing-trials.html
Presidential Symposium I: Practice-changing trials: Sat, 14.09.24; 16:30 - 18:15; Room Barcelona Auditorium - Hall 2https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/presidential-symposium-i-practice-changing-trials.html
Presidential Symposium II: Practice-changing trials; Sun, 15.09.24; 16:30 - 18:15; Room Barcelona Auditorium Hall 2https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/presidential-symposium-ii-practice-changing-trials.html
Presidential Symposium III: Eyes to the future; Mon, 16.09.24; 16:30 - 18:15 Room Barcelona Auditorium - Hall 2https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/presidential-symposium-iii-eyes-to-the-future.html
BREAST CANCERhttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/breast-cancer.html
Interviewshttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/breast-cancer/interviews-von-renate-haidinger-brustkrebs-deutschland-e-v.html
Breast cancer, early stagehttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/breast-cancer-early-stage/proffered-paper-session-I.html
Breast cancer, metastatichttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-breast-cancer-metastatic.html
LUNG CANCER & OTHER THORACIC MALIGNANCIEShttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/lung-cancer-other-thoracic-malignancies.html
Non-metastatic NSCLC and other thoracic malignancieshttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-non-metastatic-nsclc.html
NSCLC, metastatichttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-nsclc-metastatic.html
HEAD & NECK CANCERhttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/head-neck-cancer.html
Head & Neck Sessionshttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-head-and-neck-cancer.html
GYNAECOLOGICAL CANCERShttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/gynaecological-cancers.html
Gynaecological Sessionshttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-gynaecological-cancers.html
CNS TUMOURS & SARCOMAhttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/cns-tumours-sarcoma.html
CNS & SARCOMA Sessionshttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-sarcoma.html
GENITOURINARY TUMOURShttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/genitourinary-tumours.html
Statement Highlights Urothel- und Nierenzellkarzinom: OÄ Dr. Dora Niedersüß-Beke, MBAhttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/statement-highlights-urothel-und-nierenzellkarzinom.html
GU tumours, non-prostatehttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-1-gu-tumours-non-prostate.html
GU tumours, prostatehttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-gu-tumours-prostate.html
GASTROINTESTINAL TUMOURShttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/gastrointestinal-tumours.html
Statement Assoc.-Prof. Priv.-Doz. Dr. Gerald Prager: Neues bei gastrointestinalen Tumorenhttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/gastrointestinal-tumours/statement-gerald-prager.html
GI, upper digestivehttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/gastrointestinal-tumours-upper-digestive/proffered-paper-session-1.html
GI, lower digestivehttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/gastrointestinal-tumours-lower-digestive/proffered-paper-session-1.html
NETs and endocrine tumourshttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/nets-and-endocrine-tumours.html
NETs and endocrine tumours Sessionshttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-nets-and-endocrine-tumours.html
HAEMATOLOGICAL MALIGNANCIEShttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/haematological-malignancies.html
Haematological malignancies Sessionshttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/mini-oral-session-1-haematological-malignancies.html
MELANOMA AND OTHER SKIN TUMOURShttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/melanoma-and-other-skin-tumours.html
Kommentare Prof. Roger von Moos, Direktor Tumor- und Forschungszentrum, Kantonsspital Graubünden, Churhttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/melanoma-and-other-skin-tumours/kommentare-prof-roger-von-moos.html
Melanoma Sessionshttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/proffered-paper-session-melanoma.html
INVESTIGATIONAL IMMUNOTHERAPYhttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/investigational-immunotherapy.html
INVESTIGATIONAL IMMUNOTHERAPYhttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-investigational-immunotherapy.html
SUPPORTIVE AND PALLIATIVE CAREhttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/supportive-and-palliative-care.html
Supportive and palliative care sessionshttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-supportive-and-palliative-care.html
BASIC SCIENCE & TRANSLATIONAL RESEARCH & DEVELOPMENTAL THERAPEUTICShttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/basic-science-translational-research-developmental-therapeutics.html
Basic science & translational research sessions & developmental therapeuticshttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-1-basic-science-translational-research.html
 IASLC 2024 World Conference on Lung Cancerhttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer.html
IASLC World Conference on Lung Cancer Press Briefing Recordingshttps://oncoletter.ch/kongressberichte/id-2024/iaslc-world-conference-on-lung-cancer-press-briefing-recordings.html
PL02 Presidential Symposium 1https://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/pl02-presidential-symposium-1.html
PL04 Presidential Symposium 2https://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/pl04-presidential-symposium-2.html
OA01. Perioperative Strategies 1 - Sep 8 2024 - 10:45AM - 12:00PM - Room 20Ahttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/perioperative-strategies-1.html
OA02. Redefining First-Line EGFR Therapy - Sep 8 2024 - 10:45AM - 12:00PM - Room 20Dhttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/redefining-first-line-egfr-therapy.html
OA04. Antibody Drug Conjugates in SCLC - Sep 8 2024 - 2:00PM - 3:15PM - Room 20Ahttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/antibody-drug-conjugates-in-sclc.html
OA05. Local Consolidative Therapy for Metastatic NSCLC - Sep 8 2024 - 2:00PM - 3:15PM - Room 32ABhttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/local-consolidative-therapy-for-metastatic-nsclc.html
OA06. Novel Immunotherapy Strategies and Combinations - Sep 8 2024 - 3:30PM - 4:45PM - Room 20BChttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/novel-immunotherapy-strategies-and-combinations.html
OA08. The New Generation of Cytotoxics - Sep 9 2024 - 10:45AM - 12:00PM - Room 20Ahttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/the-new-generation-of-cytotoxics.html
OA09. Trailblazing Targets: New Insights - Sep 9 2024 - 10:45AM - 12:00PM - Room 20Dhttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/trailblazing-targets-new-insights.html
OA10. DLL3 Targeting BiTE Therapies in SCLC - Sep 9 2024 - 2:00PM - 3:15PM - Room 20Ahttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/dll3-targeting-bite-therapies-in-sclc.html
OA11. Shifting the Bar in the Front Line Immunotherapy Setting - Sep 9 2024 - 2:00PM - 3:15PM - Room 20BChttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/shifting-the-bar-in-the-front-line-immunotherapy-setting.html
OA12. Advancing Multimodal Therapies in Stage III NSCLC - Sep 9 2024 - 2:00PM - 3:15PM - Room 32ABhttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/advancing-multimodal-therapies-in-stage-iii-nsclc.html
OA13. Perioperative Strategies 2 - Sep 9 2024 - 3:30PM - 4:45PM - Room 20Ahttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/perioperative-strategies-2.html
OA14. New Horizons in Targeting KRAS G12C - Sep 9 2024 - 3:30PM - 4:45PM - Room 20Dhttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/new-horizons-in-targeting-kras.html
OA16. Transforming Cancer Therapy: Biomarkers and Novel ADCs - Sep 10 2024 - 1:30PM - 2:45PM - Room 20Ahttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/transforming-cancer-therapy-biomarkers-and-novel-adcs.html
OA18. Pleural, Mediastinal and Undifferentiated Thoracic Cancers - Sep 10 2024 - 3:00PM - 4:15PM - Room 30BChttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/pleural-mediastinal-and-undifferentiated-thoracic-cancers.html
More Links to Oral Sessionshttps://oncoletter.ch/kongressberichte/id-2024/wclc-2024-more-links-to-oral-sessions.html
MA01. Advances in Treatment for Stage III NSCLC - Sep 8 2024 - 2:00PM - 3:15PM - Room 20BChttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/advances-treatment-stage-iii-nsclc.html
MA06. New Strategies in ALK, ROS1, NTRK, BRAF, and MET NSCLC - Sep 10 2024 - 11:15AM - 12:30PM - Room 20Dhttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/new-strategies-alk-ros1-ntrk-braf-met-nsclc.html
MA11. Building on the Foundations of Current Immunotherapies - Sep 10 2024 - 1:30PM - 2:45PM - Room 20BChttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/building-foundations-current-immunotherapies.html
MA12. Paving the Path to Precision Oncology: Targeting EGFR and HER2 - Sep 10 2024 - 1:30PM - 2:45PM - Room 20Dhttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/precision-oncology-targeting-egfr-and-her2.html
MA16. Strategies Beyond Current Immunotherapies - Sep 10 2024 - 3:00PM - 4:15PM - Room 20BChttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/strategies-beyond-current-immunotherapies.html
MA17. Limited-stage SCLC, Novel Immunotherapy Combinations and Biomarkers in SCLC - Sep 10 2024 - 3:00PM - 4:15PM -Room 20Dhttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/ma17-limited-stage-sclc-novel-immunotherapy-combinations-and-biomarkers-in-sclc-sep-10-2024-3-00pm-4-15pm-room-20d.html
More Links to Mini Oral Sessionshttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/more-links-to-mini-oral-sessions.html
ESMO Gastrointestinal Cancers Congress 2024https://oncoletter.ch/kongressberichte/id-2024/esmo-gastrointestinal-cancers-congress-2024.html
Proffered Paper Sessionhttps://oncoletter.ch/kongressberichte/id-2024/esmo-gastrointestinal-cancers-congress-2024/proffered-paper.html
Proffered Paper Sessionhttps://oncoletter.ch/kongressberichte/id-2024/esmo-gastrointestinal-cancers-congress-2024/mini-oral-sessions.html
Mini Oral Sessionshttps://oncoletter.ch/kongressberichte/id-2024/esmo-gastrointestinal-cancers-congress-2024/mini-oral-sessions.html
Mini Oral sessionshttps://oncoletter.ch/kongressberichte/id-2024/esmo-gastrointestinal-cancers-congress-2024/mini-oral-session1.html
EHA2024 Hybrid Congress - Madrid, June 13-16, 2024.https://oncoletter.ch/kongressberichte/id-2024/eha2024.html
Plenary and Late Breaking Abstract Sessionshttps://oncoletter.ch/kongressberichte/id-2024/eha2024/plenary-and-late-breaking-abstract-sessions.html
Plenary and Late Breaking Abstract Sessionshttps://oncoletter.ch/kongressberichte/id-2024/eha2024/plenary-session.html
Acute Lymphoblastic Leukemiahttps://oncoletter.ch/kongressberichte/id-2024/eha2024/acute-lymphoblastic-leukemia.html
Acute lymphoblastic leukemiahttps://oncoletter.ch/kongressberichte/id-2024/eha2024/all-clinical-1-immunotherapy-antibodies-and-car-t-cells.html
Acute Myeloid Leukemiahttps://oncoletter.ch/kongressberichte/id-2024/eha2024/acute-myeloid-leukemia.html
Acute myeloid leukemiahttps://oncoletter.ch/kongressberichte/id-2024/eha2024/aml-clinical-1-menin-inhibitor.html
Aggressive Non-Hodgkin lymphomahttps://oncoletter.ch/kongressberichte/id-2024/eha2024/aggressive-non-hodgkin-lymphoma.html
Aggressive Non-Hodgkin lymphomahttps://oncoletter.ch/kongressberichte/id-2024/eha2024/aggressive-lymphoma-targeted-drug-therapy.html
Chronic Lymphocytic Leukemia and Related disordershttps://oncoletter.ch/kongressberichte/id-2024/eha2024/chronic-lymphocytic-leukemia.html
Chronic lymphocytic leukemia and related disordershttps://oncoletter.ch/kongressberichte/id-2024/eha2024/novel-therapies-relapsed-refractory-cll-hairy-cell-leukemia.html
Chronic Myeloid Leukemiahttps://oncoletter.ch/kongressberichte/id-2024/eha2024/chronic-myeloid-leukemia.html
Chronic Myeloid Leukemiahttps://oncoletter.ch/kongressberichte/id-2024/eha2024/chronic-myeloid-leukemia-clinical.html
Hodgkin Lymphomahttps://oncoletter.ch/kongressberichte/id-2024/eha2024/hodgkin-lymphoma.html
Hodgkin lymphomahttps://oncoletter.ch/kongressberichte/id-2024/eha2024/hodgkin-lymphoma-clinical.html
Myelodysplastic Syndromeshttps://oncoletter.ch/kongressberichte/id-2024/eha2024/myelodysplastic-syndromes.html
Myelodysplastic Syndromeshttps://oncoletter.ch/kongressberichte/id-2024/eha2024/myelodysplastic-syndromes-clinical.html
Indolent and Mantle-cell non-Hodgkin Lymphomahttps://oncoletter.ch/kongressberichte/id-2024/eha2024/indolent-mantle-cell-non-hodgkin-lymphoma.html
Indolent and Mantle-cell non-Hodgkin Lymphomahttps://oncoletter.ch/kongressberichte/id-2024/eha2024/indolent-and-mantle-cell-non-hodgkin-lymphoma-clinical.html
Myeloma and other monoclonal gammopathieshttps://oncoletter.ch/kongressberichte/id-2024/eha2024/myeloma-and-other-monoclonal-gammopathies.html
Frontline therapy for MMhttps://oncoletter.ch/kongressberichte/id-2024/eha2024/myeloma-and-other-monoclonal-gammopathies/frontline-therapy.html
CAR T cell therapy for the treatment of Multiple Myelomahttps://oncoletter.ch/kongressberichte/id-2024/eha2024/car-t-cell-therapy-for-multiple-myeloma-clinical.html
Novel agents in RRMMhttps://oncoletter.ch/kongressberichte/id-2024/eha2024/myeloma-and-other-monoclonal-gammopathies/novel-agents-clinical.html
Myeloproliferative Neoplasmshttps://oncoletter.ch/kongressberichte/id-2024/eha2024/myeloproliferative-neoplasms.html
Myeloproliferative Neoplasmshttps://oncoletter.ch/kongressberichte/id-2024/eha2024/myeloproliferative-neoplasms-clinical.html
Gene Therapyhttps://oncoletter.ch/kongressberichte/id-2024/eha2024/gene-therapy.html
Stem cell transplantation - Clinical and cell therapyhttps://oncoletter.ch/kongressberichte/id-2024/eha2024/gene-therapy/stem-cell-transplantation-cell-therapy.html
Cellular Immunotherapy and Vaccination - Biology & Translational Researchhttps://oncoletter.ch/kongressberichte/id-2024/eha2024/cellular-immunotherapy-vaccination-biology-translational-research.html
Cellular Immunotherapy and Vaccinationhttps://oncoletter.ch/kongressberichte/id-2024/eha2024/gene-therapy-cellular-immunotherapy-and-vaccination.html
ASCO Annual Meeting 2024 May 31 - June 4, 2024 - McCormick Place, Chicagohttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024.html
Saturday, June 1 - Press Briefingshttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/saturday-june-1-press-briefings.html
Interviews in Kooperation mit info@ONCO-SUISSE, moderiert von Prof. Roger von Moos: Schweizer Experten fassen die ASCO Ergebnisse zusammenhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/interviews-in-kooperation-mit-info-onco-suisse.html
Round Table und Interviews von Renate Haidinger, Brustkrebs Deutschland e.V.https://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/round-table-interviews-renate-haidinger-brustkrebs-deutschland-e-v.html
Plenary sessionhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/plenary-session.html
Plenary Session Late breaking abstracts - Sunday, June 3, 1PM-4PM, Hall B1https://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/plenary-session/abstracts.html
Schweizer Beiträge am ASCO 2024https://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/schweizer-beitraege-asco-2024.html
Links to all Poster Sessionshttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/links-to-all-poster-sessions.html
Breast Cancerhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/breast-cancer.html
Breast Cancer—Local/Regional/Adjuvanthttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/breast-cancer/local-regional-adjuvant-monday-session.html
Breast Cancer—Metastatichttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/breast-cancer/metastatic-saturday-june-1.html
Lung Cancerhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/lung-cancer.html
Lung Cancer - Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancershttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/lung-cancer-non-small-cell-friday.html
Lung Cancer—Non-Small Cell Metastatichttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/lung-cancer-non-small-cell-metastatic/friday.html
Gastrointestinal Cancerhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/gastrointestinal-cancer.html
Gastrointestinal Cancer—Colorectal and Analhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/colorectal-and-anal-sunday.html
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliaryhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/cancer-oral-gastroesophageal-pancreatic-and-hepatobiliary-tuesday.html
Genitourinary Cancerhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/genitourinary-cancer.html
Genitourinary Cancer—Kidney and Bladderhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/genitourinary-cancer-kidney-and-bladder-monday.html
Genitourinary Cancer—Prostate, Testicular, and Penilehttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/genitourinary-cancer-prostate-testicular-and-penile-saturday.html
Gynecologic Cancerhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/gynecologic-cancer.html
Gynecologic Cancerhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/gynecologic-cancer-sunday.html
Central Nervous System Tumorshttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/central-nervous-system-tumors.html
Central Nervous System Tumorshttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/central-nervous-system-tumors-monday.html
Head and Neck Cancerhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/head-and-neck-cancer.html
Head and Neck Cancerhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/head-and-neck-cancer-tuesday.html
Melanoma/Skin Cancershttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/melanoma-skin-cancers.html
Melanoma/Skin Cancershttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/melanoma-skin-cancers-friday.html
Sarcomahttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/sarcoma.html
Sarcomahttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/sarcoma-monday.html
Pediatric Oncologyhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/pediatric-oncology.html
Pediatric Oncologyhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/pediatric-oncology-sunday.html
Hematologic Malignancieshttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/hematologic-malignancies.html
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplanthttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/leukemia-myelodysplastic-syndromes-allotransplant-friday.html
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemiahttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/lymphoma-chronic-lymphocytic-leukemia-saturday.html
Hematologic Malignancies—Plasma Cell Dyscrasiahttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/plasma-cell-dyscrasia-monday.html
Developmental Therapeuticshttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/developmental-therapeutics.html
Developmental Therapeutics—Immunotherapyhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/immunotherapy-monday.html
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biologyhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/developmental-therapeutics-molecularly-targeted-agents-and-tumor-biology-saturday.html
ESGO - 25th European Congress on Gynaecological Oncologyhttps://oncoletter.ch/kongressberichte/id-2024/esgo-25th-european-congress-on-gynaecological-oncology.html
Best Oral Session - Late Breaking Abstractshttps://oncoletter.ch/kongressberichte/id-2024/esgo-25th-european-congress-on-gynaecological-oncology/best-oral-session-late-breaking-abstracts.html
Best Oral Session - Cervical Cancerhttps://oncoletter.ch/kongressberichte/id-2024/esgo-25th-european-congress-on-gynaecological-oncology/best-oral-session-cervical-cancer.html
Mini Oral Session - Cervical Cancerhttps://oncoletter.ch/kongressberichte/id-2024/esgo-25th-european-congress-on-gynaecological-oncology/mini-oral-session-cervical-cancer.html
Best Oral Session - Endometrial Cancerhttps://oncoletter.ch/kongressberichte/id-2024/esgo-25th-european-congress-on-gynaecological-oncology/best-oral-session-endometrial-cancer.html
Mini Oral Session - Endometrial Cancerhttps://oncoletter.ch/kongressberichte/id-2024/esgo-25th-european-congress-on-gynaecological-oncology/mini-oral-session-endometrial-cancer.html
Best Oral Session - Ovarian Cancerhttps://oncoletter.ch/kongressberichte/id-2024/esgo-25th-european-congress-on-gynaecological-oncology/best-oral-session-ovarian-cancer.html
Mini Oral Session - Ovarian Cancerhttps://oncoletter.ch/kongressberichte/id-2024/esgo-25th-european-congress-on-gynaecological-oncology/mini-oral-session-ovarian-cancer.html
Mini Oral Session - Miscellaneous Cancershttps://oncoletter.ch/kongressberichte/id-2024/esgo-25th-european-congress-on-gynaecological-oncology/mini-oral-session-miscellaneous-cancers.html
Young Investigator Sessionhttps://oncoletter.ch/kongressberichte/id-2024/esgo-25th-european-congress-on-gynaecological-oncology/young-investigator-session.html
Best Three Minutes Presentationshttps://oncoletter.ch/kongressberichte/id-2024/esgo-25th-european-congress-on-gynaecological-oncology/best-three-minutes-presentations.html
EBMT-EHA 6th European CAR T-cell Meetinghttps://oncoletter.ch/kongressberichte/id-2024/ebmt-eha-6th-european-car-t-cell-meeting.html
EBMT-EHA 6th European CAR T-cell Meetings Best Abstractshttps://oncoletter.ch/kongressberichte/id-2024/ebmt-eha-6th-european-car-t-cell-meetings-best-abstracts.html
ASCO Genitourinary Cancers Symposiumhttps://oncoletter.ch/kongressberichte/id-2024/ascogenitourinary-cancers-symposium.html
Rapid Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/id-2024/ascogenitourinary-cancers-symposium/rapid-abstract-sessions.html
Rapid Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/id-2024/ascogenitourinary-cancers-symposium/rapid-oral-abstract-session-a-prostate-cancer.html
Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/id-2024/ascogenitourinary-cancers-symposium/oral-abstract-sessions.html
Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/id-2024/ascogenitourinary-cancers-symposium/oral-abstract-sessions/oral-abstract-sessions.html
Trials in Progress Poster Sessionshttps://oncoletter.ch/kongressberichte/id-2024/ascogenitourinary-cancers-symposium/trials-in-progress-poster-sessions.html
Trials in Progress Poster Sessionshttps://oncoletter.ch/kongressberichte/id-2024/ascogenitourinary-cancers-symposium/trials-in-progress-poster-sessions/trials-in-progress-poster-sessions/trials-in-progress-poster-session-a-prostate-cancer.html
ASCO 2024 Gastrointestinal (GI) Cancers Symposiumhttps://oncoletter.ch/kongressberichte/id-2024/asco2024-gastrointestinal-gi-cancers-symposium.html
Rapid Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/id-2024/asco2024-gastrointestinal-gi-cancers-symposium/rapid-abstract-sessions.html
Rapid Abstract Sessionshttps://oncoletter.ch/kongressberichte/id-2024/asco2024-gastrointestinal-gi-cancers-symposium/rapid-oral-abstract-session-a-cancers-of-the-esophagus-and-stomach.html
Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/id-2024/asco2024-gastrointestinal-gi-cancers-symposium/oral-abstract-sessions.html
Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/id-2024/asco2024-gastrointestinal-gi-cancers-symposium/oral-abstract-session-a-cancers-of-the-esophagus-and-stomach.html
Trials in Progress Poster Sessionshttps://oncoletter.ch/kongressberichte/id-2024/asco2024-gastrointestinal-gi-cancers-symposium/trials-in-progress-poster-sessions.html
Trials in Progress Poster Sessionshttps://oncoletter.ch/kongressberichte/id-2024/asco2024-gastrointestinal-gi-cancers-symposium/trials-in-progress-poster-session-a-cancers-of-the-esophagus-and-stomach-and-other-gastrointestinal-cancers.html
2023https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023.html
65th ASH Annual Meeting and Exposition - December 09-12, 2023https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023.html
ASH Press Briefings on Late Breaking and other important Abstractshttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/ash-press-briefings-on-late-breaking-and-other-important-abstracts.html
ASH Press Briefingshttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/acute-lymphoblastic-leukemias/all-clinical-and-epidemiological-studies/coming-soon.html
Late-Breaking Abstracts Sessionhttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/late-breaking-abstracts-session.html
Acute Lymphoblastic Leukemiashttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/acute-lymphoblastic-leukemias.html
ALL: Clinical and Epidemiological studieshttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/late-breaking-abstracts-session/tuesday-december-12-2023.html
ALL: Therapies, Excluding Transplantation and Cellular Immunotherapieshttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/acute-lymphoblastic-leukemias/all-therapies-excluding-transplantation-and-cellular-immunotherapies/.html
Acute Myeloid Leukemiashttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/acute-myeloid-leukemias.html
AML: Clinical and Epidemiological studieshttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/acute-myeloid-leukemias/aml-clinical-and-epidemiological-studies/real-world-outcomes-and-treatment-approaches-sunday-december-10-2023-4-30-pm-6-00-pm-pacific-ballroom-salon.html
AML: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapieshttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/acute-myeloid-leukemias/commercially-available-therapies-excluding-transplantation-and-cellular-immunotherapi.html
AML: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapieshttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/acute-myeloid-leukemias/investigational-therapies-excluding-transplantation-cellular-immunotherapies-upcoming.html
AML: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosishttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/acute-myeloid-leukemias/biomarkers-molecular-markers-and-minimal-residual-disease-in-diagnosis-and-prognosis-ris.html
Chronic Myeloid Leukemiahttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/chronic-myeloid-leukemia.html
CML: Clinical and Epidemiological studieshttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/chronic-myeloid-leukemia/cml-clinical-and-epidemiological-treatment-free-remission-and-prognostication-sunday.html
Myeloproliferative Syndromes and Chronic Myeloid Leukemiahttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/myeloproliferative-syndromes-and-chronic-myeloid-leukemia.html
MPS and CML: Basic and Translationalhttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/mps-and-cml-basic-and-translational-lineage-tracing-and-novel-target-discovery.html
MPS: Clinical and Epidemiologicalhttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/mps-clinical-and-epidemiological-rare-myeloproliferative-neoplasms-unveiling-promising-pathways-and-novel-therapies.html
Lymphomashttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/lymphomas.html
Lymphomas: Translationalhttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/lymphomas-translational-molecular-and-genetic-microenvironment-and-methylome-in-lymphoma-and-misc-saturday.html
Mantle Cell, Follicular, and Other Indolent B Cell Lymphomashttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/mantle-cell-follicular-and-other-indolent-b-cell-lymphomas-clinical-and-epidemiological-immunotherapy.html
Hodgkin Lymphomas and T/NK cell Lymphomashttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/hodgkin-lymphomas-and-t-nk-cell-lymphomas-clinical-and-epidemiological-topics-in-t-cell-szary-and-hodgkin-lymphomas.html
Aggressive Lymphomashttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/aggressive-lymphomas-prospective-therapeutic-trials-novel-therapies-for-relapsed-refractory-aggressive-lymphoma.html
Chronic Lymphocytic Leukemiashttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/chronic-lymphocytic-leukemias.html
CLLhttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/cll/chronic-lymphocytic-leukemias-basic-and-translational-molecular-determinants-of-cll-and-richter-transformation.html
Myelodysplastic Syndromeshttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/myelodysplastic-syndromes.html
MDShttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/mps-and-cml-basic-and-translational-lineage-tracing-and-novel-target-discovery.html
Multiple Myeloma and Plasma Cell Dyscrasiashttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/multiple-myeloma-and-plasma-cell-dyscrasias.html
Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translationalhttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/multiple-myeloma-and-plasma-cell-dyscrasias-basic-and-translational-spatial-dissection-and-multiomics-analysis-of-the-multiple-myelom-Microenvironment.html
Multiple Myeloma: Clinical and Epidemiologicalhttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/multiple-myeloma-clinical-and-epidemiological-t-cell-redirecting-therapy-outcomes-and-associated-complications.html
Multiple Myeloma: Prospective Therapeutic Trialshttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/multiple-myeloma-prospective-therapeutic-trials-smoldering-and-newly-diagnosed-myeloma-saturday-december-9-2023.html
MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasiashttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/mgus-amyloidosis-other-non-myeloma-plasma-cell-dyscrasias-clinical-epidemiological-screening-to-vaccines-spectrum-of-plasma-cell-disorders.html
Cellular Immunotherapieshttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/cellular-immunotherapies.html
Cellular Immunotherapies: Late Phase and Commercially Available Therapieshttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/cellular-immunotherapie-late-phase-and-commercially-available-therapies/cellular-therapy-for-b-cell-lymphomas-prospective-clinical-trials-and-real-world-data.html
46th SAN ANTONIO BREAST CANCER SYMPOSIUM - December 5 - 9, 2023, San Antonio Texashttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium.html
Studies presented at the SABCS 2023 Press Briefinghttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/studies-presented-at-the-sabcs-2023-press-briefing.html
Interviews von Renate Haidinger, Brustkrebs Deutschland e.V.https://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/interviews-von-renate-haidinger-brustkrebs-deutschland-e-v.html
Kurze Videos mit Expert:innen zu ausgewählten Highlights aus Sitzungen und Vorträgen sowie speziellen Schwerpunktthemenhttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/kurze-videos-mit-expert-innen-zu-ausgewaehlten-highlights-aus-sitzungen-und-vortraegen-sowie-speziellen-schwerpunktthemen.html
General Sessions 1-3https://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/general-sessions-1-3.html
General Sessionshttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium-2023/general-session-1.html
Rapid Fire Sessions 1&2https://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/rapid-fire-sessions-1-2.html
Rapid Fire Sessions 1&2https://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/rapid-fire-session-1.html
Late Breaking Abstracts Oral Sessionhttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/late-breaking-abstracts-oral-session.html
Late Breaking Abstracts Oral Sessionhttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/late-breaking-abstracts-oral-session/late-breaking-abstracts-oral-session-friday-december-8.html
POSTER SPOTLIGHT SESSIONS 1-18https://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/poster-spotlight-sessions-1-18.html
POSTER SPOTLIGHT SESSIONShttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/poster-spotlight-sessions-1-less-is-more-minimizing-surgical-treatment-in-patients-with-early-stage-breast-cancer.html
ESMO Congress 2023 - 20. - 24. OKTOBER - MADRID, SPANIENhttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien.html
ESMO23 - Presidential Symposia I-IIIhttps://oncoletter.ch/kongressberichte/id-2023/presidential-symposia-i-iii.html
ESMO23 - Presidential Symposia I-IIIhttps://oncoletter.ch/kongressberichte/id-2023/presidential-symposium-i-sat-21-10-2023-16-30-18-15.html
BREAST CANCERhttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/esmo-23-breast-cancer.html
Interviewshttps://oncoletter.ch/kongressberichte/id-2023/interviews-von-renate-haidinger-brustkrebs-deutschland-e-v.html
Breast cancer, early stagehttps://oncoletter.ch/kongressberichte/id-2023/breast-cancer/breast-cancer-early-stage/proffered-paper-session-breast-cancer-early-stage.html
Breast cancer, metastatic.https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/proffered-paper-session-breast-cancer-metastatic.html
LUNG CANCER & OTHER THORACIC MALIGNANCIEShttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/lung-cancer-other-thoracic-malignancies.html
Statement ESMO Highlights Lungenkrebs Prof. Dr. med. Alessandra Curioni-Fontecedro, Fribourghttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/lung-cancer-other-thoracic-malignancies/statement-esmo-highlights-lungenkrebs-prof-dr-med-alessandra-curioni-fontecedro-fribourg/statement.html
Non-metastatic NSCLC and other thoracic malignancieshttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/lung-cancer-other-thoracic-malignancies/proffered-paper-session-non-metastatic-nsclc-and-other-thoracic-malignancies.html
NSCLC, metastatichttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/lung-cancer-other-thoracic-malignancies/nsclc-metastatic/proffered-paper-session-nsclc-metastatic.html
HEAD & NECK CANCERhttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/head-neck-cancer.html
Statement Highlights Head and Neck Cancer - Assoz.-Prof. Priv.-Doz. Dr. Thorsten Füreder, Wienhttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/head-neck-cancer/statement-highlights-head-and-neck-cancer-assoz-prof-priv-doz-dr-thorsten-fuereder-wien-coming-soon.html
Head & Neck Sessionshttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/proffered-paper-session-head-neck-cancer.html
GYNAECOLOGICAL CANCERShttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/gynaecological-cancers.html
Interviews von Renate Haidinger, Brustkrebs Deutschland e.V. mit Prof. Dr. med. Sven Mahner - Highlights Gynäkologische Tumorenhttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/gynaecological-cancers/interviews-kopie/interviews-von-renate-haidinger-brustkrebs-deutschland-e-v-mit-prof-dr-med-sven-mahner.html
Gynaecological Sessionshttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/proffered-paper-session-1-gynaecological-cancers-fri-20-10-2023-16-00-17-30.html
CNS TUMOURS & SARCOMAhttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/cns-tumours-sarcoma.html
CNS & SARCOMA Sessionshttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/proffered-paper-session-cns-tumours-fri-20-10-2023-16-00-17-30.html
GENITOURINARY TUMOURShttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/genitourinary-tumours.html
GU tumours, non-prostate.https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/proffered-paper-sessions-1-gu-tumours-non-prostate-sat-21-10-2023-08-30-09-50.html
GU tumours, prostatehttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/gu-tumours-prostate/proffered-paper-session-gu-tumours-prostate-fri-20-10-2023-16-00-17-20.html
GASTROINTESTINAL TUMOURShttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/gastrointestinal-tumours.html
GI, upper digestivehttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/gi-upper-digestive/proffered-paper-sessions-1-gi-upper-digestive-fri-20-10-2023-14-00-15-40.html
GI, lower digestivehttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/gastrointestinal-tumours/proffered-paper-session-gi-lower-digestive-mon-23-10-2023-08-30-10-00.html
NETs and endocrine tumourshttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/nets-and-endocrine-tumours.html
NETs and endocrine tumours Sessionshttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/proffered-paper-session-nets-and-endocrine-tumours-sun-22-10-2023-08-30-10-00.html
HAEMATOLOGICAL MALIGNANCIEShttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/haematological-malignancies.html
Haematological malignancies Sessionshttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/proffered-paper-session-haematological-malignancies-sun-22-10-2023-16-30-18-00.html
MELANOMA AND OTHER SKIN TUMOURShttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/melanoma-and-other-skin-tumours.html
Melanoma Sessionshttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/proffered-paper-session-melanoma-and-other-skin-tumours-mon-23-10-2023-08-30-10-00.html
INVESTIGATIONAL IMMUNOTHERAPYhttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/investigational-immunotherapy.html
INVESTIGATIONAL IMMUNOTHERAPYhttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/proffered-paper-session-investigational-immunotherapy-mon-23-10-2023-10-15-11-40.html
BASIC SCIENCE & TRANSLATIONAL RESEARCH & DEVELOPMENTAL THERAPEUTICS (Kopie)https://oncoletter.ch/3186.html
Basic science & translational research sessions & developmental therapeuticshttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/proffered-paper-session-1-basic-science-translational-research-sat-21-10-2023-10-15-11-45.html
SUPPORTIVE AND PALLIATIVE CAREhttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/supportive-and-palliative-care.html
Supportive and palliative care sessionshttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/supportive-and-palliative-care/proffered-paper-session-supportive-and-palliative-care-fri-20-10-2023-16-00-17-20.html
 IASLC 2023 World Conference on Lung Cancerhttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer.html
IASLC World Conference on Lung Cancer Press Briefing Recordingshttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/iaslc-world-conference-on-lung-cancer-press-briefing-recordings.html
Oral Session: Advancing Immunotherapy in ES-SCLChttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/oral-session-advancing-immunotherapy-in-es-sclc.html
Oral Session: Evolving Landscape in Mesotheliomahttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/oral-session-evolving-landscape-in-mesothelioma.html
Oral Session: Newer Generation Treatments for EGFR, ALK and ROS1https://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/oral-session-newer-generation-treatments-for-egfr-alk-and-ros1.html
Oral Session: Antibody Drug Conjugates: The Next Tsunamihttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/oral-session-antibody-drug-conjugates-the-next-tsunami.html
Oral Session: Immunotherapy for Advanced NSCLChttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/oral-session-immunotherapy-for-advanced-nsclc.html
Oral Session: Pushing the Boundaries: Adjuvant & Neoadjuvant Approaches in Early NSCLChttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/oral-session-pushing-the-boundaries-adjuvant-and-neoadjuvant-approaches-in-early-stage-non-small-cell-lung-cancer.html
Oral Session: Immune Checkpoint Therapy: Long Term Follow Uphttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/oral-session-immune-checkpoint-therapy-long-term-follow-up.html
Oral Session: MET Matters in NSCLChttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/oral-session-met-matters-in-nsclc.html
Oral Session: Integration of Local Therapies with Modern Immune Checkpoint Inhibitors and Targeted Therapies in Metastatic NSCLC: When and How?https://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/oral-session-integration-of-local-therapies-with-modern-immune-checkpoint-inhibitors-and-targeted-therapies-in-metastatic-nsclc-when-and-how.html
Oral Session: Next Steps in Locally Advanced NSCLC: Optimizing Techniques & Choosing Populations That Benefithttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/oral-session-next-steps-in-locally-advanced-nsclc-optimizing-techniques-choosing-populations-that-benefit.html
More Links to Oral Sessionshttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/more-links-to-oral-sessions.html
Mini Oral Session: Targeted Therapy: KRAS and Beyondhttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/mini-oral-session-targeted-therapy-kras-and-beyond.html
Mini Oral Session: Mediastinal Lumps and Bumpshttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/mini-oral-session-mediastinal-lumps-and-bumps.html
Mini Oral Session: New Technology and Innovations in Early Stage Lung Cancerhttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/mini-oral-session-new-technology-and-innovations-in-early-stage-lung-cancer.html
Mini Oral Session: Targeted Therapy: EGFR and HER2https://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/mini-oral-session-targeted-therapy-egfr-and-her2.html
Mini Oral Session: Bringing New Discoveries into Early Phase Clinical Trialshttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/mini-oral-session-bringing-new-discoveries-into-early-phase-clinical-trials.html
Mini Oral Session: Innovations in the Treatment of Stage III NSCLChttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/mini-oral-session-innovations-in-the-treatment-of-stage-iii-nsclc.html
Mini Oral Session: Current Standards and Future Directions in Mesotheliomahttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/mini-oral-session-current-standards-and-future-directions-in-mesothelioma.html
Mini Oral Session: Refining Practice and Redefining Standards in SCLChttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/mini-oral-session-refining-practice-and-redefining-standards-in-sclc.html
More Links to Mini Oral Sessionshttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/more-links-to-mini-oral-sessions.html
ESMO World Congress on Gastrointestinal Cancer (ESMO World GI 2023)https://oncoletter.ch/kongressberichte/id-2023/esmo-world-congress-on-gastrointestinal-cancer-2023.html
Session II: Cancer of the Pancreashttps://oncoletter.ch/kongressberichte/id-2023/esmo-world-congress-on-gastrointestinal-cancer-2023/session-ii-cancer-of-the-pancreas.html
Session III: Cancer of the Biliary Tracthttps://oncoletter.ch/kongressberichte/id-2023/esmo-world-congress-on-gastrointestinal-cancer-2023/session-iii-cancer-of-the-biliary-tract-2.html
Session V: Presentation of Selected Abstracts – Biliary Tract and Pancreatic Cancerhttps://oncoletter.ch/kongressberichte/id-2023/esmo-world-congress-on-gastrointestinal-cancer-2023/session-v-presentation-of-selected-abstracts-biliary-tract-and-pancreatic-cancer.html
Session VI: Presentation of Selected Abstracts - Esophageal and Stomach Cancershttps://oncoletter.ch/kongressberichte/id-2023/esmo-world-congress-on-gastrointestinal-cancer-2023/session-vi-presentation-of-selected-abstracts-esophageal-and-stomach-cancers.html
Session VIII: Esophageal and Gastric Cancershttps://oncoletter.ch/kongressberichte/id-2023/esmo-world-congress-on-gastrointestinal-cancer-2023/session-viii-esophageal-and-gastric-cancers.html
Session IX: Hepatocellular Cancerhttps://oncoletter.ch/kongressberichte/id-2023/esmo-world-congress-on-gastrointestinal-cancer-2023/session-ix-hepatocellular-cancer.html
Session XI: Presentation of Selected Abstracts: Colorectal Cancerhttps://oncoletter.ch/kongressberichte/id-2023/esmo-world-congress-on-gastrointestinal-cancer-2023/session-xi-presentation-of-selected-abstracts-colorectal-cancer.html
Session XVIII: Immune Mechanisms and Microbiome in GI Tumorshttps://oncoletter.ch/kongressberichte/id-2023/esmo-world-congress-on-gastrointestinal-cancer-2023/session-xviii-immune-mechanisms-and-microbiome-in-gi-tumors.html
Session XIX: Predicting and Managing Rare Toxicities in Patients With GI Cancershttps://oncoletter.ch/kongressberichte/id-2023/esmo-world-congress-on-gastrointestinal-cancer-2023/session-xix-predicting-and-managing-rare-toxicities-in-patients-with-gi-cancers.html
Session XX: Presentation of Selected Abstracts: Metastatic Colorectal Cancerhttps://oncoletter.ch/kongressberichte/id-2023/esmo-world-congress-on-gastrointestinal-cancer-2023/session-xx-presentation-of-selected-abstracts-metastatic-colorectal-cancer.html
Session XXIII: Colorectal Cancer: Metastatic Diseasehttps://oncoletter.ch/kongressberichte/id-2023/esmo-world-congress-on-gastrointestinal-cancer-2023/session-xxiii-colorectal-cancer-metastatic-disease.html
EHA2023 Congresshttps://oncoletter.ch/kongressberichte/id-2023/eha2023-congress.html
Plenary Sessionhttps://oncoletter.ch/kongressberichte/id-2023/eha2023-congress/plenary-session.html
EHA 2023 Press Briefing, Friday, June 9https://oncoletter.ch/kongressberichte/id-2023/eha2023-congress/eha-2023-press-briefing-friday-june-9.html
Late Breaking Abstracts Sessionhttps://oncoletter.ch/kongressberichte/id-2023/late-breaking-abstracts-session.html
Acute lymphoblastic leukemiahttps://oncoletter.ch/kongressberichte/id-2023/eha2023-congress/acute-lymphoblastic-leukemia.html
Acute myeloid leukemiahttps://oncoletter.ch/kongressberichte/id-2023/eha2023-congress/acute-myeloid-leukemia.html
Aggressive Non-Hodgkin lymphomahttps://oncoletter.ch/kongressberichte/id-2023/eha2023-congress/aggressive-non-hodgkin-lymphoma.html
Chronic lymphocytic leukemiahttps://oncoletter.ch/kongressberichte/id-2023/eha2023-congress/chronic-lymphocytic-leukemia.html
Chronic myeloid leukemiahttps://oncoletter.ch/kongressberichte/id-2023/eha2023-congress/chronic-myeloid-leukemia.html
Myeloma and other monoclonal gammopathies - Clinicalhttps://oncoletter.ch/kongressberichte/id-2023/eha2023-congress/myeloma-and-other-monoclonal-gammopathies-clinical.html
Gene therapy, cellular immunotherapy and vaccinationhttps://oncoletter.ch/kongressberichte/id-2023/eha2023-congress/gene-therapy-cellular-immunotherapy-and-vaccination.html
Hodgkin lymphomahttps://oncoletter.ch/kongressberichte/id-2023/eha2023-congress/hodgkin-lymphoma.html
Indolent and mantle-cell non-Hodgkin lymphoma/Waldenströmhttps://oncoletter.ch/kongressberichte/id-2023/eha2023-congress/indolent-and-mantle-cell-non-hodgkin-lymphoma-waldenstroem.html
Myelodysplastic syndromeshttps://oncoletter.ch/kongressberichte/id-2023/eha2023-congress/myelodysplastic-syndromes.html
Myeloproliferative neoplasmshttps://oncoletter.ch/kongressberichte/id-2023/eha2023-congress/myeloproliferative-neoplasms.html
Stem cell transplantationhttps://oncoletter.ch/kongressberichte/id-2023/eha2023-congress/stem-cell-transplantation.html
ASCO Annual Meeting, June 2-6, 2023 - McCormick Place, Chicagohttps://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023.html
Late-Breaking Abstract -, Plenary - & Highlights of the Day Sessionshttps://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023/late-breaking-abstract-plenary-highlights-of-the-day-sessions.html
Interviews in Kooperation mit info@ONCO-SUISSE, moderiert von Prof. Roger von Moos: Schweizer Experten fassen die ASCO Ergebnisse zusammenhttps://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023/interviews-in-kooperation-mit-info-onco-suisse-moderiert-von-prof-roger-von-moos-schweizer-experten-fassen-die-asco-ergebnisse-zusammen.html
Round Table und Interviews von Renate Haidinger, Brustkrebs Deutschland e.V.https://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023/round-table-und-interviews-von-renate-haidinger-brustkrebs-deutschland-e-v.html
Saturday, June 3 & Sunday June 4, On-Site Press Briefingshttps://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023/asco-2023-press-briefing-late-breaking-abstracts/saturday-june-3-on-site-briefing.html
Lung Cancer: Oral & Poster Discussion Sessionshttps://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023/lung-cancer-oral-poster-discussion-sessions.html
Head and Neck Cancer: Oral & Poster Discussion Sessionshttps://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023/head-and-neck-cancer-oral-poster-discussion-sessions.html
Breast Cancer: Oral & Poster Discussion Sessionshttps://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023/breast-cancer-oral-poster-discussion-sessions.html
Gynecologic Cancer: Oral & Poster Discussion Sessionshttps://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023/gynecologic-cancer-oral-poster-discussion-sessions-kopie.html
Gastrointestinal Cancer: Oral & Poster Discussion Sessionshttps://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023/gastrointestinal-cancer-oral-poster-discussion-sessions.html
Sarcoma Cancer: Oral & Poster Discussion Sessions.https://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023/sarcoma-cancer-oral-poster-discussion-sessions.html
Melanoma/Skin Cancers: Oral & Poster Discussion Sessions.https://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023/melanoma-skin-cancers-oral-poster-discussion-sessions.html
Central Nervous System Tumors: Oral & Poster Discussion Sessions.https://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023/central-nervous-system-tumors-oral-poster-discussion-sessions.html
Genitourinary Cancer: Oral & Poster Discussion Sessionshttps://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023/genitourinary-cancer-oral-poster-discussion-sessions.html
Hematologic Malignancies: Oral & Poster Discussion Sessionshttps://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023/hematologic-malignancies-oral-poster-discussion-sessions.html
Developmental Therapeutics: Oral & Poster Discussion Sessionshttps://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023/developmental-therapeutics-oral-poster-discussion-sessions.html
Pediatric Oncology: Oral & Poster Discussion Sessionshttps://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023/pediatric-oncology-oral-poster-discussion-sessions.html
Comprehensive Cancer Center Zürich: Patientenakademie – Brustkrebshttps://oncoletter.ch/kongressberichte/patientenakademie-brustkrebs.html
Neuigkeiten in der Behandlung und Nachsorge bei Brustkrebshttps://oncoletter.ch/kongressberichte/patientenakademie-brustkrebs/neuigkeiten-in-der-behandlung-und-nachsorge-bei-brustkrebs.html
18th St.Gallen International Breast Cancer Conference 2023 (SGBCC)https://oncoletter.ch/kongressberichte/id-2023/sgbcc-18th-st-gallen-international-breast-cancer-conference-2023.html
Interviews von Renate Haidinger, Brustkrebs Deutschland e.V. mit:https://oncoletter.ch/kongressberichte/id-2023/sgbcc-18th-st-gallen-international-breast-cancer-conference-2023/interviews-von-renate-haidinger-brustkrebs-deutschland-e-v-mit-kopie.html
ASCO Genitourinary Cancers Symposium 2023https://oncoletter.ch/kongressberichte/id-2023/ascogenitourinary-cancers-symposium-2023.html
General Sessionshttps://oncoletter.ch/kongressberichte/id-2023/ascogenitourinary-cancers-symposium-2023/general-sessions.html
Rapid Abstract Sessionshttps://oncoletter.ch/kongressberichte/id-2023/ascogenitourinary-cancers-symposium-2023/rapid-abstract-sessions.html
Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/id-2023/ascogenitourinary-cancers-symposium-2023/oral-abstract-sessions.html
Statements zu den Highlights des ASCO-GUhttps://oncoletter.ch/kongressberichte/id-2023/ascogenitourinary-cancers-symposium-2023/statements-zu-den-highlights-des-asco-gu.html
ASCO 2023 Gastrointestinal (GI) Cancers Symposiumhttps://oncoletter.ch/kongressberichte/id-2023/asco2023-gastrointestinal-gi-cancers-symposium.html
Rapid Abstract Sessionshttps://oncoletter.ch/kongressberichte/id-2023/asco2023-gastrointestinal-gi-cancers-symposium/rapid-abstract-sessions.html
Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/id-2023/asco2023-gastrointestinal-gi-cancers-symposium/oral-abstract-sessions.html
Links to more Abstractshttps://oncoletter.ch/kongressberichte/id-2023/asco2023-gastrointestinal-gi-cancers-symposium/links-to-more-abstracts.html
2021https://oncoletter.ch/Kongressberichte/2021/63rd-ASH-Annual-Meeting-and-Exposition_December-11-14-2021.html
63rd ASH Annual Meeting and Exposition - December 11-14, 2021https://oncoletter.ch/Kongressberichte/2021/63rd-ASH-Annual-Meeting-and-Exposition_December-11-14-2021.html
Late-Breaking Abstracts Sessionhttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/Late-Breaking-Abstracts-Session_63rd-ASH.html
Press Briefinghttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/press-briefing.html
ALLhttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/ALL.html
AMLhttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/aml/acute-myeloid-leukemia-clinical-and-epidemiological.html
Acute Myeloid Leukemia: Clinical and Epidemiologicalhttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/aml/acute-myeloid-leukemia-clinical-and-epidemiological.html
Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapieshttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/aml/acute-myeloid-leukemias-commercially-available-therapies-excluding-transplantation-and-cellular-immunotherapies.html
Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapieshttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/aml/acute-myeloid-leukemias-investigational-therapies-excluding-transplantation-and-cellular-immunotherapies.html
Lymphomahttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/cml/mantle-cell-follicular-and-other-b-cell-lymphomas.html
Mantle Cell, Follicular, and Other B-Cell Lymphomashttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/cml/mantle-cell-follicular-and-other-b-cell-lymphomas.html
Hodgkin Lymphomas and T/NK cell Lymphomashttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/lymphoma/hodgkin-lymphomas-and-t-nk-cell-lymphomas.html
Aggressive Lymphomas Prospective Therapeutic Trialshttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/lymphoma/aggressive-lymphomas-prospective-therapeutic-trials.html
Aggressive Lymphomas: Clinical and Epidemiologicalhttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/lymphoma/aggressive-lymphomas-clinical-and-epidemiological.html
CMLhttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/cml.html
Myeloproliferative Syndromeshttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/myeloproliferative-syndromes.html
MDShttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/mds.html
CLLhttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/cll.html
Multiple Myelomahttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/multiple-myeloma/multiple-myeloma-and-plasma-cell-dyscrasias-clinical-and-epidemiological.html
Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiologicalhttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/multiple-myeloma/multiple-myeloma-and-plasma-cell-dyscrasias-clinical-and-epidemiological.html
Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trialshttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/multiple-myeloma/myeloma-and-plasma-cell-dyscrasias-clinical-prospective-therapeutic-trials.html
Cellular Therapieshttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/cellular-therapies.html
SAN ANTONIO BREAST CANCER SYMPOSIUM - December 7 - 11, 2021, San Antonio Texashttps://oncoletter.ch/Kongressberichte/2021/san-antonio-breast-cancer-symposium-december-7-11-2021-san-antonio-texas.html
Interviews von Renate Haidinger, Brustkrebs Deutschland e.V. mit:https://oncoletter.ch/kongressberichte-2021/sabcs/interviews.html
General Sessions 1-4https://oncoletter.ch/kongressberichte-2021/san-antonio-breast-cancer-symposium-december-7-11-2021-san-antonio-texas/general-sessions-1-4.html
9. Interdisziplinäres Prostatakarzinom-Symposium, St. Gallen, 2. Dezember 2021https://oncoletter.ch/Kongressberichte/2021/9-interdisziplinaeres-prostatakarzinom-symposium-st-gallen-2-dezember-2021.html
Vorträge Block I: Aktuelle Trends in Diagnose und Therapie des Prostatakarzinomshttps://oncoletter.ch/id-2021/9-interdisziplinaeres-prostatakarzinom-symposium-st-gallen-2-dezember-2021/vortraege-block-i-aktuelle-trends-in-diagnose-und-therapie-des-prostatakarzinoms.html
Vorträge Block II: Indikationsstellung in der Therapie des Prostatakarzinoms und Aspekte der Lebensqualitäthttps://oncoletter.ch/id-2021/9-interdisziplinaeres-prostatakarzinom-symposium-st-gallen-2-dezember-2021/vortraege-block-ii-indikationsstellung-in-der-therapie-des-prostatakarzinoms-und-aspekte-der-lebensqualitaet.html
Kongressberichte Archiv 2021https://archiv.oncoletter.ch/kongressberichte-2020.html
Kongressberichte Archiv 2020https://archiv.oncoletter.ch/kongressberichte-2020.html
Kongressberichte Archiv 2019https://archiv.oncoletter.ch/kongressberichte-2019.html
Kongressberichte Archiv 2018https://archiv.oncoletter.ch/kongressberichte-2018.html
Kongressberichte Archiv 2017https://archiv.oncoletter.ch/kongressberichte-2017.html
Kalenderhttps://oncoletter.ch/kalender.html
Organisationenhttps://oncoletter.ch/Netzwerke.html
Netzwerkehttps://oncoletter.ch/Netzwerke.html
Fachgesellschaftenhttps://oncoletter.ch/Fachgesellschaften.html
Info für PatientINNenhttps://oncoletter.ch/Organisationen/info-fuer-patientinnen-patienten-angehoerige.html
Science Boardhttps://oncoletter.ch/science-board.html
Livehttps://oncoletter.ch/Live.html
Kongressberichtehttps://oncoletter.ch/kongressberichte/id-2024.html
2026https://oncoletter.ch/kongressberichte/id-2026.html
ASCO 2026 Gastrointestinal (GI) Cancers Symposiumhttps://oncoletter.ch/kongressberichte/id-2026/ascogi-gastrointestinal-cancers-symposium.html
Rapid Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/id-2026/ascogi-rapid-oral-abstract-sessions.html
Rapid Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/id-2026/ascogi-rapid-abstract-session-1-esophagus-stomach.html
Rapid Oral Abstract Session A: Cancers of the Esophagus and Stomach - January 8, 2026, 5:15 - 6:00 PM PST | Level 2, Ballroom & Live Streamhttps://oncoletter.ch/kongressberichte/id-2026/ascogi-rapid-abstract-session-1-esophagus-stomach.html
Rapid Oral Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract - January 9, 2026, 4:15 - 5:00 PM PST | Level 2, Ballroom & Live Streamhttps://oncoletter.ch/kongressberichte/id-2026/ascogi-rapid-abstract-session-2-pancreas-small-bowel-hepatobiliary.html
Rapid Oral Abstract Session C: Cancers of the Colon, Rectum, and Anus - January 10, 2026, 9:30 - 10:15 AM PST | Level 2, Ballroom & Live Streamhttps://oncoletter.ch/kongressberichte/id-2026/ascogi-rapid-abstract-session-3-colon-rectum-anus.html
Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/id-2026/ascogi-oral-abstract-sessions.html
Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/id-2026/ascogi-oral-abstract-session-1-esophagus-stomach.html
Oral Abstract Session A: Cancers of the Esophagus and Stomach: January 8, 2026, 8:05 - 9:45 AM PST | Level 2, Ballroom & Live Streamhttps://oncoletter.ch/kongressberichte/id-2026/ascogi-oral-abstract-session-1-esophagus-stomach.html
Oral Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract: January 9, 2026, 8:10 - 9:45 AM PST | Level 2, Ballroom & Live Streamhttps://oncoletter.ch/kongressberichte/id-2026/ascogi-oral-abstract-session-2-pancreas-small-bowel-hepatobiliary.html
Oral Abstract Session C: Cancers of the Colon, Rectum, and Anus: January 10, 2026, 1:30 - 3:00 PM PST | Level 2, Ballroom & Live Streamhttps://oncoletter.ch/kongressberichte/id-2026/ascogi-oral-abstract-sessions-3-colon-rectum-anus.html
Trials in Progress Poster Sessionshttps://oncoletter.ch/kongressberichte/id-2026/ascogi-trials-in-progress-poster-sessions.html
Trials in Progress Poster Sessionshttps://oncoletter.ch/kongressberichte/id-2026/ascogi-trials-in-progress-poster-sessions-1-stomach-other-gastrointestinal-cancers.html
Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancershttps://oncoletter.ch/kongressberichte/id-2026/ascogi-trials-in-progress-poster-sessions-1-stomach-other-gastrointestinal-cancers.html
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tracthttps://oncoletter.ch/kongressberichte/id-2026/ascogi-trials-in-progress-poster-sessions-2-pancreas-small-bowel-hepatobiliary.html
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anushttps://oncoletter.ch/kongressberichte/id-2026/ascogi-trials-in-progress-poster-sessions-3-colon-rectum-anus.html
Links to more Abstractshttps://oncoletter.ch/kongressberichte/id-2026/ascogi-gastrointestinal-cancers-symposium-more-abstracts.html
2025https://oncoletter.ch/kongressberichte/2025.html
48th SAN ANTONIO BREAST CANCER SYMPOSIUM - December 9 - 12, 2025, San Antonio Texashttps://oncoletter.ch/kongressberichte/2025/48th-san-antonio-breast-cancer-symposium-san-antonio.html
Studies presented at the SABCS 2025 Press Briefingshttps://oncoletter.ch/kongressberichte/2025/48th-sabcs-studies-presented-at-the-press-briefings.html
General Sessions 1-3https://oncoletter.ch/kongressberichte/2025/48th-sabcs/general-sessions-1-3.html
General Sessionshttps://oncoletter.ch/kongressberichte/2025/48th-sabcs/general-session-1.html
GENERAL SESSION 1 | Wednesday, December 10, 2025 - 9:30 AM–12:15 PM CST - Hall 1https://oncoletter.ch/kongressberichte/2025/48th-sabcs/general-session-1.html
GENERAL SESSION 2 | Thursday, December 11, 2025 - 9:00 AM–12:00 PM CST - Hall 1https://oncoletter.ch/kongressberichte/2025/48th-sabcs/general-session-2.html
GENERAL SESSION 3 | Friday, December 12, 2025 - 9:00 AM–11:30 AM CST - Hall 1https://oncoletter.ch/kongressberichte/2025/48th-sabcs/general-session-3.html
Rapid Fire Sessions 1-7https://oncoletter.ch/kongressberichte/2025/48th-sabcs-rapid-fire-sessions-1-7.html
Rapid Fire Sessions 1-7https://oncoletter.ch/kongressberichte/2025/48th-sabcs-rapid-fire-session-1.html
Rapid Fire Session 1 | TUESDAY, December 9, 2025 - 4:30 PM–5:30 PM CST - Stars at Night 1-2https://oncoletter.ch/kongressberichte/2025/48th-sabcs-rapid-fire-session-1.html
Rapid Fire Session 2 | TUESDAY, December 9, 2025 - 5:45 PM–6:45 PM CST - Stars at Night 1-2https://oncoletter.ch/kongressberichte/2025/48th-sabcs-rapid-fire-session-2.html
Rapid Fire Session 3 | WEDNESDAY, December 10, 2025 - 4:30 PM–5:30 PM CST - Stars at Night 1-2https://oncoletter.ch/kongressberichte/2025/48th-sabcs-rapid-fire-session-3.html
Rapid Fire Session 4 | THURSDAY, December 11, 2025 - 4:30 PM–5:30 PM CST - Stars at Night 1-2https://oncoletter.ch/kongressberichte/2025/48th-sabcs-rapid-fire-session-4.html
Rapid Fire Session 5 | FRIDAY, December 12, 2025 - 12:30 PM–1:30 PM CST - Stars at Night 1-2https://oncoletter.ch/kongressberichte/2025/48th-sabcs-rapid-fire-session-5.html
Rapid Fire Session 6 | WEDNESDAY, December 10, 2025 - 1:00 PM–2:15 PM CST - Stars at Night 1-2https://oncoletter.ch/kongressberichte/2025/48th-sabcs-rapid-fire-session-6.html
Rapid Fire Session 7 | THURSDAY, December 11, 2025 - 1:00 PM–2:00 PM CST - Stars at Night 1-2https://oncoletter.ch/kongressberichte/2025/48th-sabcs-rapid-fire-session-7.html
POSTER SPOTLIGHT SESSIONS 1-13https://oncoletter.ch/kongressberichte/2025/48th-sabcs-poster-spotlight-sessions-1-12.html
POSTER SPOTLIGHT SESSIONShttps://oncoletter.ch/kongressberichte/2025/48th-sabcs-poster-spotlight-sessions_summaries.html
Poster Spotlight Sessionshttps://oncoletter.ch/kongressberichte/2025/48th-sabcs-poster-spotlight-sessions_summaries.html
67th ASH Annual Meeting and Exposition - December 6-9, 2025, Orlando, Floridahttps://oncoletter.ch/kongressberichte/2025/67th-ash-annual-meeting.html
Late-Breaking Abstracts Session - Room OCCC - West Hall D2 - Tuesday, December 9, 07:30 AM - 09:00 AM ESThttps://oncoletter.ch/kongressberichte/2025/ash-2025-late-breaking-abstracts-session.html
ASH 2025 Plenary Scientific Session - Room OCCC - West Hall D2 - Sunday, December 7, 02:00 PM - 04:00 PM ESThttps://oncoletter.ch/kongressberichte/2025/ash-2025-plenary-scientific-session.html
Acute Lymphoblastic Leukemiashttps://oncoletter.ch/kongressberichte/2025/ASH2025-acute-lymphoblastic-leukemias.html
ALL: Clinical and Epidemiological studieshttps://oncoletter.ch/kongressberichte/2025/ASH2025-all-treatment-diagnostics-immunotherapy.html
ALL: Optimizing risk stratification, treatment, and diagnostics of ALL in the immunotherapy era - Room OCCC - W224ABEF -Sunday, December 7, 12:00 PM - 01:30 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-all-treatment-diagnostics-immunotherapy.html
ALL: Predicting and improving outcomes in common and rare subgroups of pediatric ALL - Room OCCC - W224CDGH - Monday, December 8, 10:30 AM - 12:00 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-all-improving-outcomes-pediatric.html
ALL: Therapies Excluding Allogeneic Transplantationhttps://oncoletter.ch/kongressberichte/2025/ASH2025-all-emerging-treatment-paradigms.html
ALL: Emerging Treatment Paradigms in ALL - Room OCCC - W224ABEF - Sunday, December 7, 09:30 AM - 11:00 AM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-all-emerging-treatment-paradigms.html
ALL: Risk Adapted Treatment and Immune Targeting for Frontline and Relapsed ALL in Pediatric and Adults - Room OCCC - W224CDGH Date Sunday, December 7, 04:30 PM - 06:00 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-all-risk-adapted-treatment-immune-targeting-frontline-relapsed-pediatric-adults.html
ALL: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosishttps://oncoletter.ch/kongressberichte/2025/ASH2025-all-critical-biomarkers-classifiers-b-all-and-t-all-ontogeny-outcomes.html
ALL: Prognostic Genetic and Therapeutic Response Factors in Adult and Pediatric B-ALL - Room OCCC - W224CDGH Date Saturday, December 6, 09:30 AM - 11:00 AM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-all-prognostic-genetic-therapeutic-response-factors-adult-pediatric-b-all.html
ALL: Critical biomarkers and classifiers in B-ALL and T-ALL ontogeny and outcomes - Room OCCC - W224CDGH Date Saturday, December 6, 04:00 PM - 05:30 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-all-critical-biomarkers-classifiers-b-all-and-t-all-ontogeny-outcomes.html
Acute Myeloid Leukemiashttps://oncoletter.ch/kongressberichte/2025/ASH2025-acute-myeloid-leukemias.html
AML: Clinical and Epidemiological Studieshttps://oncoletter.ch/kongressberichte/2025/ASH2025-aml-biological-and-clinical-nuances-in-patient-outcomes.html
AML: Biological and Clinical Nuances in Patient Outcomes - Room OCCC - Valencia Room W415BC - Saturday, December 6, 09:30 AM - 11:00 AM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-aml-biological-and-clinical-nuances-in-patient-outcomes.html
AML: Lessons from across the age spectrum - Room OCCC - Valencia Room W415BC - Sunday, December 7, 09:30 AM - 11:00 AM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-aml-lessons-from-across-the-age-spectrum.html
AML: Optimizing Standards of Care - Room OCCC - Valencia Room W415A - Monday, December 8, 02:45 PM - 04:15 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-aml-optimizing-standards-of-care.html
AML: AML Medley: Mutations, complications, classifications - Room OCCC - W414AB Date Monday, December 8, 04:30 PM - 06:00 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-aml-aml-medley-mutations-complications-classifications.html
AML: Investigational Drug and Cellular Therapieshttps://oncoletter.ch/kongressberichte/2025/ASH2025-aml-immunotherapy-and-chemotherapy-combinations.html
AML: Immunotherapy and chemotherapy combinations in AML - Room OCCC - Chapin Theater (W320) - Sunday, December 7, 04:30 PM - 06:00 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-aml-immunotherapy-and-chemotherapy-combinations.html
AML: Menin inhibitors and FLT3 inhibitors in AML - Room OCCC - Chapin Theater (W320) - Monday, December 8, 10:30 AM - 12:00 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-aml-menin-inhibitors-and-flt3-inhibitors-in-aml.html
AML: Commercially Available Therapieshttps://oncoletter.ch/kongressberichte/2025/ASH2025-aml-frontline-treatment-with-intensive-or-lower-intensity-regimens.html
AML: Frontline treatment with intensive or lower-intensity regimens - Room OCCC - Valencia Room W415A Date Saturday, December 6, 09:30 AM - 11:00 AM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-aml-frontline-treatment-with-intensive-or-lower-intensity-regimens.html
AML: Pediatric, adolescent and young adult AML - Room OCCC - Valencia Room W415BC - Monday, December 8, 02:45 PM - 04:15 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-aml-pediatric-adolescent-and-young-adult.html
AML: Combination regimens and targeted therapies - Room OCCC - Chapin Theater (W320) - Monday, December 8, 04:30 PM - 06:00 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-aml-combination-regimens-and-targeted-therapies.html
AML: Disease Burden and Measurable Residual Disease in Prognosis and Treatmenthttps://oncoletter.ch/kongressberichte/2025/ASH2025-aml-disease-burden-and-measurable-residual-disease-in-prognosis-and-treatment/cml-decoding-the-molecular-drivers-of-response-and-resistance.html
AML: Disease Burden and Measurable Residual Disease in Prognosis and Treatment: From Detection to Decision: MRD as the Compass in AML - Room OCCC - Valencia Room W415A - Saturday, December 6, 04:00 PM - 05:30 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-aml-disease-burden-and-measurable-residual-disease-in-prognosis-and-treatment/cml-decoding-the-molecular-drivers-of-response-and-resistance.html
Chronic Myeloid Leukemiahttps://oncoletter.ch/kongressberichte/2025/ASH2025-chronic-myeloid-leukemia.html
CML: Clinical and Epidemiologicalhttps://oncoletter.ch/kongressberichte/2025/ASH2025-cml-decoding-molecular-drivers-response-resistance.html
CML: Decoding the Molecular Drivers of response and resistance - Room OCCC - Valencia Room W415D - Saturday, December 6, 09:30 AM - 11:00 AM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-cml-decoding-molecular-drivers-response-resistance.html
CML: Therapeutic agents to enhance patient outcomes - Room OCCC - Chapin Theater (W320) - Monday, December 8, 02:45 PM - 04:15 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-cml-therapeutic-agents-to-enhance-patient-outcomes.html
Myeloproliferative Syndromes: Clinical and Epidemiologicalhttps://oncoletter.ch/kongressberichte/2025/ASH2025-myeloproliferative-syndromes.html
MPS: Clinical and Epidemiologicalhttps://oncoletter.ch/kongressberichte/2025/ASH2025-mps-therapeutic-prognostic-myeloproliferative-neoplasms-mastocytosis-hypereosinophilic-syndrome.html
MPS: Expanding the Therapeutic and Prognostic Landscape in Myeloproliferative Neoplasms, Mastocytosis and Hypereosinophilic Syndrome - Room OCCC - W414CD - Saturday, December 6, 09:30 AM - 11:00 AM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-mps-therapeutic-prognostic-myeloproliferative-neoplasms-mastocytosis-hypereosinophilic-syndrome.html
MPS: Between a Rock and a Ropeg - Innovative Therapies for MPNs - Room OCCC - W414AB Date Sunday, December 7, 09:30 AM - 11:00 AM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-mps-innovative-therapies-for-mpns.html
MPS: Beyond JAK Inhibition - Therapeutic Innovation and Transplant Strategies in Myelofibrosis - Room OCCC - W414AB Date Monday, December 8, 02:45 PM - 04:15 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-mps-beyond-jak-inhibition-therapeutic-innovation-transplant-strategies-myelofibrosis.html
MPS: Drivers and Mast Cells and Blasts, Oh My! - Insights and Treatments for MPNs and Mastocytosis - Room OCCC - West Hall D2 Date Monday, December 8, 04:30 PM - 06:00 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-mps-drivers-mast-cells-blasts-insights-treatments-mastocytosis.html
Lymphomashttps://oncoletter.ch/kongressberichte/2025/ASH2025-lymphomas.html
Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological:https://oncoletter.ch/kongressberichte/2025/ASH2025-lymphomas/mantle-cell-follicular-waldenstrom-s-and-other-indolent-b-cell-lymphomas/mantle-cell-follicular-waldenstrom-s-and-other-indolent-b-cell-lymphomas-fl-and-wm.html
Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: FL and WM - Room OCCC - Tangerine Ballroom F2 - Saturday, December 6, 02:00 PM - 03:30 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-lymphomas/mantle-cell-follicular-waldenstrom-s-and-other-indolent-b-cell-lymphomas/mantle-cell-follicular-waldenstrom-s-and-other-indolent-b-cell-lymphomas-fl-and-wm.html
Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Immunotherapies for Follicular Lymphoma - Room OCCC - West Hall D2 - Sunday, December 7, 09:30 AM - 11:00 AM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-lymphomas-immunotherapies-for-follicular-lymphoma.html
Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Novel Treatments for and Insights into Mantle Cell Lymphoma - Room OCCC - Tangerine Ballroom F2 - Sunday, December 7, 04:30 PM - 06:00 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-lymphomas-novel-treatments-insights-mantle-cell-lymphoma.html
Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Single Agent and Combination therapy for MCL - Room OCCC - Tangerine Ballroom F1 - Monday, December 8, 02:45 PM - 04:15 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-lymphomas-single-agent-combination-therapy-mantle-cell.html
Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Follicular Lymphoma - Room OCCC - Tangerine Ballroom F2 - Monday, December 8, 04:30 PM - 06:00 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-lymphomas-follicular.html
Hodgkin Lymphomas: Clinical and Epidemiologicalhttps://oncoletter.ch/kongressberichte/2025/ASH2025-improving-outcomes-in-hodgkin-lymphoma-utilizing-targeted-therapeutics-prognostic-modeling-predictive-tools.html
Improving Outcomes in Hodgkin Lymphoma Utilizing Targeted Therapeutics, Prognostic Modeling, and Predictive Tools - Room OCCC - Tangerine Ballroom F2 Da-te Saturday, December 6, 12:00 PM - 01:30 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-improving-outcomes-in-hodgkin-lymphoma-utilizing-targeted-therapeutics-prognostic-modeling-predictive-tools.html
T Cell, NK Cell, or NK/T Cell Lymphomashttps://oncoletter.ch/kongressberichte/2025/ASH2025-lymphomas-fresh-insight-for-cutaneous-and-virus-associated-tcls.html
T Cell, NK Cell, or NK/T Cell Lymphomas: Fresh insight for Cutaneous and Virus-associated TCLs - Room OCCC - Tangerine Ballroom F2 Date Sunday, December 7, 12:00 PM - 01:30 PM -https://oncoletter.ch/kongressberichte/2025/ASH2025-lymphomas-fresh-insight-for-cutaneous-and-virus-associated-tcls.html
T Cell, NK Cell, or NK/T Cell Lymphomas: Novel agents or therapeutic approaches in T-cell Lymphoma - Room OCCC - Tangerine Ballroom F1 Date Monday, December 8, 10:30 AM - 12:00 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-t-cell-nk-cell-or-nk-t-cell-lymphomas-novel-agents-or-therapeutic-approaches-in-t-cell-lymphoma.html
T Cell, NK Cell, or NK/T Cell Lymphomas: From bench to bedside and retrospective studies to inform treatment consideration in TCL - Room OCCC - Tangerine Ballroom F2 Date Monday, December 8, 02:45 PM - 04:15 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-lymphomas/retrospective-studies-to-inform-treatment-consideration-in-tcl.html
Aggressive Lymphomashttps://oncoletter.ch/kongressberichte/2025/ASH2025-aggressive-lymphomas-targeted-pharmacologic-therapies-front-line-btki-based-combination-therapy-DLBCL-PCNSL.html
Aggressive Lymphomas: Targeted and Pharmacologic Therapies - Front-line BTKi-based Combination Therapy in DLBCL and PCNSL - Room OCCC - Tangerine Ballroom F3-4 Date Saturday, December 6, 09:30 AM - 11:00 AM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-aggressive-lymphomas-targeted-pharmacologic-therapies-front-line-btki-based-combination-therapy-DLBCL-PCNSL.html
Aggressive Lymphomas: Targeted and Pharmacologic Therapies - Targeted Agents and Chemotherapy Intensification in Aggressive B-cell Lymphomas - Room OCCC - Tangerine Ballroom F3-4 Date Sunday, December 7, 09:30 AM - 11:00 AM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-aggressive-lymphomas-targeted-pharmacologic-therapies-chemotherapy-intensification-in-aggressive-b-cell-lymphomas.html
Aggressive Lymphomas: Cellular Therapies: Clinical Insights and Determinants of Resistance to Cellular Therapies in Aggressive Lymphomas - Room OCCC - Tangerine Ballroom F3-4 Date Sunday, December 7, 12:00 PM - 01:30 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-cellular-therapies-clinical-insights-determinants-resistance-to-cellular-therapies-in-aggressive-lymphomas.html
Aggressive Lymphomas: Cellular Therapies: Novel Cellular Therapeutic Strategies for Aggressive Lymphomas - Room OCCC - Tangerine Ballroom F3-4 Date Sunday, December 7, 04:30 PM - 06:00 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-cellular-therapies-novel-cellular-therapeutic-strategies-for-aggressive-lymphomas.html
Aggressive Lymphomas: Cellular Therapies: Emerging Approaches to Enhance Cellular Therapies and Real World Outcomes in Aggressive Lymphomas - Room OCCC - Tangerine Ballroom F3-4 Date Monday, December 8, 04:30 PM - 06:00 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-emerging-approaches-enhance-cellular-therapies-real-world-outcomes-aggressive-lymphomas.html
Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Overcoming Barriers in Frontline Therapy: Bispecific Antibodies for Older Adults with DLBCL - Room OCCC - Tangerine Ballroom F2 Date Saturday, December 6, 09:30 AM - 11:00 AM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-aggressive-lymphomas-immunotherapy-bispecific-antibodies-older-adults-dlbcl.html
Aggressive Lymphomas, Immunotherapy including Bispecific Antibodies: Improving Outcomes in Rare Large Cell Lymphomas - Room OCCC - Tangerine Ballroom F1 Date Monday, December 8, 04:30 PM - 06:00 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-aggressive-lymphomas-immunotherapy-bispecific-antibodies-large-cell-lymphomas.html
Chronic Lymphocytic Leukemiashttps://oncoletter.ch/kongressberichte/2025/ASH2025-chronic-lymphocytic-leukemias.html
Chronic Lymphocytic Leukemia: Clinical and Epidemiologicalhttps://oncoletter.ch/kongressberichte/2025/ASH2025-cll-clinical-epidemiological-treatment-relapse-richter-transformation.html
CLL: Clinical and Epidemiological: Treatment of CLL in Relapse and in Richter Transformation - Room OCCC - W224ABEF - Saturday, December 6, 09:30 AM - 11:00 AM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-cll-clinical-epidemiological-treatment-relapse-richter-transformation.html
CLL: Clinical and Epidemiological: Clinical and Epidemiological: Frontline Treatment Strategies for CLL - Room OCCC - W224ABEF - Sunday, December 7, 04:30 PM - 06:00 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-cll-clinical-epidemiological-frontline-treatment-strategies.html
CLL: Clinical and Epidemiological: Clinical and Epidemiological: MRD Guided Therapy and Emergence of Resistance - Room OCCC - W224ABEF - Monday, December 8, 10:30 AM - 12:00 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-cll-mrd-guided-therapy-emergence-resistance.html
Myelodysplastic Syndromeshttps://oncoletter.ch/kongressberichte/2025/ASH2025-myelodysplastic-syndromes.html
Myelodysplastic Syndromes: Clinical and Epidemiologicalhttps://oncoletter.ch/kongressberichte/2025/ASH2025-treatment-advances-in-higher-risk-myelodysplastic-syndromes.html
MDS: Clinical and Epidemiological: Treatment Advances in Higher Risk Myelodysplastic Syndromes - Room OCCC - Valencia Room W415BC - Saturday, December 6, 02:00 PM - 03:30 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-treatment-advances-in-higher-risk-myelodysplastic-syndromes.html
MDS: Clinical and Epidemiological: Moving the Needle Through Novel Approaches in MDS and CMML - Room OCCC - Valencia Room W415D - Sunday, December 7, 09:30 AM - 11:00 AM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-mds-clinical-and-epidemiological-moving-the-needle-through-novel-approaches-in-mds-and-cmml.html
MDS: Clinical and Epidemiological: Treatment Advances in Lower risk Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms - Room OCCC - Valencia Room W415A - Monday, December 8, 10:30 AM - 12:00 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-treatment-advances-in-lower-risk-myelodysplastic-syndromes-and-myeloproliferative-neoplasms.html
Multiple Myeloma and Plasma Cell Dyscrasiashttps://oncoletter.ch/kongressberichte/2025/ASH2025-multiple-myeloma-and-plasma-cell-dyscrasias.html
MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias:https://oncoletter.ch/kongressberichte/2025/ASH2025-multiple-myeloma-plasma-cell-dyscrasias-mgus-amyloidosis-other-non-myeloma.html
MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Redefining diagnosis, monitoring and treatment approaches - Room OCCC - West Hall E2 - Sunday, December 7, 12:00 PM - 01:30 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-multiple-myeloma-plasma-cell-dyscrasias-mgus-amyloidosis-other-non-myeloma.html
MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: New therapies and treatment goals for AL amyloidosis - Room OCCC - Tangerine Ballroom F1 - Sunday, December 7, 04:30 PM - 06:00 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-multiple-mgus-other-non-myeloma-plasma-cell-dyscrasias-clinical-epidemiological-new-therapies-treatment-goals-al-amyloidosis.html
Multiple Myeloma: Clinical and Epidemiologicalhttps://oncoletter.ch/kongressberichte/2025/ASH2025-multiple-myeloma-and-plasma-cell-dyscrasias-clinical-and-epidemiological-clinical-epidemiological-optimizing-immune-based-therapies.html
Multiple Myeloma: Clinical and Epidemiological: Optimizing Immune-Based Therapies in Myeloma: From T-Cell Fitness to Clinical Outcomes - Room OCCC - West Hall D2 - Saturday, December 6, 09:30 AM - 11:00 AM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-multiple-myeloma-and-plasma-cell-dyscrasias-clinical-and-epidemiological-clinical-epidemiological-optimizing-immune-based-therapies.html
Multiple Myeloma: Clinical and Epidemiological: Genomic and Cytogenetic Drivers of Prognosis in Multiple Myeloma - Room OCCC - West Hall D1 Date Saturday, December 6, 04:00 PM - 05:30 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-multiple-myeloma-and-plasma-cell-dyscrasias-clinical-and-epidemiological-genomic-cytogenetic-drivers-prognosis.html
Multiple Myeloma: Clinical and Epidemiological: From Biomarkers to Biology: Evolving Risk Stratification and Disease Modeling in Multiple Myeloma - Room OCCC - West Hall D1 Date Sunday, December 7, 09:30 AM - 11:00 AM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-multiple-myeloma-plasma-cell-dyscrasias-clinical-epidemiological-biomarkers-biology-evolving-risk-stratification-and-disease-modeling.html
Multiple Myeloma: Clinical and Epidemiological: Novel Baseline and Dynamic Risk Factors in Multiple Myeloma - Room OCCC - West Hall E1 Date Monday, December 8, 02:45 PM - 04:15 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-multiple-myeloma-and-plasma-cell-dyscrasias-novel-baseline-and-dynamic-risk-factors-in-multiple-myeloma.html
Multiple Myeloma: Clinical and Epidemiological: Direct from podium to clinic - Room OCCC - West Hall D1 Date Monday, December 8, 04:30 PM - 06:00 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-multiple-myeloma-and-plasma-cell-dyscrasias-from-podium-to-clinic.html
Multiple Myeloma: Pharmacologic Therapieshttps://oncoletter.ch/kongressberichte/2025/ASH2025-multiple-myeloma-plasma-cell-dyscrasias-pharmacologic-therapies-improving-myeloma-treatment-through-diagnosis-maintenance-and-relapse.html
Multiple Myeloma: Pharmacologic Therapies: Advancing the Standard: Improving Myeloma Treatment through Diagnosis, Maintenance and Relapse - Room OCCC - West Hall E1 - Saturday, December 6, 09:30 AM - 11:00 AM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-multiple-myeloma-plasma-cell-dyscrasias-pharmacologic-therapies-improving-myeloma-treatment-through-diagnosis-maintenance-and-relapse.html
Multiple Myeloma: Pharmacologic Therapies: Advances in Treatment Strategies for Relapsed/Refractory Multiple Myeloma - Room OCCC - West Hall D1 - Saturday, December 6, 02:00 PM - 03:30 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-multiple-myeloma-plasma-cell-dyscrasias-pharmacologic-therapies-advances-in-treatment-strategies-for-relapsed-refractory-multiple-myeloma.html
Multiple Myeloma: Pharmacologic Therapies: Are we achieving cures for multiple myeloma patients using early intervention strategies? - Room OCCC - West Hall E1 - Saturday, December 6, 04:00 PM - 05:30 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-multiple-myeloma-plasma-cell-dyscrasias-pharmacologic-therapies-achieving-cures-for-multiple-myeloma-patients-using-early-intervention-strategies.html
Multiple Myeloma: Pharmacologic Therapies: Bi, Tri and Beyond: Innovations in Bispecific and Trispecific Antibodies for Multiple Myeloma - Room OCCC - West Hall E1 Date Sunday, December 7, 04:30 PM - 06:00 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-multiple-myeloma-plasma-cell-dyscrasias-pharmacologic-therapies-innovations-in-bispecific-trispecific-antibodies-for-multiple-myeloma.html
Multiple Myeloma: Cellular Therapieshttps://oncoletter.ch/kongressberichte/2025/ASH2025-multiple-myeloma-and-plasma-cell-dyscrasias-cellular-therapies-clinical-trial-advances-in-car-t-cell-therapy.html
Multiple Myeloma: Cellular Therapies: Clinical Trial Advances in CAR T-Cell Therapy for Multiple Myeloma - Room OCCC - West Hall E1 Date Saturday, December 6, 02:00 PM - 03:30 PM ESThttps://oncoletter.ch/kongressberichte/2025/ASH2025-multiple-myeloma-and-plasma-cell-dyscrasias-cellular-therapies-clinical-trial-advances-in-car-t-cell-therapy.html
CAR-T Cell and Cellular Immunotherapieshttps://oncoletter.ch/kongressberichte/2025/67th-ash-annual-meeting/car-t-cell-and-cellular-immunotherapies.html
ESMO Congress 2025 - 17. - 21. OKTOBER - BERLIN, DEUTSCHLANDhttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025.html
ESMO25 - Presidential Symposia I-IIIhttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/esmo25-presidential-symposia-i-iii.html
ESMO25 - Presidential Symposia I-IIIhttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/presidential-symposium-i-practice-changing-trials.html
Presidential Symposium 1 - Sat, 18.10.2025 - Berlin Auditorium - Hub 27 - 16:30 - 18:15https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/presidential-symposium-1.html
Presidential Symposium 2 - Sun, 19.10.2025 - Berlin Auditorium - Hub 27 - 16:30 - 18:15https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/presidential-symposium-2.html
Presidential Symposium 3 - Mon, 20.10.2025 - Berlin Auditorium - Hub 27 - 16:30 - 18:15https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/presidential-symposium-3.html
BREAST CANCERhttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/breast-cancer.html
Interviewshttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/breast-cancer/interviews-renate-haidinger-brustkrebs-deutschland-e-v.html
Interviews von Renate Haidinger, Brustkrebs Deutschland e.V.https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/breast-cancer/interviews-renate-haidinger-brustkrebs-deutschland-e-v.html
Breast cancer, early stagehttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/proffered-paper-session-breast-cancer-early-stage.html
Proffered paper session: Breast cancer, early stage; Fri, 17.10.2025 - Munich Auditorium - CityCube B - 14:00 - 15:30https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/proffered-paper-session-breast-cancer-early-stage.html
Mini oral session: Breast cancer, early stage; Sun, 19.10.2025 - Munich Auditorium - CityCube B - 10:15 - 11:45https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/mini-oral-session-breast-cancer-early-stage.html
Breast cancer, metastatichttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/proffered-paper-session-1-breast-cancer-metastatic.html
Proffered Paper session 1: Breast cancer, metastatic; Sat, 18.10.2025 - Berlin Auditorium - Hub 27 Time 10:15 - 11:45https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/proffered-paper-session-1-breast-cancer-metastatic.html
Proffered Paper session 2: Breast cancer, metastatic; Sun, 19.10.2025 - Munich Auditorium - CityCube B - 08:30 - 10:00https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/proffered-paper-session-2-breast-cancer-metastatic.html
Mini oral session: Breast cancer, metastatic; Mon, 20.10.2025 - Munich Auditorium - CityCube B - 10:15 - 11:45https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/mini-oral-session-1-breast-cancer-metastatic.html
LUNG CANCER & OTHER THORACIC MALIGNANCIEShttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/lung-cancer-other-thoracic-malignancies.html
Non-metastatic NSCLC and other thoracic malignancieshttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/non-metastatic-nsclc-proffered-paper-session.html
Proffered Paper session: Non-metastatic NSCLC; Sat, 18.10.2025 - Bonn Auditorium - Hall 7.1c - 08:30 - 10:00https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/non-metastatic-nsclc-proffered-paper-session.html
Mini oral session 1: Non-metastatic NSCLC; Sat, 18.10.2025 - Hamburg Auditorium - CityCube A - 16:30 - 18:00https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/non-metastatic-nsclc-mini-oral-session-1.html
Mini oral session 2: Non-metastatic NSCLC; Mon, 20.10.2025 - Hamburg Auditorium - CityCube A - 14:45 - 16:15https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/non-metastatic-nsclc-and-other-thoracic-malignancies/mini-oral-session-2.html
NSCLC, metastatichttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/nsclc-metastatic/proffered-paper-session.html
Proffered paper session: NSCLC metastatic; Fri, 17.10.2025 - Berlin Auditorium - Hub 27 - 16:00 - 17:30https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/nsclc-metastatic/proffered-paper-session.html
Mini oral session 1: NSCLC metastatic; Sun, 19.10.2025 - Berlin Auditorium - Hub 27 - 08:30 - 10:00https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/nsclc-metastatic-mini-oral-session-1.html
Mini Oral session 2: NSCLC, metastatic; Mon, 20.10.2025 - Berlin Auditorium - Hub 27 - 10:15 - 11:45https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/nsclc-metastatic-mini-oral-session-2.html
Mesotheliomahttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/proffered-paper-session-mesothelioma.html
Proffered paper session: Mesothelioma Date Sun, 19.10.2025 - Hanover Auditorium - Hall 7.2c - 16:30 - 18:00https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/proffered-paper-session-mesothelioma.html
HEAD & NECK CANCERhttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/head-neck-cancer.html
Head & Neck Sessionshttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/head-neck-sessions/proffered-paper-session-1.html
Proffered paper session 1: Head and neck cancer; Sat, 18.10.2025 - Dortmund Auditorium - Hall 7.1a - 10:15 - 11:45https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/head-neck-sessions/proffered-paper-session-1.html
Proffered paper session 2: Head and neck cancer; Mon, 20.10.2025 - Cologne Auditorium - CityCube A - 08:30 - 10:00https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/head-neck-sessions/proffered-paper-session-2.html
Mini oral session: Head and neck cancer; Sun, 19.10.2025 - Cologne Auditorium - CityCube A - 16:30 - 18:00https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/head-neck-sessions/mini-oral-session.html
GYNAECOLOGICAL CANCERShttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/gynaecological-cancers.html
Interview Renate Haidinger, Brustkrebs Deutschland e.V. mit Prof. Sven Mahner - Highlights Gynäkologische Tumoren (Ovarialkarzinom)https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/gynaecological-cancers/interviews-haidinger-mahner/interviews.html
Interviewhttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/gynaecological-cancers/interviews-haidinger-mahner/interviews.html
Gynaecological Sessionshttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/gynaecological-cancer-sessions/proffered-paper-session.html
Proffered paper session: Gynaecological cancers; Sun, 19.10.2025 - Hamburg Auditorium - CityCube A - 14:45 - 16:15https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/gynaecological-cancer-sessions/proffered-paper-session.html
Mini oral session: Gynaecological cancers; Sun, 19.10.2025 - Cologne Auditorium - CityCube A - 10:15 - 11:45https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/gynaecological-cancer-sessions/mini-oral-session.html
CNS TUMOURS & SARCOMAhttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/cns-tumours-sarcoma.html
CNS & SARCOMA Sessionshttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/proffered-paper-session-sarcoma.html
Proffered paper session: Sarcoma; Sun, 19.10.2025 - Dortmund Auditorium - Hall 7.1a - 16:30 - 18:00https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/proffered-paper-session-sarcoma.html
Proffered paper session: CNS tumours; Mon, 20.10.2025 - Karlsruhe Auditorium - Hall 5.2 - 10:15 - 11:45https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/proffered-paper-session-cns-tumours.html
Mini oral session: CNS tumours; Mon, 20.10.2025 - Karlsruhe Auditorium - Hall 5.2 - 08:30 - 10:00https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/mini-oral-session-cns-tumours.html
Mini oral session: Sarcoma; Fri, 17.10.2025 - Essen Auditorium - Hall 7.2a - 16:00 - 17:30https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/mini-oral-session-sarcoma.html
GENITOURINARY TUMOURShttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/genitourinary-tumours.html
GU tumours, renal-urothelialhttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/renal-urothelial-tumours-proffered-paper-session-1.html
Proffered paper session 1: GU tumours, renal-urothelial; Fri, 17.10.2025 - Dortmund Auditorium - Hall 7.1a - 14:00 - 15:30https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/renal-urothelial-tumours-proffered-paper-session-1.html
Proffered Paper session 2: GU tumours, renal-urothelial; Sat, 18.10.2025 - Berlin Auditorium - Hub 27 - 08:30 - 10:00https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/gu-renal-urothelial-proffered-paper-session-2.html
Mini Oral session 1 : GU tumours, renal & urothelial; Date Fri, 17.10.2025 - Karlsruhe Auditorium - Hall 5.2 - 16:00 - 17:30https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/renal-urothelial-mini-oral-session-1.html
Mini oral session 2: GU tumours, renal & urothelial; Sun, 19.10.2025 - Bonn Auditorium - Hall 7.1c - 08:30 - 10:00https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/renal-urothelial-mini-oral-session-2.html
GU tumours, prostate, penile and testishttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/proffered-paper-session-GU-tumours-prostate-penile-testis.html
Proffered paper session: GU tumours, prostate, penile and testis; Sun, 19.10.2025 - Hamburg Auditorium - CityCube A - 10:15 - 11:45https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/proffered-paper-session-GU-tumours-prostate-penile-testis.html
Mini oral session: GU tumours, prostate, penile and testis; Fri, 17.10.2025 - Heidelberg Auditorium - Hall 6.2 - 14:00 - 15:30https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/GU-tumours-prostate-penile-testis-mini-oral-session.html
GASTROINTESTINAL TUMOURShttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/gastrointestinal-tumours.html
GI, upper digestivehttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/proffered-paper-session-2-gi-tumours-upper-digestive.html
Proffered paper session 1: GI tumours, upper digestive; Fri, 17.10.2025 - Hamburg Auditorium - CityCube A - 14:00 - 15:30https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/proffered-paper-session-1-gi-tumours-upper-digestives.html
Proffered paper session 2: GI tumours, upper digestive; Sun, 19.10.2025 - Berlin Auditorium - Hub 27 - 10:15 - 11:45https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/proffered-paper-session-2-gi-tumours-upper-digestive.html
Mini oral session 1: GI tumours, upper digestive; Sat, 18.10.2025 - Hanover Auditorium - Hall 7.2c - 10:15 - 11:45https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/mini-oral-session-1-gi-tumours-upper-digestive.html
Mini oral session 2: GI tumours, upper digestive; Mon, 20.10.2025 - Bonn Auditorium - Hall 7.1c - 08:30 - 10:00https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/mini-oral-session-2-gi-tumours-upper-digestive.html
GI, lower digestivehttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/proffered-paper-session-1-gi-tumours-lower-digestive.html
Proffered paper session 1: GI tumours, lower digestive; Sat, 18.10.2025 - Hamburg Auditorium - CityCube A - 14:45 - 16:15https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/proffered-paper-session-1-gi-tumours-lower-digestive.html
Proffered paper session 2: GI tumours, lower digestive; Mon, 20.10.2025 - Berlin Auditorium - Hub 27 - 08:30 - 10:00https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/proffered-paper-session-2-gi-tumours-lower-digesti.html
Mini oral session: GI tumours, lower digestive; Sun, 19.10.2025 - Cologne Auditorium - CityCube A - 14:45 - 16:15https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/mini-oral-session-gi-tumours-lower-digestive.html
NETs and endocrine tumourshttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/nets-and-endocrine-tumours.html
NETs and endocrine tumours Sessionshttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/proffered-paper-session-nets-and-endocrine-tumours.html
Proffered paper session: NETs and endocrine tumours; Sat, 18.10.2025 - Karlsruhe Auditorium - Hall 5.2 - 10:15 - 11:45https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/proffered-paper-session-nets-and-endocrine-tumours.html
Mini oral session: NETs and endocrine tumours; Mon, 20.10.2025 - Koblenz Auditorium - Hall 5.2 - 08:30 - 10:00https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/mini-oral-session-nets-and-endocrine-tumours.html
MELANOMA AND OTHER SKIN TUMOURShttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/melanoma-and-other-skin-tumours.html
Melanoma Sessionshttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/proffered-paper-session-melanoma.html
Proffered paper session: Melanoma and other skin tumours; Mon, 20.10.2025 - Cologne Auditorium - CityCube A - 08:30 - 10:00https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/proffered-paper-session-melanoma.html
Mini oral session: Melanoma and other skin tumours; Sat, 18.10.2025 - Koblenz Auditorium - Hall 5.2 - 14:45 - 16:15https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/mini-oral-session-melanoma-and-other-skin-tumours.html
HAEMATOLOGICAL MALIGNANCIEShttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/haematological-malignancies.html
Haematological malignancies Sessionshttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/haematological-malignancies-proffered-paper-session.html
Proffered Paper session: Haematological malignancies; Fri, 17.10.2025 - Bochum Auditorium - Hall 6.1 - 14:00 - 15:30https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/haematological-malignancies-proffered-paper-session.html
Mini oral session: Haematological malignancies; Sun, 19.10.2025 - Solingen Auditorium - Hall 23 - 08:30 - 10:00https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/haematological-malignancies-mini-oral-session.html
INVESTIGATIONAL IMMUNOTHERAPYhttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/investigational-immunotherapy.html
INVESTIGATIONAL IMMUNOTHERAPYhttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/investigational-immunotherapy/proffered-paper-session.html
Proffered paper session: Investigational immunotherapy; Mon, 20.10.2025 - Hanover Auditorium - Hall 7.2c - 10:15 - 11:45https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/investigational-immunotherapy/proffered-paper-session.html
Mini oral session: Investigational immunotherapy; Fri, 17.10.2025 - Nuremberg Auditorium - Hall 5.2 - 14:00 - 15:30https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/investigational-immunotherapy/mini-oral-session.html
SUPPORTIVE AND PALLIATIVE CAREhttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/supportive-and-palliative-care.html
Supportive and palliative care sessionshttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/proffered-paper-session-supportive-and-palliative-care.html
Proffered paper session: Supportive and palliative care; Fri, 17.10.2025 - Hanover Auditorium - Hall 7.2c - 16:00 - 17:30https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/proffered-paper-session-supportive-and-palliative-care.html
Mini oral session: Supportive and palliative care; Sat, 18.10.2025 - Karlsruhe Auditorium - Hall 5.2 - 14:45 - 16:15https://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/mini-oral-session-supportive-and-palliative-care.html
 IASLC 2025 World Conference on Lung Cancerhttps://oncoletter.ch/kongressberichte/2025/iaslc-2025-world-conference-on-lung-cancer.html
PL02 Presidential Symposium 1 - Sunday, September 7, 2025 at 8:15 AM CEST / Plenary Hallhttps://oncoletter.ch/kongressberichte/2025/pl02presidential-symposium-1.html
PL03 Presidential Symposium 2 - Monday, September 8, 2025 at 8:15 AM CEST / Plenary Hallhttps://oncoletter.ch/kongressberichte/2025/iaslc-2025-world-conference-on-lung-cancer/pl03-presidential-symposium-2.html
OA02 Latest Diagnostic and Management Options to Improve Survival Outcomes in Early-stage Resectable Non-small Cell Lung Cancer - Sep 7 2025 12:00PM - 1:15PM / Room 06https://oncoletter.ch/kongressberichte/2025/iaslc-2025-latest-diagnostic-and-management-options.html
OA05 Immunotherapy for Special Populations - Sep 7 2025 4:45PM - 6:00PM / Room 06https://oncoletter.ch/kongressberichte/2025/iaslc-2025-immunotherapy-for-special-populations.html
OA06. Novel ADCs in SCLC - Sep 7 2025 4:45PM - 6:00PM / Room 02https://oncoletter.ch/kongressberichte/2025/iaslc-2025-novel-adcs-in-sclc.html
OA07. Expanding Horizons in Advanced NSCLC Integrating Local Therapy - Sep 8 2025 12:00PM - 1:15PM / Room 08https://oncoletter.ch/kongressberichte/2025/iaslc-2025-expanding-horizons-in-advanced-nsclc-integrating-local-therapy.html
OA08. Improving Outcomes in EGFR and KRAS Mutant Tumours, More is Better? - Sep 8 2025 12:00PM - 1:15PM / Room 02https://oncoletter.ch/kongressberichte/2025/iaslc-2025-improving-outcomes-in-egfr-kras-mutant-tumours-more-is-better.html
OA10. Optimizing Systemic Therapy: Bridging New and Old - Sep 8 2025 3:30PM - 4:45PM / Room 07https://oncoletter.ch/kongressberichte/2025/iaslc-2025optimizing-systemic-therapy-bridging-new-and-old.html
OA12. Novel Clinical Approaches and Translational Investigation in Mesothelioma - Sep 8 2025 5:00PM - 6:15PM / Room 01https://oncoletter.ch/kongressberichte/2025/iaslc-2025-novel-clinical-approaches-and-translational-investigation-in-mesothelioma.html
OA13. Optimizing Front-Line Treatment in SCLC - Sep 8 2025 5:00PM - 6:15PM / Room 06https://oncoletter.ch/kongressberichte/2025/iaslc-2025-optimizing-front-line-treatment-in-sclc.html
OA16. Building Bridges Between Resectable and Unresectable Stage III NSCLC - Sep 9 2025 11:30AM - 12:45PM / Room 06https://oncoletter.ch/kongressberichte/2025/iaslc-2025-building-bridges-between-resectable-and-unresectable-stage-iii-nsclc.html
More Links to Oral Sessionshttps://oncoletter.ch/kongressberichte/2025/iaslc-2025-more-links-to-oral-sessions.html
MA01. New Drugs and Strategies in Locally Advanced NSCLC - Sep 7 2025 12:00PM - 1:15PM / Room 01https://oncoletter.ch/kongressberichte/2025/iaslc-2025-new-drugs-and-strategies-in-locally-advanced-nsclc.html
MA02. New Treatment Strategies in Other Than EGFR-Positive Tumors - Sep 7 2025 12:00PM - 1:15PM / Room 02https://oncoletter.ch/kongressberichte/2025/iaslc-2025-new-treatment-strategies-in-other-than-egfr-positive-tumors.html
MA04. Multi-Modal Treatment of Resectable Lung Cancer - Outcomes of Targeted Treatments and Immunotherapies in Early-Stage Lung Cancer - Sep 8 2025 12:00PM - 1:15PM / Room 01https://oncoletter.ch/kongressberichte/2025/iaslc-2025-multi-modal-treatment-of-resectable-lung-cancer-outcomes-of-targeted-treatments-and-immunotherapies-in-early-stage-lung-cancer.html
MA08. Common and Uncommon EGFR Mutations, New Treatments in the Horizon - Sep 9 2025 11:30AM - 12:45PM / Room 01https://oncoletter.ch/kongressberichte/2025/iaslc-2025-common-and-uncommon-egfr-mutations-new-treatments-in-the-horizon.html
MA10. Longer Follow Up and New IO Combinations - Sep 9 2025 1:00PM - 2:15PM / Room 06https://oncoletter.ch/kongressberichte/2025/iaslc-2025-longer-follow-up-and-new-io-combinations.html
MA11. Innovative Therapeutic Strategies and Molecular Insights in SCLC and Neuroendocrine Tumors - Sep 9 2025 1:00PM - 2:15PM Room 01https://oncoletter.ch/kongressberichte/2025/iaslc-2025-innovative-therapeutic-strategies-and-molecular-insights-in-sclc-and-neuroendocrine-tumors.html
More Links to Mini Oral Sessionshttps://oncoletter.ch/kongressberichte/2025/iaslc-2025-world-conference-on-lung-cancer/more-links-to-mini-oral-sessions.html
ESMO Gastrointestinal Cancers Congress 2025https://oncoletter.ch/kongressberichte/2025/esmo-gastrointestinal-cancers-congress-2025.html
Mini Oral session - Innovation in GI cancershttps://oncoletter.ch/kongressberichte/2025/esmo-gastrointestinal-cancers-congress-2025/mini-oral-session-innovation-in-gi-cancers.html
Proffered Paper session 1https://oncoletter.ch/kongressberichte/2025/esmo-gastrointestinal-cancers-congress-2025/proffered-paper-session-1.html
Proffered Paper session 2https://oncoletter.ch/kongressberichte/2025/esmo-gastrointestinal-cancers-congress-2025/proffered-paper-session-2.html
Mini Oral sessionhttps://oncoletter.ch/kongressberichte/2025/esmo-gastrointestinal-cancers-congress-2025/mini-oral-session.html
EHA2025 Congress - Milano, June 12-15, 2025https://oncoletter.ch/kongressberichte/2025/eha2025.html
Plenary and Late Breaking Abstract Sessionshttps://oncoletter.ch/kongressberichte/2025/eha2025-congress-milano-june-12-15-2025/plenary-and-late-breaking-abstract-sessions.html
Plenary and Late Breaking Abstract Sessionshttps://oncoletter.ch/kongressberichte/2025/eha2025/plenary-session.html
Plenary Sessionhttps://oncoletter.ch/kongressberichte/2025/eha2025/plenary-session.html
Late Breaking Abstract Sessionhttps://oncoletter.ch/kongressberichte/2025/eha2025/late-breaking-abstract-session.html
Acute Lymphoblastic Leukemiahttps://oncoletter.ch/kongressberichte/2025/eha2025/acute-lymphoblastic-leukemia.html
Acute lymphoblastic leukemiahttps://oncoletter.ch/kongressberichte/2025/eha2025/all-clinical.html
ALL Clinicalhttps://oncoletter.ch/kongressberichte/2025/eha2025/all-clinical.html
Acute Myeloid Leukemiahttps://oncoletter.ch/kongressberichte/2025/eha2025/acute-myeloid-leukemia.html
Acute myeloid leukemiahttps://oncoletter.ch/kongressberichte/2025/eha2025/acute-myeloid-leukemia/aml-clinical.html
AML - Clinicalhttps://oncoletter.ch/kongressberichte/2025/eha2025/acute-myeloid-leukemia/aml-clinical.html
Aggressive, indolente und Mantelzell Non-Hodgkin lymphomahttps://oncoletter.ch/kongressberichte/2025/eha2025/aggressive-indolente-und-mantelzell-non-hodgkin-lymphoma.html
Aggressive Non-Hodgkin lymphoma.https://oncoletter.ch/kongressberichte/2025/eha2025/aggressive-non-hodgkin-lymphoma-clinical.html
Aggressive Non-Hodgkin Lymphomahttps://oncoletter.ch/kongressberichte/2025/eha2025/aggressive-non-hodgkin-lymphoma-clinical.html
Indolente und Mantelzell Non-Hodgkin lymphomahttps://oncoletter.ch/kongressberichte/2025/eha2025/aggressive-indolente-und-mantelzell-non-hodgkin-lymphoma/indolente-und-mantelzell-non-hodgkin-lymphoma/indolente-und-mantelzell-non-hodgkin-lymphoma.html
Indolente und Mantelzell Non-Hodgkin lymphomahttps://oncoletter.ch/kongressberichte/2025/eha2025/aggressive-indolente-und-mantelzell-non-hodgkin-lymphoma/indolente-und-mantelzell-non-hodgkin-lymphoma/indolente-und-mantelzell-non-hodgkin-lymphoma.html
Chronic Lymphocytic Leukemia and Related disorders - Clinicalhttps://oncoletter.ch/kongressberichte/2025/eha2025/chronic-lymphocytic-leukemia.html
Chronic lymphocytic leukemia and related disordershttps://oncoletter.ch/kongressberichte/2025/eha2025/chronic-lymphocytic-leukemia-clinical.html
Chronic lymphocytic leukemia and related disorders - Clinicalhttps://oncoletter.ch/kongressberichte/2025/eha2025/chronic-lymphocytic-leukemia-clinical.html
Chronic Myeloid Leukemiahttps://oncoletter.ch/kongressberichte/2025/eha2025/chronic-myeloid-leukemia.html
Chronic Myeloid Leukemiahttps://oncoletter.ch/kongressberichte/2025/eha2025/chronic-myeloid-leukemia-clinical/CML.html
Chronic Myeloid Leukemiahttps://oncoletter.ch/kongressberichte/2025/eha2025/chronic-myeloid-leukemia-clinical/CML.html
Hodgkin Lymphomahttps://oncoletter.ch/kongressberichte/2025/eha2025/hodgkin-lymphoma.html
Hodgkin lymphomahttps://oncoletter.ch/kongressberichte/2025/eha2025/hodgkin-lymphoma/hodgkin.html
Hodgkin Lymphomahttps://oncoletter.ch/kongressberichte/2025/eha2025/hodgkin-lymphoma/hodgkin.html
Myelodysplastic Syndromeshttps://oncoletter.ch/kongressberichte/2025/eha2025/myelodysplastic-syndromes.html
Myelodysplastic Syndromeshttps://oncoletter.ch/kongressberichte/2025/eha2025/myelodysplastic-syndromes/mds.html
Myelodysplastic Syndromeshttps://oncoletter.ch/kongressberichte/2025/eha2025/myelodysplastic-syndromes/mds.html
Myeloma and other monoclonal gammopathies - clinicalhttps://oncoletter.ch/kongressberichte/2025/eha2025/myeloma-and-other-monoclonal-gammopathies-clinical.html
Myeloma and other monoclonal gammopathies - clinicalhttps://oncoletter.ch/kongressberichte/2025/eha2025/myeloma-monoclonal-gammopathies.html
Myeloma and other monoclonal gammopathieshttps://oncoletter.ch/kongressberichte/2025/eha2025/myeloma-monoclonal-gammopathies.html
Myeloproliferative Neoplasmshttps://oncoletter.ch/kongressberichte/2025/eha2025/myeloproliferative-neoplasms.html
Myeloproliferative Neoplasmshttps://oncoletter.ch/kongressberichte/2025/eha2025/myeloproliferative-neoplasms/mpn.html
Myeloproliferative neoplasmshttps://oncoletter.ch/kongressberichte/2025/eha2025/myeloproliferative-neoplasms/mpn.html
Gen Therapie und zelluläre Immuntherapiehttps://oncoletter.ch/kongressberichte/2025/eha2025/gene-therapy.html
Gen Therapie und zelluläre Immuntherapiehttps://oncoletter.ch/kongressberichte/2025/eha2025/gene-therapies/gene-therapy.html
Gen Therapie und zelluläre Immuntherapiehttps://oncoletter.ch/kongressberichte/2025/eha2025/gene-therapies/gene-therapy.html
ASCO Annual Meeting 2025 May 30 - June 3, 2025 - McCormick Place, Chicagohttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025.html
Plenary sessionhttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/plenary-session.html
Plenary Session Late breaking abstracts - Sunday, June 1 - 13:00 – 16:00 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/plenary-session-late-breaking-abstracts-sunday-june-1.html
Breast Cancerhttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/breast-cancer.html
Breast Cancer—Local/Regional/Adjuvanthttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/breast-cancer-local-regional-adjuvant/2-juni.html
Breast Cancer—Local/Regional/Adjuvant - Oral Abstract Session | LocationHall B1 | Live Stream | 2. Juni 2025 | 15:00 – 18:00 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/breast-cancer-local-regional-adjuvant/2-juni.html
Breast Cancer —Local/Regional/Adjuvant - Rapid Oral Abstract Session | LocationHall B1 | Live Stream | 1. Juni 2025 | 08:00 – 09:30 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/breast-cancer-local-regional-adjuvant/1-juni-2025.html
Breast Cancer—Metastatichttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/breast-cancer-metastatic/31-mai.html
Breast Cancer—Metastatic - Oral Abstract Session | Hall B1 | Live Stream | 31. Mai 2025 | 13:15 – 16:15 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/breast-cancer-metastatic/31-mai.html
Breast Cancer — Metastatic - Rapid Oral Abstract Session | Hall D2 | Live Stream | 30. Mai 2025 | 14:45 – 16:15 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/breast-cancer-metastatic/30-mai.html
Lung Cancerhttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/lung-cancer.html
Lung Cancer - Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancershttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/lung-cancer-nsclc-sclc-thoracic-cancer/2-juni-2025.html
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers - Oral Abstract Session | Arie Crown Theater | Live Stream | 2. Juni 2025 | 15:00 – 18:00 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/lung-cancer-nsclc-sclc-thoracic-cancer/2-juni-2025.html
Lung Cancer —Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers - Rapid Oral Abstract Session | Hall D1 | Live Stream | 1. Juni 2025 | 16:30 – 18:00 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/lung-cancer-nsclc-sclc-thoracic-cancer/1-juni-2025.html
Lung Cancer—Non-Small Cell Metastatichttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/lung-cancer-non-small-cell-metastatic/1-juni-2025.html
Lung Cancer—Non-Small Cell Metastatic - Oral Abstract Session | Arie Crown Theater | Live Stream | 1. Juni 2025 | 08:00 – 11:00 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/lung-cancer-non-small-cell-metastatic/1-juni-2025.html
Lung Cancer —Non-Small Cell Metastatic - Rapid Oral Abstract Session | Arie Crown Theater | Live Stream | 2. Juni 2025 | 08:00 – 09:30 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/lung-cancer-non-small-cell-metastatic/2-juni-2025.html
Gastrointestinal Cancerhttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/gastrointestinal-cancer.html
Gastrointestinal Cancer—Colorectal and Analhttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/gastrointestinal-cancer-colorectal-and-anal/30-mai.html
Gastrointestinal Cancer—Colorectal and Anal - Oral Abstract Session | Arie Crown Theater | Live Stream | 30. Mai 2025 | 14:45 – 17:45 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/gastrointestinal-cancer-colorectal-and-anal/30-mai.html
Gastrointestinal Cancer— Colorectal and Anal - Rapid Oral Abstract Session | Hall D1 | Live Stream | 1. Juni 2025 | 11:30 – 13:00 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/colorectal-and-anal-1-juni.html
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliaryhttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/gastrointestinal-cancer-gastroesophageal-pancreatic-and-hepatobiliary-31-mai.html
Gastrointestinal Cancer — Gastroesophageal, Pancreatic, and Hepatobiliary - Oral Abstract Session | Hall D1 | Live Stream | 31. Mai 2025 | 15:00 – 18:00 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/gastrointestinal-cancer-gastroesophageal-pancreatic-and-hepatobiliary-31-mai.html
Gastrointestinal Cancer — Gastroesophageal, Pancreatic, and Hepatobiliary - Rapid Oral Abstract Session | Hall D2 | Live Stream | 2. Juni 2025 | 11:30 – 13:00 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/gastrointestinal-cancer-gastroesophageal-pancreatic-and-hepatobiliary/2-juni.html
Genitourinary Cancerhttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/genitourinary-cancer.html
Genitourinary Cancer—Kidney and Bladderhttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/genitourinary-cancer-kidney-bladder/1-juni.html
Genitourinary Cancer — Kidney and Bladder Oral Abstract Session | Hall D2 | Live Stream | 1. Juni 2025 | 09:45 – 12:45 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/genitourinary-cancer-kidney-bladder/1-juni.html
Genitourinary Cancer— Kidney and Bladder Rapid Oral Abstract Session | Arie Crown Theater | Live Stream | 31. Mai 2025 | 13:15 – 14:45 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/genitourinary-cancer-kidney-bladder/31-mai.html
Genitourinary Cancer—Prostate, Testicular, and Penilehttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/genitourinary-cancer-prostate-testicular-and-penile-3-juni.html
Genitourinary Cancer—Prostate, Testicular, and Penile Oral Abstract Session| Hall D1 | Live Stream | 3. Juni 2025 | 09:45 – 12:45 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/genitourinary-cancer-prostate-testicular-and-penile-3-juni.html
Genitourinary Cancer— Prostate, Testicular, and Penile Rapid Oral Abstract Session | Hall D2 | Live Stream | 1. Juni 2025 | 16:30 – 18:00 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/genitourinary-cancer-prostate-testicular-and-penile-1-juni.html
Gynecologic Cancerhttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/gynecologic-cancer.html
Gynecologic Cancerhttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/gynecologic-cancer/2-juni.html
Gynecologic Cancer Oral Abstract Session | S100a | Live Stream | 2. Juni 2025 | 08:00 – 11:00 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/gynecologic-cancer/2-juni.html
Gynecologic Cancer Rapid Oral Abstract Session | S100bc | Live Stream | 3. Juni 2025 | 08:00 – 09:30 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/gynecologic-cancer/3-juni.html
Central Nervous System Tumorshttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/central-nervous-system-tumors.html
Central Nervous System Tumorshttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/central-nervous-system-tumors/30-mai.html
Central Nervous System Tumors Oral Abstract Session | S100bc | Live Stream | 30. Mai 2025 | 14:45 – 17:45 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/central-nervous-system-tumors/30-mai.html
Central Nervous System Tumors Rapid Oral Abstract Session | S102 | On Demand | 31. Mai 2025 | 15:00 – 16:30 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/central-nervous-system-tumors/31-mai.html
Head and Neck Cancerhttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/head-and-neck-cancer-2.html
Head and Neck Cancerhttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/head-and-neck-cancer/31-mai.html
Head and Neck Cancer Oral Abstract Session | S100a | Live Stream | 31. Mai 2025 | 13:15 – 16:15 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/head-and-neck-cancer/31-mai.html
Head and Neck Cancer Rapid Oral Abstract Session | E450a | On Demand | 1. Juni 2025 | 11:30 – 13:00 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/head-and-neck-cancer/1-juni.html
Melanoma/Skin Cancershttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/melanoma-skin-cancers.html
Melanoma/Skin Cancershttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/melanoma-skin-cancers/3-juni.html
Melanoma/Skin Cancers Oral Abstract Session | S100a | Live Stream | 3. Juni 2025 | 09:45 – 12:45 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/melanoma-skin-cancers/3-juni.html
Melanoma/Skin Cancers Rapid Oral Abstract Session | E451 | On Demand | 2. Juni 2025 | 09:45 – 11:15 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/melanoma-skin-cancers-2-juni.html
Sarcomahttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/sarcoma.html
Sarcoma.https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/sarcomas/1-juni.html
Sarcoma Oral Abstract Session| S100a | Live Stream | 1. Juni 2025 | 09:45 – 12:45 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/sarcomas/1-juni.html
Sarcoma Rapid Oral Abstract Session | S504 | On Demand | 2. Juni 2025 | 11:30 – 13:00 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/sarcomas/2-juni.html
Pediatric Oncologyhttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/pediatric-oncology.html
Pediatric Oncologyhttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/pediatric-oncology/31.html
Pediatric Oncology I Oral Abstract Session | S100bc | Live Stream | 31. Mai 2025 | 15:00 – 18:00 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/pediatric-oncology/31.html
Pediatric Oncology II Oral Abstract Session | S504 | On Demand | 2. Juni 2025 | 08:00 – 11:00 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/pediatric-oncology/2-juni.html
Pediatric Oncology Rapid Oral Absract Session | S504 | On Demand | 2. Juni 2025 | 15:00 – 16:30 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/pediatric-oncology-rapid/2-juni.html
Hematologic Malignancieshttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/hematologic-malignancies.html
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplanthttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/leukemia-myelodysplastic-syndromes-and-allotransplant/2-juni.html
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Oral Abstract Session | S100a | Live Stream | 2. Juni 2025 | 15:00 – 18:00 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/leukemia-myelodysplastic-syndromes-and-allotransplant/2-juni.html
Hematologic Malignancies— Leukemia, Myelodysplastic Syndromes, and Allotransplant Rapid Oral Abstract Session | E450a | On Demand | 30. Mai 2025 | 13:00 – 14:30 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/leukemia-myelodysplastic-syndromes-and-allotransplant-30-mai.html
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemiahttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/lymphoma-and-chronic-lymphocytic-leukemia/30-mai.html
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Oral Abstract Session | S100a | Live Stream | 30. Mai 2025 | 14:45 – 17:45 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/lymphoma-and-chronic-lymphocytic-leukemia/30-mai.html
Hematologic Malignancies— Lymphoma and Chronic Lymphocytic Leukemia Rapid Oral Abstract Session | E450a | On Demand | 31. Mai 2025 | 08:00 – 09:30 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/lymphoma-and-chronic-lymphocytic-leukemia/31-mai.html
Hematologic Malignancies—Plasma Cell Dyscrasiahttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/plasma-cell-dyscrasia/3-juni.html
Hematologic Malignancies — Plasma Cell Dyscrasia Oral Abstract Session | S100bc | Live Stream | 3. Juni 2025 | 09:45 – 12:45 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/plasma-cell-dyscrasia/3-juni.html
Hematologic Malignancies — Plasma Cell Dyscrasia Rapid Oral Abstract Session | E450b | On Demand | 2. Juni 2025 | 08:00 – 09:30 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/plasma-cell-dyscrasia/2-juni.html
Developmental Therapeuticshttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/developmental-therapeutics.html
Developmental Therapeutics—Immunotherapyhttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/developmental-therapeutics-immunotherapy/1-juni-2025.html
Developmental Therapeutics—Immunotherapy Oral Abstract Session | Hall D2 | Live Stream | 31. Mai 2025 | 15:00 – 18:00 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/developmental-therapeutics-immunotherapy/1-juni-2025.html
Developmental Therapeutics—Immunotherapy Rapid Oral Abstract Session | S406 | On Demand | 1. Juni 2025 | 11:15 – 12:45 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/developmental-therapeutics-immunotherapy-1-juni.html
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biologyhttps://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/molecularly-targeted-agents-and-tumor-biology/30-mai.html
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Oral Abstract Session | Hall D1 | Live Stream | 30. Mai 2025 | 14:45 – 17:45 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/molecularly-targeted-agents-and-tumor-biology/30-mai.html
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Rapid Oral Abstract Session | S406 | On Demand | 2. Juni 2025 | 08:00 – 09:30 GMT-5https://oncoletter.ch/kongressberichte/2025/ascoannualmeeting-2025/molecularly-targeted-agents-and-tumor-biology/-2-juni.html
European Lung Cancer Congress 2025https://oncoletter.ch/kongressberichte/2025/european-lung-cancer-congress-2025-elcc.html
Proffered Paper Sessionshttps://oncoletter.ch/kongressberichte/2025/elcc-proffered-paper-sessions.html
Proffered Paper Sessionshttps://oncoletter.ch/kongressberichte/2025/proffered-paper-session-1-elcc.html
Proffered Paper Session 1https://oncoletter.ch/kongressberichte/2025/proffered-paper-session-1-elcc.html
Proffered Paper Session 2https://oncoletter.ch/kongressberichte/2025/proffered-paper-session-2-elcc.html
Mini Oral Sessionshttps://oncoletter.ch/kongressberichte/2025/mini-oral-sessions-elcc.html
Mini Oral Sessionshttps://oncoletter.ch/kongressberichte/2025/mini-oral-session-1-elcc.html
Mini Oral Session 1https://oncoletter.ch/kongressberichte/2025/mini-oral-session-1-elcc.html
Mini Oral Session 2https://oncoletter.ch/kongressberichte/2025/mini-oral-session-2-elcc.html
St.Gallen International Breast Cancer Conference 2025https://oncoletter.ch/kongressberichte/2025/sgbcc-2025.html
BREAST CANCERhttps://oncoletter.ch/kongressberichte/2025/sgbcc-2025/breast-cancer.html
Interviews SGBCC 2025https://oncoletter.ch/kongressberichte/2025/sgbcc-2025/interviews/interviews-renate-haidinger-brustkrebs-deutschland.html
Interviews von Renate Haidinger, Brustkrebs Deutschland e.V.https://oncoletter.ch/kongressberichte/2025/sgbcc-2025/interviews/interviews-renate-haidinger-brustkrebs-deutschland.html
ASCO Genitourinary Cancers Symposiumhttps://oncoletter.ch/kongressberichte/2025/ascogenitourinary-cancers-symposium.html
Rapid Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/2025/rapid-oral-abstract-sessions.html
Rapid Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/2025/rapid-oral-abstract-session-a-prostate-cancer.html
Rapid Oral Abstract Session A: Prostate Cancerhttps://oncoletter.ch/kongressberichte/2025/rapid-oral-abstract-session-a-prostate-cancer.html
Rapid Oral Abstract Session B: Urothelial Carcinomahttps://oncoletter.ch/kongressberichte/2025/rapid-oral-abstract-session-b-urothelial-carcinoma.html
Rapid Oral Abstract Session C: Renal Cell Cancer and Penile Cancerhttps://oncoletter.ch/kongressberichte/2025/rapid-oral-abstract-session-c-renal-cell-penile-cancer.html
Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/2025/oral-abstract-sessions.html
Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/2025/oral-abstract-session-a-prostate-cancer.html
Oral Abstract Session A: Prostate Cancerhttps://oncoletter.ch/kongressberichte/2025/oral-abstract-session-a-prostate-cancer.html
3 Oral Abstracts from the General Sessions: Prostate Cancerhttps://oncoletter.ch/kongressberichte/2025/oral-abstracts/general-sessions-c-prostate-cancer.html
Oral Abstract Session B: Urothelial Carcinomahttps://oncoletter.ch/kongressberichte/2025/oral-abstract-session-b-urothelial-carcinoma.html
Oral Abstract Session C: Renal Cell and Testicular Cancerhttps://oncoletter.ch/kongressberichte/2025/oral-abstract-session-c-renal-cell-cancer.html
2 Oral Abstracts from the General Sessions: Renal Cell and Urothelial carcinomahttps://oncoletter.ch/kongressberichte/2025/oral-abstracts/general-sessions-c-renal-cell-and-urothelial-carcinoma.html
Trials in Progress Poster Sessionshttps://oncoletter.ch/kongressberichte/2025/ascogenitourinary-cancers-symposium/trials-in-progress.html
Trials in Progress Poster Sessionshttps://oncoletter.ch/kongressberichte/2025/trials-in-progress-poster-session-a-prostate-cancer.html
Trials in Progress Poster Session A: Prostate Cancerhttps://oncoletter.ch/kongressberichte/2025/trials-in-progress-poster-session-a-prostate-cancer.html
Trials in Progress Poster Session B: Urothelial Carcinomahttps://oncoletter.ch/kongressberichte/2025/trials-in-progress-poster-session-b-urothelial-carcinoma.html
Trials in Progress Poster Session C: Renal Cell, Adrenal, and Testicular Cancershttps://oncoletter.ch/kongressberichte/2025/trials-in-progress-poster-session-c-renal-cell-adrenal-and-testicular-cancers.html
ASCO 2025 Gastrointestinal (GI) Cancers Symposiumhttps://oncoletter.ch/kongressberichte/2025/ascogi2025-gastrointestinal-gi-cancers-symposium.html
Rapid Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/2025/asco-2025-gastrointestinal-gi-cancers-symposium/rapid-oral-abstract-sessions.html
Rapid Abstract Sessionshttps://oncoletter.ch/kongressberichte/2025/ascogi-2025-rapid-oral-abstract-cancers-of-the-colon-rectum-and-anus.html
Rapid Oral Abstract Session A: Cancers of the Esophagus and Stomachhttps://oncoletter.ch/kongressberichte/2025/ascogi-2025-rapid-oral-abstract-cancers-of-the-esophagus-and-stomach.html
Rapid Oral Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tracthttps://oncoletter.ch/kongressberichte/2025/ascogi-2025/rapid-oral-cancers-of-the-pancreas-small-bowel-and-hepatobiliary-tract.html
Rapid Oral Abstract Session C: Cancers of the Colon, Rectum, and Anushttps://oncoletter.ch/kongressberichte/2025/ascogi-2025-rapid-oral-abstract-cancers-of-the-colon-rectum-and-anus.html
Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/2025/ascogi-2025/oral-abstracts.html
Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/2025/ascogi-2025/oral-abstracts-cancers-of-the-esophagus-and-stomach.html
Oral Abstract Session A: Cancers of the Esophagus and Stomachhttps://oncoletter.ch/kongressberichte/2025/ascogi-2025/oral-abstracts-cancers-of-the-esophagus-and-stomach.html
Oral Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tracthttps://oncoletter.ch/kongressberichte/2025/ascogi-2025/oral-abstracts-cancers-of-the-pancreas-small-bowel-and-hepatobiliary-tract.html
Oral Abstract Session C: Cancers of the Colon, Rectum, and Anushttps://oncoletter.ch/kongressberichte/2025/ascogi-2025/oral-abstracts-cancers-of-the-colon-rectum-and-anus.html
Trials in Progress Poster Sessionshttps://oncoletter.ch/kongressberichte/2025/ascogi-2025/trials-in-progress-poster-sessions.html
Trials in Progress Poster Sessionshttps://oncoletter.ch/kongressberichte/2025/ascogi-2025/trials-in-progress-posters-cancers-of-the-esophagus-and-stomach-and-other-gastrointestinal-cancers.html
Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancershttps://oncoletter.ch/kongressberichte/2025/ascogi-2025/trials-in-progress-posters-cancers-of-the-esophagus-and-stomach-and-other-gastrointestinal-cancers.html
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tracthttps://oncoletter.ch/kongressberichte/2025/ascogi-2025/trials-in-progress-posters-cancers-of-the-pancreas-small-bowel-and-hepatobiliary-tract.html
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anushttps://oncoletter.ch/kongressberichte/2025/ascogi-2025/trials-in-progress-posters-cancers-of-the-colon-rectum-and-anus.html
Links to more Abstractshttps://oncoletter.ch/kongressberichte/2025/ascogi2025-gastrointestinal-gi-cancers-symposium/links-to-more-abstracts.html
2024https://oncoletter.ch/kongressberichte/id-2024.html
47th SAN ANTONIO BREAST CANCER SYMPOSIUM - December 10 - 13, 2024, San Antonio Texashttps://oncoletter.ch/kongressberichte/id-2024/47th-san-antonio-breast-cancer-symposium.html
Studies presented at the SABCS 2024 Press Briefinghttps://oncoletter.ch/kongressberichte/id-2024/studies-presented-at-the-sabcs-2024-press-briefing.html
Interviews von Renate Haidinger, Brustkrebs Deutschland e.V.https://oncoletter.ch/kongressberichte/id-2024/sabcs-interviews-von-renate-haidinger-brustkrebs-deutschland-e-v.html
Kurze Videos mit Expert:innen zu ausgewählten Highlights aus Sitzungen und Vorträgen sowie speziellen Schwerpunktthemenhttps://oncoletter.ch/kongressberichte/id-2024/sabcs-kurze-videos-mit-expert-innen-zu-ausgewaehlten-highlights-aus-sitzungen-und-vortraegen-sowie-speziellen-schwerpunktthemen.html
General Sessions 1-3https://oncoletter.ch/kongressberichte/id-2024/general-sessions-1-3.html
General Sessionshttps://oncoletter.ch/kongressberichte/id-2024/sabcs-general-session-1.html
GENERAL SESSION 1 | WEDNESDAY, DECEMBER 11 | 9:15-11:30 am. Location: Hall 1https://oncoletter.ch/kongressberichte/id-2024/sabcs-general-session-1.html
GENERAL SESSION 2 | THURSDAY, DECEMBER 12 | 9-11:45 am. Location: Hall 1https://oncoletter.ch/kongressberichte/id-2024/sabcs-general-session-2.html
GENERAL SESSION 3 | FRIDAY, DECEMBER 13 | 9-11:45 am. Location: Hall 1https://oncoletter.ch/kongressberichte/id-2024/sabcs-general-session-3.html
Rapid Fire Sessions 1&2https://oncoletter.ch/kongressberichte/id-2024/rapid-fire-sessions-1-2.html
Rapid Fire Sessions 1&2https://oncoletter.ch/kongressberichte/id-2024/sabcs-rapid-fire-session-1.html
Rapid Fire Session 1 | WEDNESDAY, DECEMBER 11 | 12-12:50 pm. Location: Hall 1https://oncoletter.ch/kongressberichte/id-2024/sabcs-rapid-fire-session-1.html
Rapid Fire Session 2 | THURSDAY, DECEMBER 12 | 12:00-12:50 pm. Location: Hall 1https://oncoletter.ch/kongressberichte/id-2024/sabcs-rapid-fire-session-2.html
Rapid Fire Session 3 | FRIDAY, DECEMBER 13 | 12-12:50 pm. Location: Hall 1 (Kopie)https://oncoletter.ch/kongressberichte/id-2024/sabcs-rapid-fire-session-3.html
Late Breaking Abstracts Oral Sessionhttps://oncoletter.ch/kongressberichte/id-2024/sabcs-late-breaking-abstracts-oral-session.html
Late Breaking Abstracts Oral Sessionhttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/late-breaking-abstracts-oral-session/late-breaking-abstracts-oral-session-friday-december-8.html
Late Breaking Abstracts Oral Session| TUESDAY, DECEMBER 10 | 6 - 7 pm. Location: Stars at Night 1-2https://oncoletter.ch/kongressberichte/id-2024/sabcs-late-breaking-abstracts-oral-session-tuesday-december-10/late-breaking-abstracts-oral-session/late-breaking-abstracts-oral-session-tuesday-december-10-6-7-pm-location-stars-at-night-1-2.html
POSTER SPOTLIGHT SESSIONS 1-18https://oncoletter.ch/kongressberichte/id-2024/poster-spotlight-sessions-1-18.html
POSTER SPOTLIGHT SESSIONShttps://oncoletter.ch/kongressberichte/id-2024/sabcs-poster-spotlight-session-1-new-insights-into-immune-biomarkers.html
Session 1: New Insights into Immune Biomarkers - Wednesday December 11, 7-8:30 am. Location: Room 221ABChttps://oncoletter.ch/kongressberichte/id-2024/sabcs-poster-spotlight-session-1-new-insights-into-immune-biomarkers.html
Session 2: Personalizing CDK 4/6 inhibitor therapy for patients with Metastatic Breast Cancer: Survival, QOL and biomarkers - Thursday, December 12, 7-8:30 am. Location: Hemisfair Ballroom 1-2https://oncoletter.ch/kongressberichte/id-2024/poster-spotlight-sessions-2-personalizing-cdk-4-6-inhibitor-therapy-for-patients-with-metastatic-breast-cancer-survival-qol-and-biomarkers.html
Session 3: Highlights on Novel Therapeutics - Wednesday December 11, 7-8:30 am. Location: Stars at Night 1-2https://oncoletter.ch/kongressberichte/id-2024/sabcs-poster-spotlight-session-3-highlights-on-novel-therapeutics.html
Session 4: Prediction of Chemotherapy Response - Wednesday December 11, 7-8:30 am. Location: Stars at Night 3-4https://oncoletter.ch/kongressberichte/id-2024/sabcs-poster-spotlight-session-4-prediction-of-chemotherapy-response.html
Session 5: The Heart of the Matter - Improving Adverse Effects - Wednesday December 11, 7-8:30 am. Location: Hemisfair Ballroom 3https://oncoletter.ch/kongressberichte/id-2024/sabcs-poster-spotlight-session-5-the-heart-of-the-matter-improving-adverse-effects.html
Session 6: Locoregional Therapy - Thursday, December 12, 7-8:30 am. Location: Room 221ABChttps://oncoletter.ch/kongressberichte/id-2024/sabcs-poster-spotlight-session-6-locoregional-therapy-thursday-december-12-7-8-30-am-location-room-221abc.html
Session 7: Targeting the ER and PI3K pathway: Novel drugs and combinations - Wednesday December 11, 7-8:30 am. Location: Hemisfair Ballroom 1-2https://oncoletter.ch/kongressberichte/id-2024/sabcs-poster-spotlight-session-7-targeting-the-er-and-pi3k-pathway-novel-drugs-and-combinations.html
Session 8: Novel HER2 Therapeutics - Thursday, December 12, 7-8:30 am. Location: Stars at Night 1-2https://oncoletter.ch/kongressberichte/id-2024/sabcs-poster-spotlight-sessions-8-novel-her2-therapeutics-thursday-december-12-7-8-30-am-location-stars-at-night-1-2.html
Session 9: ctDNA uses for Minimal Residual Disease testing, tumor evolution, and novel technologies - Thursday, December 12, 7-8:30 am. Location: Stars at Night 3-4https://oncoletter.ch/kongressberichte/id-2024/sabcs-poster-spotlight-sessions-9-ctdna-uses-for-minimal-residual-disease-testing-tumor-evolution-and-novel-technologies.html
Session 10: Addressing Racial Disparities in Breast Cancer Outcomes - Friday, December 13, 7-8:30 am. Location: Hemisfair Ballroom 3https://oncoletter.ch/kongressberichte/id-2024/sabcs-poster-spotlight-sessions-10-addressing-racial-disparities-in-breast-cancer-outcomes.html
Session 11: Imaging to Guide Breast Cancer Treatment – Molecular Imaging and AI - Friday, December 13, 7-8:30 am. Location: Hemisfair Ballroom 1-2https://oncoletter.ch/kongressberichte/id-2024/sabcs-poster-spotlight-sessions-11imaging-to-guide-breast-cancer-treatment-molecular-imaging-and-ai.html
Session 12: Immunobiology Impact on Therapeutic Efficacy - Friday, December 13, 7-8:30 am. Location: Room 221ABChttps://oncoletter.ch/kongressberichte/id-2024/sabcs-poster-spotlight-sessions-12-immunobiology-impact-on-therapeutic-efficacy.html
Session 13: Molecular determinants of therapeutic response and resistance - Spotight on CDK 4/6i and ADCs Location: Stars at Night 1-2https://oncoletter.ch/kongressberichte/id-2024/sabcs-poster-spotlight-sessions-1-18/poster-spotlight-sessions/session-13-molecular-determinants-of-therapeutic-response-and-resistance-spotight-on-cdk-4-6i-and-adcs-location-stars-at-night-1-2.html
Session 14: Brain Metastasis - Friday, December 13, 7-8:30 am. Location: Stars at Night 3-4https://oncoletter.ch/kongressberichte/id-2024/sabcs-poster-spotlight-session-14-brain-metastasis.html
Session 15: Survivorship – Biomarker predictors and other survival-associated factors- Thursday, December 12, 7-8:30 am. Location: Room 221ABChttps://oncoletter.ch/kongressberichte/id-2024/sabcs-poster-spotlight-session-15-survivorship-biomarker-predictors-and-other-survival-associated-factors.html
Session 16: Polygenic Risk - Thursday, December 12, 5:30-7 pm am. Location: Hemisfair Ballroom 3https://oncoletter.ch/kongressberichte/id-2024/sabcs-poster-spotlight-session-16-polygenic-risk.html
Session 17: Early Triple Negative Breast Cancer - Thursday, December 12, 5:30-7 pm am. Location: Stars at Night 1-2https://oncoletter.ch/kongressberichte/id-2024/sabcs-poster-spotlight-session-17-early-triple-negative-breast-cancer.html
Session 18: Advancing our understanding of invasive lobular carcinoma: Potential to develop personalized therapeutic strategies? - Thursday, December 12, 5:30-7 pm am. Location: Stars at Night 3-4https://oncoletter.ch/kongressberichte/id-2024/poster-spotlight-sessions-18-advancing-our-understanding-of-invasive-lobular-carcinoma-potential-to-develop-personalized-therapeutic-strategies.html
Session 19: “A penny for your thoughts.” How cost influences care Location: Thursday December 12, 5:30-7 pm. Hemisfair Ballroom 1-2https://oncoletter.ch/kongressberichte/id-2024sabcs-poster-spotlight-sessions-19-a-penny-for-your-thoughts-how-cost-influences-care.html
66th ASH Annual Meeting and Exposition - December 7-10, 2024https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024.html
ASH 24 Press Briefings on Late Breaking and other important Abstractshttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024-press-briefings.html
ASH Press Briefingshttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024-press-briefings/december-8.html
ASH Press Briefing 3, Sunday December 8, 2024https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024-press-briefings/december-8.html
ASH Press Briefing 4, Monday December 9, 2024 Late Breaking Abstractshttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024-press-briefings/december-9.html
ASH 2024 Late-Breaking Abstracts Sessionhttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024-late-breaking-abstracts-session.html
ASH 2024 Plenary Scientific Sessionhttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/plenary-scientific-session.html
Acute Lymphoblastic Leukemiashttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/acute-lymphoblastic-leukemias.html
ALL: Clinical and Epidemiological studieshttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/outcome-predictors-in-all.html
Look into the Crystal B-ALL: Genetic, Phenotypic and Dynamic Outcome Predictors in Lymphoblastic Leukemia: Monday, December 9, 2024: 10:30 AM-12:00 PM Marriott Grand Ballroom 11-13 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/outcome-predictors-in-all.html
ALL: Therapies, Excluding Allogeneic Transplantation:https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/all-risk-stratification-and-car-t-therapies.html
Risk Stratification and CAR-T Therapies: Monday, December 9, 2024: 4:30 PM-6:00 PM Marriott Grand Ballroom 5-6 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/all-risk-stratification-and-car-t-therapies.html
Treatment of BCR:ABL+ and T Cell Diseases: Monday, December 9, 2024: 2:45 PM-4:15 PM Marriott Grand Ballroom 2-4 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/all-treatment-of-bcr-abl-and-t-cell-diseases.html
Clinical Trials in Pediatric and Young Adult Patients: Saturday, December 7, 2024: 4:00 PM-5:30 PM Marriott Grand Ballroom 5-6 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/all-clinical-trials-in-pediatric-and-young-adult-patients.html
Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosishttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/genomic-determinants-of-outcomes-in-all.html
Genomic Determinants of Outcomes In ALL: Saturday, December 7, 2024: 4:00 PM-5:30 PM Marriott Grand Ballroom 8-9 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/genomic-determinants-of-outcomes-in-all.html
Understanding and Exploiting Molecular Therapeutic Targets in ALL: Sunday, December 8, 2024: 4:30 PM-6:00 PM Marriott Grand Ballroom 5-6 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/understanding-and-exploiting-molecular-therapeutic-targets-in-all.html
ALL Links to Poster Sessionshttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/all-links-to-poster-sessions.html
Acute Myeloid Leukemiashttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/acute-myeloid-leukemias.html
AML: Clinical and Epidemiological studieshttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/aml-in-specific-age-groups-blastic-plasmacytoid-dendritic-cell-neoplasms.html
Treatments and Outcomes in AML in Specific Age Groups, and in Blastic Plasmacytoid Dendritic Cell Neoplasms: Saturday, December 7, 2024: 4:00 PM-5:30 PM Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/aml-in-specific-age-groups-blastic-plasmacytoid-dendritic-cell-neoplasms.html
Frailty, Age, and Care Provisions-Impact on AML Outcomes: Sunday, December 8, 2024: 9:30 AM-11:00 AM Seaport Ballroom ABCD (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/frailty-age-and-care-provisions-impact-on-aml-outcomes.html
Genetic Markers and Outcomes in AML: Monday, December 9, 2024: 2:45 PM-4:15 PM Grand Hall C (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/genetic-markers-and-outcomes-in-aml.html
AML: Investigational Drug and Cellular Therapieshttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/aml-investigational-drug-and-cellular-therapies/menin-inhibitors.html
Menin Inhibitors in AML: Saturday, December 7, 2024: 2:00 PM-3:30 PM Ballroom 20CD (San Diego Convention Center)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/aml-investigational-drug-and-cellular-therapies/menin-inhibitors.html
New Treatment Approaches for AML: Monday, December 9, 2024: 10:30 AM-12:00 PM Grand Hall B (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/aml-investigational-drug-and-cellular-therapies/new-treatment-approaches-for-aml.html
AML: Commercially Available Therapies:https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/impact-of-molecularly-targeted-agents-in-aml.html
Impact of Molecularly-Targeted Agents in AML: Saturday, December 7, 2024: 2:00 PM-3:30 PM Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/impact-of-molecularly-targeted-agents-in-aml.html
How Do We Start? Upfront Regimens with Commercially Available Therapies: Saturday, December 7, 2024: 9:30 AM-11:00 AM Hall B (San Diego Convention Center)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/aml-how-do-we-start-upfront-regimens-with-commercially-available-therapies.html
Optimizing Regimens in Children/Young Adults and Around the World: Monday, December 9, 2024: 4:30 PM-6:00 PM Grand Hall B (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/aml-optimizing-regimens-in-children-young-adults-and-around-the-world.html
AML: Biomarkers and Molecular Markers in Diagnosis and Prognosis:https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/aml-multi-omic-applications-for-disease-evolution-and-response-to-therapy.html
Multi-omic Applications for Disease Evolution and Response to Therapy: Saturday, December 7, 2024: 9:30 AM-11:00 AM Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/aml-multi-omic-applications-for-disease-evolution-and-response-to-therapy.html
Functional Genomics in Prognosis and Novel Therapies: Saturday, December 7, 2024: 4:00 PM-5:30 PM Seaport Ballroom ABCD (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/aml-functional-genomics-in-prognosis-and-novel-therapies.html
Deciphering the Mechanisms Underlying Prognosis: Sunday, December 8, 2024: 4:30 PM-6:00 PM Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/aml-deciphering-the-mechanisms-underlying-prognosis.html
Refining Diagnostic Risk Assessment: Monday, December 9, 2024: 2:45 PM-4:15 PM Grand Hall B (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/aml-refining-diagnostic-risk-assessment.html
AML: Disease Burden and Minimal Residual Disease in Prognosis and Treatmenthttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/aml-measurable-residual-disease-in-aml-in-2024-and-beyond.html
Measurable Residual Disease in AML in 2024 and Beyond: Saturday, December 7, 2024: 2:00 PM-3:30 PM Seaport Ballroom ABCD (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/aml-measurable-residual-disease-in-aml-in-2024-and-beyond.html
AML Links to Poster Sessionshttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/aml-links-to-poster-sessions.html
Chronic Myeloid Leukemiahttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/chronic-myeloid-leukemia.html
CML: Clinical and Epidemiological Programmhttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/cml-novel-molecules-in-clinical-practice.html
CML: Novel Molecules in Clinical Practice: Sunday, December 8, 2024: 9:30 AM-11:00 AM Harbor Ballroom DEFG (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/cml-novel-molecules-in-clinical-practice.html
CML: Alternative Laboratory Predictors of Outcome: Monday, December 9, 2024: 4:30 PM-6:00 PM Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/Cml-alternative-laboratory-predictors-of-outcome.html
CML Links to Poster Sessionshttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/chronic-myeloid-leukemia/cml-links-to-poster-sessions.html
Myeloproliferative Syndromes and Chronic Myeloid Leukemiahttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/myeloproliferative-syndromes-and-chronic-myeloid-leukemia.html
Myeloproliferative Syndromes and Chronic Myeloid Leukemiahttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/mps-basic-and-translational-stem-cell-biology-in-myeloproliferative-syndromes.html
MPS: Basic and Translational: Stem Cell Biology in Myeloproliferative Syndromes: Monday, December 9, 2024: 10:30 AM-12:00 PM Grand Hall C (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/mps-basic-and-translational-stem-cell-biology-in-myeloproliferative-syndromes.html
MPS: Basic and Translational: New Insights into The Biology of Myeloproliferative Syndromes: Monday, December 9, 2024: 2:45 PM-4:15 PM Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/mps-basic-and-translational-new-insights-into-the-biology-of-myeloproliferative-syndromes.html
MPS: Clinical and Epidemiologicalhttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/mps-risk-stratification-and-therapeutic-implications.html
MPS: Risk Stratification and Therapeutic Implications: Saturday, December 7, 2024: 2:00 PM-3:30 PM Ballroom 20AB (San Diego Convention Center)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/mps-risk-stratification-and-therapeutic-implications.html
MPS: Advancing Treatment Paradigms in Myeloproliferative Neoplasms and Mastocytosis: Sunday, December 8, 2024: 4:30 PM-6:00 PM Grand Hall D (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/mps-clinical-and-epidemiological/mps-advancing-treatment-paradigms-myeloproliferative-neoplasms-mastocytosis.html
MPS: JAK Inhibitors in MPDs, Novel Insights and Next-Gen Agents: Sunday, December 8, 2024: 9:30 AM-11:00 AM Grand Hall C (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/mps-jak-inhibitors-in-mpds-novel-insights-and-next-gen-agents.html
MPS: Advancing MPN Care: Innovative Therapies and Clinical Breakthroughs in Myelofibrosis: Monday, December 9, 2024: 4:30 PM-6:00 PM Harbor Ballroom DEFG (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/advancing-mpn-care-innovative-therapies-clinical-breakthroughs-myelofibrosis.html
Myeloproliferative Syndromes: Links to Poster Sessionshttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/myeloproliferative-syndromes-links-to-poster-sessions.html
Lymphomashttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/lymphomas.html
Lymphomas: Translationalhttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/molecular-and-genetic-single-cell-spatial-analyses-aggressive-t-cell-lymphomas.html
Molecular and genetic: Molecular Profiling and Targets in Aggressive Lymphomas: Saturday, December 7, 2024: 2:00 PM-3:30 PM Pacific Ballroom Salons 15-17 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/molecular-and-genetic-single-cell-spatial-analyses-aggressive-t-cell-lymphomas.html
Molecular and Genetic: Single-cell and Spatial Analyses in Aggressive and T Cell Lymphomas: Sunday, December 8, 2024: 9:30 AM-11:00 AM Marriott Grand Ballroom 5-6 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/lymphomas/aggressive-and-t-cell-lymphomas.html
Molecular and Genetic: Single-cell and Spatial Analyses in Indolent Lymphomas: Monday, December 9, 2024: 10:30 AM-12:00 PM Marriott Grand Ballroom 5-6 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/lymphomas/lymphomas-translational/molecular-and-genetic-single-cell-and-spatial-analyses-in-indolent-lymphomas.html
Molecular and Genetic: Molecular Profiling and Prognostic Biomarkers in Hodgkin and Non-Hodgkin Lymphomas: Monday, December 9, 2024: 2:45 PM-4:15 PM Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/lprognostic-biomarkers-in-hodgkin-and-non-hodgkin-lymphomas.html
Non-Genetic: Novel Immune Evasion Strategies in B Cell Lymphomas: Saturday, December 7, 2024: 4:00 PM-5:30 PM Pacific Ballroom Salons 15-17 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/non-genetic-novel-immune-evasion-strategies-in-b-cell-lymphomas.html
Non-Genetic: New Approaches and Models for Improving Lymphoma Therapies: Monday, December 9, 2024: 4:30 PM-6:00 PM Marriott Grand Ballroom 11-13 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/new-approaches-and-models-for-improving-lymphoma-therapies.html
Non-Genetic: Demystifying the Complexity of the Lymphoma Tumor Microenvironment and Immune Responses: Sunday, December 8, 2024: 4:30 PM-6:00 PM Pacific Ballroom Salons 15-17 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/complexity-of-the-lymphoma-tumor-microenvironment-and-immune-responses.html
Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological:https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/therapies-mantle-cell-lymphoma.html
Therapies for Mantle Cell Lymphoma: Saturday, December 7, 2024: 2:00 PM-3:30 PM Marriott Grand Ballroom 11-13 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/therapies-mantle-cell-lymphoma.html
Novel Treatment Strategies and New Data on Old Standards for Follicular Lymphoma: Saturday, December 7, 2024: 4:00 PM-5:30 PM Marriott Grand Ballroom 11-13 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/Follicular-Lymphoma-Novel-Treatment-Strategies.html
Updates on Drug Treatments for Mantle Cell Lymphoma, and CAR-T and Transplants for Indolent Lymphomas: Monday, December 9, 2024: 10:30 AM-12:00 PM Marriott Grand Ballroom 8-9 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/phomas/updates-on-drug-treatments-for-mantle-cell-lymphoma-cart.html
Clinical and Epidemiological: Clinical Trials for Marginal Zone Lymphoma, Waldenstrom's Macroglobulinemia and Hairy Cell Leukemia: Monday, December 9, 2024: 2:45 PM-4:15 PM Marriott Grand Ballroom 11-13 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/mantle-cell-follicular-and-other-indolent-b-cell-lymphomas/clinical-and-epidemiological-clinical-trials-for-marginal-zone-lymphoma-waldenstrom-s-macroglobulinemia-and-hairy-cell-leukemia.html
ASH Update Results Zanubrutinib & Video Statementhttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/ash-update-results-zanubrutinib-video-statement.html
Hodgkin Lymphomas and T Cell, NK Cell, or NK/T Lymphomashttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/potentially-practice-changing-trials-in-hodgkin-lymphoma.html
Clinical and Epidemiological: Potentially Practice-Changing Trials in Hodgkin Lymphoma: Sunday, December 8, 2024: 9:30 AM-11:00 AM Ballroom 20AB (San Diego Convention Center)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/potentially-practice-changing-trials-in-hodgkin-lymphoma.html
Clinical and Epidemiological: Optimization of Therapy: Sunday, December 8, 2024: 12:00 PM-1:30 PM Ballroom 20CD (San Diego Convention Center)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/hodgkin-lymphomas-optimization-of-therapy.html
T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Are We Ready to Move the Needle in T Cell Lymphomas? Monday, December 9, 2024: 4:30 PM-6:00 PM Pacific Ballroom Salons 15-17 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/t-cell-nk-cell-or-nk-t-cell-lymphomasare-we-ready-to-move-the-needle-in-t-cell-lymphomas.html
T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: When Old Meets New in T Cell Lymphomas: Sunday, December 8, 2024: 9:30 AM-11:00 AM Ballroom 20CD (San Diego Convention Center)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/t-cell-nk-cell-nk-t-lymphomas/t-cell-nk-cell-or-nk-t-cell-lymphomas-when-old-meets-new-in-t-cell-lymphomas.html
Aggressive Lymphomashttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/cars-bispecifics-and-adcs-progress-and-challenges-in-aggressive-b-cell-lymphoma.html
Clinical and Epidemiological: CARs, Bispecifics, and ADCs: Progress and Challenges in Aggressive B Cell Lymphoma: Sunday, December 8, 2024: 9:30 AM-11:00 AM Marriott Grand Ballroom 8-9 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/cars-bispecifics-and-adcs-progress-and-challenges-in-aggressive-b-cell-lymphoma.html
Clinical and Epidemiological: Challenging Subtypes of Aggressive Lymphomas: Sunday, December 8, 2024: 12:00 PM-1:30 PM Marriott Grand Ballroom 5-6 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/challenging-subtypes-of-aggressive-lymphomas.html
Clinical and Epidemiological: New Prognostic Tools and Treatment Outcomes in Diffuse Large B Cell Lymphoma: Sunday, December 8, 2024: 4:30 PM-6:00 PM Marriott Grand Ballroom 8-9 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/new-prognostic-tools-and-treatment-outcomes-in-diffuse-large-b-cell-lymphoma.html
Pharmacologic Therapies: Novel Monotherapies or Novel Disease Indications: Monday, December 9, 2024: 2:45 PM-4:15 PM Pacific Ballroom Salons 15-17 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/aggressive-lymphomas/pharmacologic-therapies-novel-monotherapies-or-novel-disease-indications.html
Pharmacologic Therapies: New R-CHOP Combinations for Treatment Naïve DLBCL: Sunday, December 8, 2024: 12:00 PM-1:30 PM Ballroom 20AB (San Diego Convention Center)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/new-r-chop-combinations-for-treatment-naive-dlbcl.html
Pharmacologic Therapies: Chemotherapy-free Combinations for Relapsed Aggressive Lymphomas: Monday, December 9, 2024: 4:30 PM-6:00 PM Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/chemotherapy-free-combinations-for-relapsed-aggressive-lymphomas.html
Cellular Therapies: Novel Strategies for Cell Therapies in Aggressive Lymphomas: Saturday, December 7, 2024: 9:30 AM-11:00 AM Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/cellular-therapies-novel-strategies-for-cell-therapies-in-aggressive-lymphomas.html
Lymphomas: Links to Poster Sessionshttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/ymphomas-links-to-poster-sessions.html
Chronic Lymphocytic Leukemiashttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/chronic-lymphocytic-leukemias.html
CLL - Clinical and Epidemiological:https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/chronic-lymphocytic-leukemias/cll/frontline-targeted-therapy-combinations.html
Frontline Targeted Therapy Combinations: Monday, December 9, 2024: 4:30 PM-6:00 PM Marriott Grand Ballroom 8-9 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/chronic-lymphocytic-leukemias/cll/frontline-targeted-therapy-combinations.html
Mutations, Prognosis and MRD in CLL: Sunday, December 8, 2024: 12:00 PM-1:30 PM Marriott Grand Ballroom 8-9 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/chronic-lymphocytic-leukemias/cll/mutations-prognosis-and-mrd-in-cll.html
Treating Refractory Disease-Novel Agents and Quality-of-Life: Monday, December 9, 2024: 2:45 PM-4:15 PM Marriott Grand Ballroom 5-6 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/chronic-lymphocytic-leukemias/cll/treating-refractory-disease-novel-agents-and-quality-of-life.html
ASH Update Results Zanubrutinib & Video Statementhttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/cll/ash-update-results-zanubrutinib-video-statement.html
Chronic Lymphocytic Leukemia: Link to Postershttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/chronic-lymphocytic-leukemias/chronic-lymphocytic-leukemia-link-to-posters.html
Myelodysplastic Syndromeshttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/myelodysplastic-syndromes.html
MDShttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/mechanisms-and-therapeutic-vulnerabilities-in-molecular-genetic-subtypes-of-mds.html
Basic and Translational: Disease Mechanisms and Therapeutic Vulnerabilities in Molecular Genetic Subtypes of MDS: Saturday, December 7, 2024: 4:00 PM-5:30 PM Ballroom 20CD (San Diego Convention Center)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/mechanisms-and-therapeutic-vulnerabilities-in-molecular-genetic-subtypes-of-mds.html
Basic and Translational: Novel Mechanisms of Aberrant Hematopoiesis and Immune Evasion in MDS: Monday, December 9, 2024: 2:45 PM-4:15 PM Grand Hall D (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/mechanisms-of-aberrant-hematopoiesis-and-immune-evasion-in-mds.html
Clinical and Epidemiological: Defining and Treating Low Risk MDS: Saturday, December 7, 2024: 4:00 PM-5:30 PM Ballroom 20AB (San Diego Convention Center)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/clinical-and-epidemiological-defining-and-treating-low-risk-mds.html
Clinical and Epidemiological: Treatment and Prognostication of MDS: Sunday, December 8, 2024: 4:30 PM-6:00 PM Harbor Ballroom DEFG (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/treatment-and-prognostication-of-mds.html
Clinical and Epidemiological: Defining and Treating Chronic Myelomonocytic Leukemia: Monday, December 9, 2024: 4:30 PM-6:00 PM Grand Hall D (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/defining-and-treating-chronic-myelomonocytic-leukemia.html
MDS: Link to Postershttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/myelodysplastic-syndromes/mds-link-to-posters.html
Multiple Myeloma and Plasma Cell Dyscrasiashttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/multiple-myeloma-and-plasma-cell-dyscrasias.html
Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translationalhttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/genomic-and-epigenomic-insights-into-myeloma-outcomes.html
Genomic and Epigenomic Insights into Myeloma Outcomes: Saturday, December 7, 2024: 2:00 PM-3:30 PM San Diego Ballroom AB (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/genomic-and-epigenomic-insights-into-myeloma-outcomes.html
Understanding and Improving TCE and CAR-T Cell Therapies for Plasma Cell Disorders: Saturday, December 7, 2024: 4:00 PM-5:30 PM Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/understanding-and-improving-tce-and-car-t-cell-therapies-for-plasma-cell-disorders.html
Resistance and Response to Anti-Myeloma Therapies: Sunday, December 8, 2024: 12:00 PM-1:30 PM San Diego Ballroom AB (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/resistance-and-response-to-anti-myeloma-therapies.html
Microenvironment and Immunity in Myeloma: Sunday, December 8, 2024: 4:30 PM-6:00 PM Pacific Ballroom Salons 24-26 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/microenvironment-and-immunity-in-myeloma.html
Uncovering New Targets and Disease Mechanisms in Myeloma: Monday, December 9, 2024: 10:30 AM-12:00 PM Pacific Ballroom Salons 24-26 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/uncovering-new-targets-and-disease-mechanisms-in-myeloma.html
Multiple Myeloma: Clinical and Epidemiologicalhttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/advancing-minimal-residual-disease-mrd-detection-impact-on-prognosis-and-treatment-decisions.html
Advancing Minimal Residual Disease (MRD): Detection, Impact on Prognosis and Treatment Decisions: Saturday, December 7, 2024: 4:00 PM-5:30 PM San Diego Ballroom AB (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/advancing-minimal-residual-disease-mrd-detection-impact-on-prognosis-and-treatment-decisions.html
Addressing Hematologic and Immune Toxicities and the Status of Quad Therapies: Saturday, December 7, 2024: 2:00 PM-3:30 PM Pacific Ballroom Salons 21-22 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/multiple-myeloma/addressing-hematologic-and-immune-toxicities-and-the-status-of-quad-therapies.html
Decluttering Responses and Dynamic Risk: How Can We Improve Prognostication in Multiple Myeloma? Saturday, December 7, 2024: 9:30 AM-11:00 AM Pacific Ballroom Salons 24-26 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/how-can-we-improve-prognostication-in-multiple-myeloma.html
Cellular and Molecular Profiling of Multiple Myeloma: Implications for Clinical Practice: Sunday, December 8, 2024: 9:30 AM-11:00 AM Pacific Ballroom Salons 21-22 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/cellular-and-molecular-profiling-of-multiple-myeloma-implications-for-clinical-practice.html
Exploring T Cell Redirecting Therapies, Mutation Profiles and Early Relapse: Monday, December 9, 2024: 2:45 PM-4:15 PM Pacific Ballroom Salons 24-26 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/multiple-myeloma-exploring-t-cell-redirecting-therapies-mutation-profiles-and-early-relapse.html
Multiple Myeloma: Pharmacologic and Cellular Therapieshttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/optimizing-therapy-in-newly-diagnosed-myeloma-and-beyond.html
Optimizing Therapy in Newly Diagnosed Myeloma and Beyond: Sunday, December 8, 2024: 4:30 PM-6:00 PM Pacific Ballroom Salons 21-22 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/optimizing-therapy-in-newly-diagnosed-myeloma-and-beyond.html
Refining the Evidence: Randomized Trials in Multiple Myeloma: Monday, December 9, 2024: 10:30 AM-12:00 PM Pacific Ballroom Salons 21-22 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/refining-the-evidence-randomized-trials-in-multiple-myeloma.html
Targeting BCMA: Sunday, December 8, 2024: 9:30 AM-11:00 AM Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/multiple-myeloma-targeting-bcma.html
Into the Future: New Drugs and Combinations in Multiple Myeloma: Monday, December 9, 2024: 4:30 PM-6:00 PM Hall B (San Diego Convention Center)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/new-drugs-and-combinations-in-multiple-myeloma.html
Cellular Therapies: Unleashing Cell Therapies Against Myeloma: Monday, December 9, 2024: 4:30 PM-6:00 PM Pacific Ballroom Salons 24-26 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/unleashing-cell-therapies-against-myeloma.html
MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasiashttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/ignored-no-longer-progress-in-al-amyloidosis.html
Clinical and Epidemiological: Ignored no Longer-Progress in AL Amyloidosis: Monday, December 9, 2024: 2:45 PM-4:15 PM Pacific Ballroom Salons 21-22 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/ignored-no-longer-progress-in-al-amyloidosis.html
Clinical and Epidemiological: Genes, Cells and Algorithms: Novel Methods of Predicting Progression in MGUS and SMM: Monday, December 9, 2024: 4:30 PM-6:00 PM Pacific Ballroom Salons 21-22 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/mgus-amyloidosis-and-other-non-myeloma-plasma-cell-dyscrasias/novel-methods-of-predicting-progression.html
Multiple Myeloma and Plasma Dyscrasias: Link to Postershttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/multiple-myeloma-and-plasma-cell-dyscrasias-posters.html
CAR-T Cell and Cellular Immunotherapies other than CAR-T Cellshttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/car-t-cell-and-cellular-immunotherapies-other-than-car-t-cells.html
CAR-T Cell and Cellular Immunotherapies other than CAR-T Cellshttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/enhancements-in-car-t-cell-signaling-delivery-Manufacturing.html
CAR-T Cell Therapies: Basic and Translational: Myeloid Biology and CAR-T Cells: Saturday, December 7, 2024: 4:00 PM-5:30 PM Grand Hall C (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/car-t-cell-and-cellular-immunotherapies-myeloid-biology.html
CAR-T Cell Therapies: Basic and Translational: Enhancements in CAR-T Cell Signaling, Delivery & Manufacturing: Sunday, December 8, 2024: 9:30 AM-11:00 AM Room 6A (San Diego Convention Center)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/enhancements-in-car-t-cell-signaling-delivery-Manufacturing.html
CAR-T Cell Therapies: Basic and Translational: Acute and Late Toxicities Following CAR-T Cell Therapy: Monday, December 9, 2024: 2:45 PM-4:15 PM Room 6CF (San Diego Convention Center)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/acute-and-late-toxicities-following-car-t-cell-therapy.html
CAR-T Cell Therapies: Basic and Translational: Novel Targets and Therapeutic Approaches for CAR-T Cells: Monday, December 9, 2024: 4:30 PM-6:00 PM Room 6CF (San Diego Convention Center)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/novel-targets-and-therapeutic-approaches-for-car-t-cell.html
Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Novel Cell Platforms and Delivery Strategies: Saturday, December 7, 2024: 9:30 AM-11:00 AM Ballroom 20AB (San Diego Convention Center)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/novel-cell-platforms-and-Delivery-Strategies.html
Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Enhancing NK Cell Therapeutics: Monday, December 9, 2024: 2:45 PM-4:15 PM Marriott Grand Ballroom 8-9 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/basic-and-translational-enhancing-nk-cell-therapeutics.html
Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Emerging Targeting Approaches of Cell Therapies for Hematologic Malignancies: Monday, December 9, 2024: 2:45 PM-4:15 PM Hall B (San Diego Convention Center)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/emerging-targeting-approaches-of-Cell-Therapies-Hematologic-Malignancies.html
Cellular Immunotherapies: Early Phase Clinical Trials & Toxicities: CAR-T Cell Therapies for Lymphomas & ALL: New Strategies & Toxicities: Saturday, December 7, 2024: 9:30-11:00 AM Marriott Grand Ballroom 11-13 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/car-t-cell-therapies-for-lymphoma-ALL-New-Strategies-Toxicities.html
Cellular Immunotherapies: Early Phase Clinical Trials & Toxicities: B Cell-directed CAR T Cell Therapies for ALL & for Autoimmunity: Sunday, December 8, 2024: 4:30 PM-6:00 PM Marriott Grand Ballroom 2-4 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/b-cell-directed-car-t-cell-therapies-ALL-Autoimmunity.html
Cell Therapieshttps://oncoletter.ch/kongressberichte/id-2024/66th-ash-annual-meeting-2024/adoptive-cell-therapies/cell-therapies.html
ESMO Congress 2024 - 13. - 17. SEPTEMBER - BARCELONA, SPANIENhttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024.html
ESMO 2024 Press Conference Recordinghttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024-press-conference-recordings.html
ESMO24 - Presidential Symposia I-IIIhttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/presidential-symposia-i-iii.html
ESMO24 - Presidential Symposia I-IIIhttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/presidential-symposium-i-practice-changing-trials.html
Presidential Symposium I: Practice-changing trials: Sat, 14.09.24; 16:30 - 18:15; Room Barcelona Auditorium - Hall 2https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/presidential-symposium-i-practice-changing-trials.html
Presidential Symposium II: Practice-changing trials; Sun, 15.09.24; 16:30 - 18:15; Room Barcelona Auditorium Hall 2https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/presidential-symposium-ii-practice-changing-trials.html
Presidential Symposium III: Eyes to the future; Mon, 16.09.24; 16:30 - 18:15 Room Barcelona Auditorium - Hall 2https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/presidential-symposium-iii-eyes-to-the-future.html
BREAST CANCERhttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/breast-cancer.html
Interviewshttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/breast-cancer/interviews-von-renate-haidinger-brustkrebs-deutschland-e-v.html
Interviews von Renate Haidinger, Brustkrebs Deutschland e.V.https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/breast-cancer/interviews-von-renate-haidinger-brustkrebs-deutschland-e-v.html
Breast cancer, early stagehttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/breast-cancer-early-stage/proffered-paper-session-I.html
Proffered paper session: Breast cancer, early stage; Mon, 16.09.24; Time 10:15 - 11:45; Room Barcelona Auditorium - Hall 2https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/breast-cancer-early-stage/proffered-paper-session-I.html
Mini oral session: Breast cancer, early stage; Sat, 14.09.24; 10:15 - 11:45; Room Barcelona Auditorium - Hall 2https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/mini-oral-session-breast-cancer-early-stage.html
Breast cancer, metastatichttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-breast-cancer-metastatic.html
Proffered Paper session: Breast cancer, metastatic; Fri, 13.09.24; 16:00 - 17:30; Room Barcelona Auditorium - Hall 2https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-breast-cancer-metastatic.html
Mini oral session 1: Breast cancer, metastatic Sun, 15.09.2024; 08:30 - 10:00; Room Barcelona Auditorium - Hall 2https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/mini-oral-session-1-breast-cancer-metastatic.html
Mini oral session 2: Breast cancer, metastatic; Mon, 16.09.24; 08:30 - 10:00; Room Barcelona Auditorium - Hall 2https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/mini-oral-session-2-breast-cancer-metastatic.html
LUNG CANCER & OTHER THORACIC MALIGNANCIEShttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/lung-cancer-other-thoracic-malignancies.html
Non-metastatic NSCLC and other thoracic malignancieshttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-non-metastatic-nsclc.html
Proffered Paper session: Non-metastatic NSCLC; Fri, 13.09.24; 14:00 - 15:30; Room Bilbao Auditorium - Hall 2https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-non-metastatic-nsclc.html
Mini oral session 1: Non-metastatic NSCLC; Sun, 15.09.24; 10:15 - 11:30; Room Barcelona Auditorium - Hall 2https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/mini-oral-session-1-non-metastatic-nsclc-1.html
Mini oral session 2: Non-metastatic NSCLC; Mon, 16.09.24; 14:45 - 15:45; Room Sevilla Auditorium - Hall 2https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/mini-oral-session-2-non-metastatic-nsclc.html
NSCLC, metastatichttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-nsclc-metastatic.html
Proffered paper session: NSCLC metastatic; Sat, 14.09.24; 08:30 - 10:00; Room Barcelona Auditorium - Hall 2https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-nsclc-metastatic.html
Mini oral session: NSCLC metastatic; Sat, 14.09.24; 10:15 - 11:45; Room Santander Auditoriumhttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/mini-oral-session-nsclc-metastatic-1.html
HEAD & NECK CANCERhttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/head-neck-cancer.html
Head & Neck Sessionshttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-head-and-neck-cancer.html
Proffered paper session: Head and neck cancer; Sun, 15.09.24; 10:15 - 11:45; Room Valencia Auditorium - Hall 5https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-head-and-neck-cancer.html
Mini oral session: Head and neck cancer; Sat, 14.09.24; 08:30 - 10:00; Room Bilbao Auditorium - Hall 2https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/mini-oral-session-head-and-neck-cancer.html
GYNAECOLOGICAL CANCERShttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/gynaecological-cancers.html
Gynaecological Sessionshttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-gynaecological-cancers.html
Proffered paper session: Gynaecological cancers; Sat, 14.09.24; 14:45 - 16:15;Room Sevilla Auditorium - Hall 2https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-gynaecological-cancers.html
Mini oral session 1: Gynaecological cancers; Sun, 15.09.24; 08:30 - 10:00; Room Burgos Auditorium - Hall 5https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/mini-oral-session-1-gynaecological-cancers.html
Mini oral session 2: Gynaecological cancers; Sun, 15.09.24; 14:45 - 16:15; Room Santander Auditorium - Hall 5https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/mini-oral-session-2-gynaecological-cancers.html
CNS TUMOURS & SARCOMAhttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/cns-tumours-sarcoma.html
CNS & SARCOMA Sessionshttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-sarcoma.html
Proffered paper session: Sarcoma; Mon, 16.09.24; 14:45 - 16:15; Room Santander Auditorium - Hall 5https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-sarcoma.html
Proffered paper session: CNS tumours; Fri, 13.09.24; 14:00 - 15:30; Room Pamplona Auditorium - Hall 3https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-cns-tumours.html
Mini oral session: CNS tumours; Sun, 15.09.24; 08:30 - 10:00; Room Salamanca Auditorium - Hall 5https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/mini-oral-session-cns-tumours.html
Mini oral session: Sarcoma; Fri, 13.09.24; 16:00 - 17:30; Room Alicante Auditorium - Hall 3https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/mini-oral-session-sarcoma.html
GENITOURINARY TUMOURShttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/genitourinary-tumours.html
Statement Highlights Urothel- und Nierenzellkarzinom: OÄ Dr. Dora Niedersüß-Beke, MBAhttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/statement-highlights-urothel-und-nierenzellkarzinom.html
GU tumours, non-prostatehttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-1-gu-tumours-non-prostate.html
Proffered paper session 1: GU tumours, non-prostate; Fri, 13.09.24; 14:00 - 15:30; Room Santander Auditorium - Hall 5https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-1-gu-tumours-non-prostate.html
Proffered Paper session 2: GU, non-prostate; Mon, 16.09.24; 08:30 - 10:00; Room Sevilla Auditorium - Hall 2https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-2-gu-non-prostate.html
Mini oral session: GU tumours, non-prostate; Sun, 15.09.24; 08:30 - 10:00; Room Bilbao Auditorium - Hall 2https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/mini-oral-session-gu-tumours-non-prostate.html
GU tumours, prostatehttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-gu-tumours-prostate.html
Proffered paper session: GU tumours, prostate; Sun, 15.09.24; 14:45 - 16:15; Room Valencia Auditorium - Hall 5https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-gu-tumours-prostate.html
Mini oral session: GU tumours, prostate; Mon, 16.09.24; 10:15 - 11:45; Room Madrid Auditorium - Hallhttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/mini-oral-session-gu-tumours-prostate.html
GASTROINTESTINAL TUMOURShttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/gastrointestinal-tumours.html
Statement Assoc.-Prof. Priv.-Doz. Dr. Gerald Prager: Neues bei gastrointestinalen Tumorenhttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/gastrointestinal-tumours/statement-gerald-prager.html
GI, upper digestivehttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/gastrointestinal-tumours-upper-digestive/proffered-paper-session-1.html
Proffered paper session 1: GI tumours, upper digestive; Fri, 13.09.24; 16:00 - 17:30; Room Sevilla Auditorium - Hall 2https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/gastrointestinal-tumours-upper-digestive/proffered-paper-session-1.html
Proffered paper session 2: GI tumours, upper digestive; Sat, 14.09.24; 08:30 - 10:00; Room Madrid Auditorium - Hall 2https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/gastrointestinal-tumours-upper-digestive/proffered-paper-session-2.html
Mini oral session: GI tumours, upper; Mon, 16.09.24; 08:30 - 10:00; Room Bilbao Auditorium -https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/gastrointestinal-tumours/-upper-digestive/mini-oral-session.html
GI, lower digestivehttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/gastrointestinal-tumours-lower-digestive/proffered-paper-session-1.html
Proffered paper session 1: GI tumours, lower; Sun, 15.09.24; 08:30 - 10:00; Room Sevilla Auditorium - Hall 2https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/gastrointestinal-tumours-lower-digestive/proffered-paper-session-1.html
Proffered paper session 2: GI tumours, lower; Sun, 15.09.24; 14:45 - 16:15; Room Madrid Auditorium - Hall 2https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/gastrointestinal-tumours-lower-digestive/proffered-paper-session-2.html
Mini oral session: GI tumours, lower; Sat, 14.09.24; 14:45 - 16:15; Room Granada Auditorium - Hall 6https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/gastrointestinal-tumours-lower-digestive/mini-oral-session.html
NETs and endocrine tumourshttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/nets-and-endocrine-tumours.html
NETs and endocrine tumours Sessionshttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-nets-and-endocrine-tumours.html
Proffered paper session: NETs and endocrine tumours; Mon, 16.09.24; 14:45 - 16:15; Room Pamplona Auditorium - Hall 3https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-nets-and-endocrine-tumours.html
Mini oral session: NETs and endocrine tumours; Fri, 13.09.24; 16:00 - 17:30; Room Pamplona Auditorium - Hall 3https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/mini-oral-session-nets-and-endocrine-tumours.html
HAEMATOLOGICAL MALIGNANCIEShttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/haematological-malignancies.html
Haematological malignancies Sessionshttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/mini-oral-session-1-haematological-malignancies.html
Mini oral session 1: Haematological malignancies; Fri, 13.09.24; 14:00 - 15:30; Room Toledo Auditorium - Hall 3https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/mini-oral-session-1-haematological-malignancies.html
Mini oral session 2: Haematological malignancies; Sun, 15.09.24; 08:30 - 10:00; Room Oviedo Auditorium - Hall 3https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/mini-oral-session-2-haematological-malignancies.html
MELANOMA AND OTHER SKIN TUMOURShttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/melanoma-and-other-skin-tumours.html
Kommentare Prof. Roger von Moos, Direktor Tumor- und Forschungszentrum, Kantonsspital Graubünden, Churhttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/melanoma-and-other-skin-tumours/kommentare-prof-roger-von-moos.html
Melanoma Sessionshttps://oncoletter.ch/kongressberichte/2025/esmo-congress-2025/proffered-paper-session-melanoma.html
Proffered paper session: Melanoma and other skin tumours; Sat, 14.09.24; 10:15 - 11:45; Room Salamanca Auditorium - Hall 5https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-melanoma-and-other-skin-tumours.html
Mini oral session: Melanoma and other skin tumours; Sun, 15.09.24; 14:45 - 16:15; Room Oviedo Auditorium - Hall 3https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/mini-oral-session-melanoma-and-other-skin-tumours.html
INVESTIGATIONAL IMMUNOTHERAPYhttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/investigational-immunotherapy.html
INVESTIGATIONAL IMMUNOTHERAPYhttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-investigational-immunotherapy.html
Proffered paper session: Investigational immunotherapy; Fri, 13.09.24; 16:00 - 17:30; Room Burgos Auditorium - Hall 5https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-investigational-immunotherapy.html
Mini oral session: Investigational immunotherapy; Mon, 16.09.24; 10:15 - 11:45; Room Granada Auditorium - Hall 6https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/mini-oral-session-investigational-immunotherapy.html
SUPPORTIVE AND PALLIATIVE CAREhttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/supportive-and-palliative-care.html
Supportive and palliative care sessionshttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-supportive-and-palliative-care.html
Proffered paper session: Supportive and palliative care; Sat, 14.09.24; 14:45 - 16:25; Room Pamplona Auditorium - Hall 3https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-supportive-and-palliative-care.html
Mini oral session: Supportive and palliative care; Sun, 15.09.24; 10:15 - 11:45; Room Toledo Auditorium - Hall 3https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/mini-oral-session-supportive-and-palliative-care.html
BASIC SCIENCE & TRANSLATIONAL RESEARCH & DEVELOPMENTAL THERAPEUTICShttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/basic-science-translational-research-developmental-therapeutics.html
Basic science & translational research sessions & developmental therapeuticshttps://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-1-basic-science-translational-research.html
Proffered paper session 1: Basic science & Translational research; Sat, 14.09.24; 14:45 - 16:15; Room Salamanca Auditorium - Hall 5https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-1-basic-science-translational-research.html
Proffered paper session 2: Basic science & Translational research; Mon, 16.09.24; 14:45 - 16:15; Room Madrid Auditorium - Hall 2https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-2-basic-science-translational-research.html
Proffered paper session 1: Developmental therapeutics; Fri, 13.09.24; 16:00 - 17:30; Room Santander Auditorium - Hall 5https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-1-developmental-therapeutics.html
Proffered paper session 2: Developmental therapeutics; Sun, 15.09.24; 14:45 - 16:15; Room Salamanca Auditorium - Hall 5https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/proffered-paper-session-2-developmental-therapeutics.html
Mini oral session: Developmental therapeutics; Sat, 14.09.24; 14:45 - 16:15; Room Oviedo Auditorium - Hall 3https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/mini-oral-session-developmental-therapeutics.html
Mini oral session: Basic science & Translational research; Mon, 16.09.24; 08:30 - 10:00; Room Valencia Auditorium - Hall 5https://oncoletter.ch/kongressberichte/id-2024/esmo-2024/mini-oral-session-basic-science-translational-research.html
 IASLC 2024 World Conference on Lung Cancerhttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer.html
IASLC World Conference on Lung Cancer Press Briefing Recordingshttps://oncoletter.ch/kongressberichte/id-2024/iaslc-world-conference-on-lung-cancer-press-briefing-recordings.html
PL02 Presidential Symposium 1https://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/pl02-presidential-symposium-1.html
PL04 Presidential Symposium 2https://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/pl04-presidential-symposium-2.html
OA01. Perioperative Strategies 1 - Sep 8 2024 - 10:45AM - 12:00PM - Room 20Ahttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/perioperative-strategies-1.html
OA02. Redefining First-Line EGFR Therapy - Sep 8 2024 - 10:45AM - 12:00PM - Room 20Dhttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/redefining-first-line-egfr-therapy.html
OA04. Antibody Drug Conjugates in SCLC - Sep 8 2024 - 2:00PM - 3:15PM - Room 20Ahttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/antibody-drug-conjugates-in-sclc.html
OA05. Local Consolidative Therapy for Metastatic NSCLC - Sep 8 2024 - 2:00PM - 3:15PM - Room 32ABhttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/local-consolidative-therapy-for-metastatic-nsclc.html
OA06. Novel Immunotherapy Strategies and Combinations - Sep 8 2024 - 3:30PM - 4:45PM - Room 20BChttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/novel-immunotherapy-strategies-and-combinations.html
OA08. The New Generation of Cytotoxics - Sep 9 2024 - 10:45AM - 12:00PM - Room 20Ahttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/the-new-generation-of-cytotoxics.html
OA09. Trailblazing Targets: New Insights - Sep 9 2024 - 10:45AM - 12:00PM - Room 20Dhttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/trailblazing-targets-new-insights.html
OA10. DLL3 Targeting BiTE Therapies in SCLC - Sep 9 2024 - 2:00PM - 3:15PM - Room 20Ahttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/dll3-targeting-bite-therapies-in-sclc.html
OA11. Shifting the Bar in the Front Line Immunotherapy Setting - Sep 9 2024 - 2:00PM - 3:15PM - Room 20BChttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/shifting-the-bar-in-the-front-line-immunotherapy-setting.html
OA12. Advancing Multimodal Therapies in Stage III NSCLC - Sep 9 2024 - 2:00PM - 3:15PM - Room 32ABhttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/advancing-multimodal-therapies-in-stage-iii-nsclc.html
OA13. Perioperative Strategies 2 - Sep 9 2024 - 3:30PM - 4:45PM - Room 20Ahttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/perioperative-strategies-2.html
OA14. New Horizons in Targeting KRAS G12C - Sep 9 2024 - 3:30PM - 4:45PM - Room 20Dhttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/new-horizons-in-targeting-kras.html
OA16. Transforming Cancer Therapy: Biomarkers and Novel ADCs - Sep 10 2024 - 1:30PM - 2:45PM - Room 20Ahttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/transforming-cancer-therapy-biomarkers-and-novel-adcs.html
OA18. Pleural, Mediastinal and Undifferentiated Thoracic Cancers - Sep 10 2024 - 3:00PM - 4:15PM - Room 30BChttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/pleural-mediastinal-and-undifferentiated-thoracic-cancers.html
More Links to Oral Sessionshttps://oncoletter.ch/kongressberichte/id-2024/wclc-2024-more-links-to-oral-sessions.html
MA01. Advances in Treatment for Stage III NSCLC - Sep 8 2024 - 2:00PM - 3:15PM - Room 20BChttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/advances-treatment-stage-iii-nsclc.html
MA06. New Strategies in ALK, ROS1, NTRK, BRAF, and MET NSCLC - Sep 10 2024 - 11:15AM - 12:30PM - Room 20Dhttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/new-strategies-alk-ros1-ntrk-braf-met-nsclc.html
MA11. Building on the Foundations of Current Immunotherapies - Sep 10 2024 - 1:30PM - 2:45PM - Room 20BChttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/building-foundations-current-immunotherapies.html
MA12. Paving the Path to Precision Oncology: Targeting EGFR and HER2 - Sep 10 2024 - 1:30PM - 2:45PM - Room 20Dhttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/precision-oncology-targeting-egfr-and-her2.html
MA16. Strategies Beyond Current Immunotherapies - Sep 10 2024 - 3:00PM - 4:15PM - Room 20BChttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/strategies-beyond-current-immunotherapies.html
MA17. Limited-stage SCLC, Novel Immunotherapy Combinations and Biomarkers in SCLC - Sep 10 2024 - 3:00PM - 4:15PM -Room 20Dhttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/ma17-limited-stage-sclc-novel-immunotherapy-combinations-and-biomarkers-in-sclc-sep-10-2024-3-00pm-4-15pm-room-20d.html
More Links to Mini Oral Sessionshttps://oncoletter.ch/kongressberichte/id-2024/iaslc-2024-wclc-lung-cancer/more-links-to-mini-oral-sessions.html
ESMO Gastrointestinal Cancers Congress 2024https://oncoletter.ch/kongressberichte/id-2024/esmo-gastrointestinal-cancers-congress-2024.html
Proffered Paper Sessionhttps://oncoletter.ch/kongressberichte/id-2024/esmo-gastrointestinal-cancers-congress-2024/proffered-paper.html
Proffered Paper Sessionhttps://oncoletter.ch/kongressberichte/id-2024/esmo-gastrointestinal-cancers-congress-2024/mini-oral-sessions.html
Proffered Paper Sessionhttps://oncoletter.ch/kongressberichte/id-2024/esmo-gastrointestinal-cancers-congress-2024/proffered-papers.html
Mini Oral Sessionshttps://oncoletter.ch/kongressberichte/id-2024/esmo-gastrointestinal-cancers-congress-2024/mini-oral-sessions.html
Mini Oral sessionshttps://oncoletter.ch/kongressberichte/id-2024/esmo-gastrointestinal-cancers-congress-2024/mini-oral-session1.html
Mini Oral Session 1https://oncoletter.ch/kongressberichte/id-2024/esmo-gastrointestinal-cancers-congress-2024/mini-oral-session1.html
Mini Oral session 2https://oncoletter.ch/kongressberichte/id-2024/esmo-gastrointestinal-cancers-congress-2024/mini-oral-session-2.html
Mini Oral session 3https://oncoletter.ch/kongressberichte/id-2024/esmo-gastrointestinal-cancers-congress-2024/mini-oral-session-1-2/mini-oral-session-3.html
EHA2024 Hybrid Congress - Madrid, June 13-16, 2024.https://oncoletter.ch/kongressberichte/id-2024/eha2024.html
Plenary and Late Breaking Abstract Sessionshttps://oncoletter.ch/kongressberichte/id-2024/eha2024/plenary-and-late-breaking-abstract-sessions.html
Plenary and Late Breaking Abstract Sessionshttps://oncoletter.ch/kongressberichte/id-2024/eha2024/plenary-session.html
Plenary Sessionhttps://oncoletter.ch/kongressberichte/id-2024/eha2024/plenary-session.html
Late Breaking Abstract Sessionhttps://oncoletter.ch/kongressberichte/id-2024/eha2024/late-breaking-abstract-session.html
Acute Lymphoblastic Leukemiahttps://oncoletter.ch/kongressberichte/id-2024/eha2024/acute-lymphoblastic-leukemia.html
Acute lymphoblastic leukemiahttps://oncoletter.ch/kongressberichte/id-2024/eha2024/all-clinical-1-immunotherapy-antibodies-and-car-t-cells.html
ALL Clinical 1: Immunotherapy: antibodies and CAR-T cellshttps://oncoletter.ch/kongressberichte/id-2024/eha2024/all-clinical-1-immunotherapy-antibodies-and-car-t-cells.html
ALL Clinical 2: Translational insights and new therapeutic optionshttps://oncoletter.ch/kongressberichte/id-2024/eha2024/all-clinical-2-translational-insights-and-new-therapeutic-options.html
Acute Myeloid Leukemiahttps://oncoletter.ch/kongressberichte/id-2024/eha2024/acute-myeloid-leukemia.html
Acute myeloid leukemiahttps://oncoletter.ch/kongressberichte/id-2024/eha2024/aml-clinical-1-menin-inhibitor.html
AML - Clinical 1 - Menin inhibitorhttps://oncoletter.ch/kongressberichte/id-2024/eha2024/aml-clinical-1-menin-inhibitor.html
AML - Clinical 2 - VEN-AZAhttps://oncoletter.ch/kongressberichte/id-2024/eha2024/aml-clinical-2-ven-aza.html
AML - Clinical 3https://oncoletter.ch/kongressberichte/id-2024/eha2024/aml-clinical-3.html
AML - Clinical 4https://oncoletter.ch/kongressberichte/id-2024/eha2024/aml-clinical-4.html
Aggressive Non-Hodgkin lymphomahttps://oncoletter.ch/kongressberichte/id-2024/eha2024/aggressive-non-hodgkin-lymphoma.html
Aggressive Non-Hodgkin lymphomahttps://oncoletter.ch/kongressberichte/id-2024/eha2024/aggressive-lymphoma-targeted-drug-therapy.html
Aggressive lymphoma - Targeted drug therapyhttps://oncoletter.ch/kongressberichte/id-2024/eha2024/aggressive-lymphoma-targeted-drug-therapy.html
Aggressive lymphoma - CAR-T cell therapyhttps://oncoletter.ch/kongressberichte/id-2024/eha2024/aggressive-lymphoma-car-t-cell-therapy.html
T cell lymphoma from biology to clinichttps://oncoletter.ch/kongressberichte/id-2024/eha2024/t-cell-lymphoma-from-biology-to-clinic.html
Chronic Lymphocytic Leukemia and Related disordershttps://oncoletter.ch/kongressberichte/id-2024/eha2024/chronic-lymphocytic-leukemia.html
Chronic lymphocytic leukemia and related disordershttps://oncoletter.ch/kongressberichte/id-2024/eha2024/novel-therapies-relapsed-refractory-cll-hairy-cell-leukemia.html
Novel therapies in relapsed and refractory CLL and hairy cell leukemiahttps://oncoletter.ch/kongressberichte/id-2024/eha2024/novel-therapies-relapsed-refractory-cll-hairy-cell-leukemia.html
Frontline therapy for CLL and Richterhttps://oncoletter.ch/kongressberichte/id-2024/eha2024/frontline-therapy-for-cll-and-richter.html
Dr. med. Michael Gregor comments on the CLL 1L therapy in light of EHA24 results and on the SEQUOIA Arm D datahttps://oncoletter.ch/kongressberichte/id-2024/eha2024/CLL-michael-gregor-comments-sequoia-arm-d-data.html
Chronic Myeloid Leukemiahttps://oncoletter.ch/kongressberichte/id-2024/eha2024/chronic-myeloid-leukemia.html
Chronic Myeloid Leukemiahttps://oncoletter.ch/kongressberichte/id-2024/eha2024/chronic-myeloid-leukemia-clinical.html
Chronic Myeloid Leukemiahttps://oncoletter.ch/kongressberichte/id-2024/eha2024/chronic-myeloid-leukemia-clinical.html
Hodgkin Lymphomahttps://oncoletter.ch/kongressberichte/id-2024/eha2024/hodgkin-lymphoma.html
Hodgkin lymphomahttps://oncoletter.ch/kongressberichte/id-2024/eha2024/hodgkin-lymphoma-clinical.html
Hodgkin Lymphomahttps://oncoletter.ch/kongressberichte/id-2024/eha2024/hodgkin-lymphoma-clinical.html
Myelodysplastic Syndromeshttps://oncoletter.ch/kongressberichte/id-2024/eha2024/myelodysplastic-syndromes.html
Myelodysplastic Syndromeshttps://oncoletter.ch/kongressberichte/id-2024/eha2024/myelodysplastic-syndromes-clinical.html
Myelodysplastic Syndromeshttps://oncoletter.ch/kongressberichte/id-2024/eha2024/myelodysplastic-syndromes-clinical.html
Indolent and Mantle-cell non-Hodgkin Lymphomahttps://oncoletter.ch/kongressberichte/id-2024/eha2024/indolent-mantle-cell-non-hodgkin-lymphoma.html
Indolent and Mantle-cell non-Hodgkin Lymphomahttps://oncoletter.ch/kongressberichte/id-2024/eha2024/indolent-and-mantle-cell-non-hodgkin-lymphoma-clinical.html
Indolent and Mantle-cell non-Hodgkin Lymphomahttps://oncoletter.ch/kongressberichte/id-2024/eha2024/indolent-and-mantle-cell-non-hodgkin-lymphoma-clinical.html
Myeloma and other monoclonal gammopathieshttps://oncoletter.ch/kongressberichte/id-2024/eha2024/myeloma-and-other-monoclonal-gammopathies.html
Frontline therapy for MMhttps://oncoletter.ch/kongressberichte/id-2024/eha2024/myeloma-and-other-monoclonal-gammopathies/frontline-therapy.html
Frontline therapy for MMhttps://oncoletter.ch/kongressberichte/id-2024/eha2024/myeloma-and-other-monoclonal-gammopathies/frontline-therapy.html
CAR T cell therapy for the treatment of Multiple Myelomahttps://oncoletter.ch/kongressberichte/id-2024/eha2024/car-t-cell-therapy-for-multiple-myeloma-clinical.html
CAR T cell therapy for the treatment of Multiple Myelomahttps://oncoletter.ch/kongressberichte/id-2024/eha2024/car-t-cell-therapy-for-multiple-myeloma-clinical.html
Novel agents in RRMMhttps://oncoletter.ch/kongressberichte/id-2024/eha2024/myeloma-and-other-monoclonal-gammopathies/novel-agents-clinical.html
Novel agents in RRMMhttps://oncoletter.ch/kongressberichte/id-2024/eha2024/myeloma-and-other-monoclonal-gammopathies/novel-agents-clinical.html
Myeloproliferative Neoplasmshttps://oncoletter.ch/kongressberichte/id-2024/eha2024/myeloproliferative-neoplasms.html
Myeloproliferative Neoplasmshttps://oncoletter.ch/kongressberichte/id-2024/eha2024/myeloproliferative-neoplasms-clinical.html
Myeloproliferative neoplasmshttps://oncoletter.ch/kongressberichte/id-2024/eha2024/myeloproliferative-neoplasms-clinical.html
Gene Therapyhttps://oncoletter.ch/kongressberichte/id-2024/eha2024/gene-therapy.html
Stem cell transplantation - Clinical and cell therapyhttps://oncoletter.ch/kongressberichte/id-2024/eha2024/gene-therapy/stem-cell-transplantation-cell-therapy.html
Stem cell transplantation - Clinical and cell therapyhttps://oncoletter.ch/kongressberichte/id-2024/eha2024/gene-therapy/stem-cell-transplantation-cell-therapy.html
Cellular Immunotherapy and Vaccination - Biology & Translational Researchhttps://oncoletter.ch/kongressberichte/id-2024/eha2024/cellular-immunotherapy-vaccination-biology-translational-research.html
Cellular Immunotherapy and Vaccination - Biology & Translational Researchhttps://oncoletter.ch/kongressberichte/id-2024/eha2024/cellular-immunotherapy-vaccination-biology-translational-research.html
Cellular Immunotherapy and Vaccinationhttps://oncoletter.ch/kongressberichte/id-2024/eha2024/gene-therapy-cellular-immunotherapy-and-vaccination.html
Cellular Immunotherapy and Vaccinationhttps://oncoletter.ch/kongressberichte/id-2024/eha2024/gene-therapy-cellular-immunotherapy-and-vaccination.html
ASCO Annual Meeting 2024 May 31 - June 4, 2024 - McCormick Place, Chicagohttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024.html
Saturday, June 1 - Press Briefingshttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/saturday-june-1-press-briefings.html
Interviews in Kooperation mit info@ONCO-SUISSE, moderiert von Prof. Roger von Moos: Schweizer Experten fassen die ASCO Ergebnisse zusammenhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/interviews-in-kooperation-mit-info-onco-suisse.html
Round Table und Interviews von Renate Haidinger, Brustkrebs Deutschland e.V.https://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/round-table-interviews-renate-haidinger-brustkrebs-deutschland-e-v.html
Plenary sessionhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/plenary-session.html
Plenary Session Late breaking abstracts - Sunday, June 3, 1PM-4PM, Hall B1https://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/plenary-session/abstracts.html
Schweizer Beiträge am ASCO 2024https://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/schweizer-beitraege-asco-2024.html
Links to all Poster Sessionshttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/links-to-all-poster-sessions.html
Breast Cancerhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/breast-cancer.html
Breast Cancer—Local/Regional/Adjuvanthttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/breast-cancer/local-regional-adjuvant-monday-session.html
Breast Cancer—Local/Regional/Adjuvant - Oral Session | Monday, June 3, 3PM-6PM, Hall B1https://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/breast-cancer/local-regional-adjuvant-monday-session.html
Breast Cancer —Local/Regional/Adjuvant - Rapid Oral Session | Friday, May 31, 2:45PM-4:15PM, E451https://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/breast-cancer/local-regional-adjuvant-friday-session.html
Breast Cancer—Metastatichttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/breast-cancer/metastatic-saturday-june-1.html
Breast Cancer—Metastatic - Oral Session | Saturday, June 1, 3PM-6PM, Hall B1https://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/breast-cancer/metastatic-saturday-june-1.html
Breast Cancer — Metastatic - Rapid Oral Session | Monday, June 3, 11.30AM-1PM, Hall D1https://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/breast-cancer/metastatic-monday-june-3.html
Lung Cancerhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/lung-cancer.html
Lung Cancer - Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancershttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/lung-cancer-non-small-cell-friday.html
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers - Oral Session | Monday, June 3, 8AM-11AM, Arie Crown Theaterhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/lung-cancer-non-small-cell-friday.html
Lung Cancer —Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers - Rapid Oral Session | Sunday, June 2, 4:30PM-6PM, S406https://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/lung-cancer-non-small-cell-sunday.html
Lung Cancer—Non-Small Cell Metastatichttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/lung-cancer-non-small-cell-metastatic/friday.html
Lung Cancer—Non-Small Cell Metastatic - Oral Session | Friday, May 31, 2:45PM-5:15PM, Arie Crown Theaterhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/lung-cancer-non-small-cell-metastatic/friday.html
Lung Cancer —Non-Small Cell Metastatic - Rapid Oral Session | Saturday, June 1, 4:30PM-6PM, S406https://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/lung-cancer-non-small-cell-metastatic-saturday.html
Gastrointestinal Cancerhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/gastrointestinal-cancer.html
Gastrointestinal Cancer—Colorectal and Analhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/colorectal-and-anal-sunday.html
Gastrointestinal Cancer—Colorectal and Anal - Oral Session | Sunday, June 2, 8AM-11AM, Arie Crown Theaterhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/colorectal-and-anal-sunday.html
Gastrointestinal Cancer— Colorectal and Anal - Rapid Oral Session | Monday, June 3, 1:15PM-2:45PM, Arie Crown Theaterhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/colorectal-and-anal-monday.html
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliaryhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/cancer-oral-gastroesophageal-pancreatic-and-hepatobiliary-tuesday.html
Gastrointestinal Cancer — Gastroesophageal, Pancreatic, and Hepatobiliary - Oral Session | Tuesday, June 4, 9:45AM-12:45PM, Hall D1https://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/cancer-oral-gastroesophageal-pancreatic-and-hepatobiliary-tuesday.html
Gastrointestinal Cancer — Gastroesophageal, Pancreatic, and Hepatobiliary - Rapid Oral Session | Monday, June 3, 9:45AM-11:15AM, E451https://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/cancer-gastroesophageal-pancreatic-and-hepatobiliary-monday.html
Genitourinary Cancerhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/genitourinary-cancer.html
Genitourinary Cancer—Kidney and Bladderhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/genitourinary-cancer-kidney-and-bladder-monday.html
Genitourinary Cancer — Kidney and Bladder Oral | Monday, June 3, 8AM-11AM, Hall B1https://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/genitourinary-cancer-kidney-and-bladder-monday.html
Genitourinary Cancer— Kidney and Bladder Rapid Oral| Saturday, June 1, 8AM-9:30AM, S100bchttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/genitourinary-cancer-kidney-and-bladder-saturday.html
Genitourinary Cancer—Prostate, Testicular, and Penilehttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/genitourinary-cancer-prostate-testicular-and-penile-saturday.html
Genitourinary Cancer—Prostate, Testicular, and Penile Oral | Saturday, June 1, 15PM-18PM, Arie Crown Theaterhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/genitourinary-cancer-prostate-testicular-and-penile-saturday.html
Genitourinary Cancer— Prostate, Testicular, and Penile Rapid Oral| Monday, June 3, 1:15PM-2:45PM, Hall B1https://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/genitourinary-cancer-prostate-testicular-and-penile-monday.html
Gynecologic Cancerhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/gynecologic-cancer.html
Gynecologic Cancerhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/gynecologic-cancer-sunday.html
Gynecologic Cancer Oral | Sunday, June 2, 8AM-11AM, Hall D2https://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/gynecologic-cancer-sunday.html
Gynecologic Cancer Rapid Oral | Saturday, June 1, 8AM-930AM, E451https://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/gynecologic-cancer-saturday.html
Interviews von Renate Haidinger, Brustkrebs Deutschland e.V. mit Prof. Sven Mahner, Direktor der Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Münchenhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/gynecologic-cancer/gynecologic-cancer/interviews-von-renate-haidinger-brustkrebs-deutschland-e-v-mit-prof-sven-mahner-muenchen.html
Central Nervous System Tumorshttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/central-nervous-system-tumors.html
Central Nervous System Tumorshttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/central-nervous-system-tumors-monday.html
Central Nervous System Tumors Oral | Monday, June 3, 8AM-11AM, S100bchttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/central-nervous-system-tumors-monday.html
Central Nervous System Tumors Rapid Oral | Sunday, June 2, 11:30AM-1PM, E350https://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/central-nervous-system-tumors-sunday.html
Head and Neck Cancerhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/head-and-neck-cancer.html
Head and Neck Cancerhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/head-and-neck-cancer-tuesday.html
Head and Neck Cancer Oral | Tuesday, June 4, 9:45AM-12:45PM, S100ahttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/head-and-neck-cancer-tuesday.html
Head and Neck Cancer Rapid Oral | Monday, June 3, 8AM-9:30AM, E450bhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/head-and-neck-cancer-monday.html
Melanoma/Skin Cancershttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/melanoma-skin-cancers.html
Melanoma/Skin Cancershttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/melanoma-skin-cancers-friday.html
Melanoma/Skin Cancers Oral | Friday, May 31, 2:45PM-5:45PM, Hall D1https://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/melanoma-skin-cancers-friday.html
Melanoma/Skin Cancers Rapid Oral | Monday, June 3, 9:45AM-11:15AM, S406https://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/melanoma-skin-cancers-monday.html
Sarcomahttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/sarcoma.html
Sarcomahttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/sarcoma-monday.html
Sarcoma Oral | Monday, June 3, 3PM-6PM, S100bchttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/sarcoma-monday.html
Sarcoma Rapid Oral | Friday, May 31, 2:45PM-4:15PM, S102https://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/sarcoma-friday.html
Pediatric Oncologyhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/pediatric-oncology.html
Pediatric Oncologyhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/pediatric-oncology-sunday.html
Pediatric Oncology I Oral | Sunday, June 2, 8AM-11AM, S100bchttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/pediatric-oncology-sunday.html
Pediatric Oncology II Oral | Monday, June 3, 11:30AM-2:30PM, S504https://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/pediatric-oncology-monday.html
Pediatric Oncology Rapid Oral | Sunday, June 2, 4:30PM-6PM, S504https://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/pediatric-oncology-sunday-Rapid.html
Hematologic Malignancieshttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/hematologic-malignancies.html
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplanthttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/leukemia-myelodysplastic-syndromes-allotransplant-friday.html
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Oral | Friday, May 31; 2:45PM-5:45PM, S100bchttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/leukemia-myelodysplastic-syndromes-allotransplant-friday.html
Hematologic Malignancies— Leukemia, Myelodysplastic Syndromes, and Allotransplant Rapid Oral| Saturday, June 1, 8AM-9:30AM, E450bhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/leukemia-myelodysplastic-syndromes-allotransplant-saturday.html
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemiahttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/lymphoma-chronic-lymphocytic-leukemia-saturday.html
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Oral | Saturday, June 1, 3PM-6PM, S100bchttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/lymphoma-chronic-lymphocytic-leukemia-saturday.html
Hematologic Malignancies— Lymphoma and Chronic Lymphocytic Leukemia Rapid Oral | Saturday, June 2, 4:30PM-6PM, E450bhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/lymphoma-chronic-lymphocytic-leukemia-saturday-rapid.html
Hematologic Malignancies—Plasma Cell Dyscrasiahttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/plasma-cell-dyscrasia-monday.html
Hematologic Malignancies — Plasma Cell Dyscrasia Oral | Monday, June 3, 3PM-6PM, Hall D1https://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/plasma-cell-dyscrasia-monday.html
Hematologic Malignancies — Plasma Cell Dyscrasia Rapid Oral | Tuesday, June4, 9:45AM-11:15AM, S102https://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/plasma-cell-dyscrasia-tuesday.html
Developmental Therapeuticshttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/developmental-therapeutics.html
Developmental Therapeutics—Immunotherapyhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/immunotherapy-monday.html
Developmental Therapeutics—Immunotherapy Oral | Monday, June 3. 11:30AM-2:30PM, Hall D2https://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/immunotherapy-monday.html
Developmental Therapeutics—Immunotherapy Rapid Oral | Sunday, June 2, 11:30AM-1:30PM, S406https://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/immunotherapy-sunday.html
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biologyhttps://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/developmental-therapeutics-molecularly-targeted-agents-and-tumor-biology-saturday.html
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Oral | Saturday, June 1, 3PM-6PM, Hall D1https://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/developmental-therapeutics-molecularly-targeted-agents-and-tumor-biology-saturday.html
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Rapid Oral | Monday, June 3, 8AM-9:30AM, S406https://oncoletter.ch/kongressberichte/id-2024/ascoannual-meeting-2024/developmental-therapeutics-molecularly-targeted-agents-and-tumor-biology-monday.html
ESGO - 25th European Congress on Gynaecological Oncologyhttps://oncoletter.ch/kongressberichte/id-2024/esgo-25th-european-congress-on-gynaecological-oncology.html
Best Oral Session - Late Breaking Abstractshttps://oncoletter.ch/kongressberichte/id-2024/esgo-25th-european-congress-on-gynaecological-oncology/best-oral-session-late-breaking-abstracts.html
Best Oral Session - Cervical Cancerhttps://oncoletter.ch/kongressberichte/id-2024/esgo-25th-european-congress-on-gynaecological-oncology/best-oral-session-cervical-cancer.html
Mini Oral Session - Cervical Cancerhttps://oncoletter.ch/kongressberichte/id-2024/esgo-25th-european-congress-on-gynaecological-oncology/mini-oral-session-cervical-cancer.html
Best Oral Session - Endometrial Cancerhttps://oncoletter.ch/kongressberichte/id-2024/esgo-25th-european-congress-on-gynaecological-oncology/best-oral-session-endometrial-cancer.html
Mini Oral Session - Endometrial Cancerhttps://oncoletter.ch/kongressberichte/id-2024/esgo-25th-european-congress-on-gynaecological-oncology/mini-oral-session-endometrial-cancer.html
Best Oral Session - Ovarian Cancerhttps://oncoletter.ch/kongressberichte/id-2024/esgo-25th-european-congress-on-gynaecological-oncology/best-oral-session-ovarian-cancer.html
Mini Oral Session - Ovarian Cancerhttps://oncoletter.ch/kongressberichte/id-2024/esgo-25th-european-congress-on-gynaecological-oncology/mini-oral-session-ovarian-cancer.html
Mini Oral Session - Miscellaneous Cancershttps://oncoletter.ch/kongressberichte/id-2024/esgo-25th-european-congress-on-gynaecological-oncology/mini-oral-session-miscellaneous-cancers.html
Young Investigator Sessionhttps://oncoletter.ch/kongressberichte/id-2024/esgo-25th-european-congress-on-gynaecological-oncology/young-investigator-session.html
Best Three Minutes Presentationshttps://oncoletter.ch/kongressberichte/id-2024/esgo-25th-european-congress-on-gynaecological-oncology/best-three-minutes-presentations.html
EBMT-EHA 6th European CAR T-cell Meetinghttps://oncoletter.ch/kongressberichte/id-2024/ebmt-eha-6th-european-car-t-cell-meeting.html
EBMT-EHA 6th European CAR T-cell Meetings Best Abstractshttps://oncoletter.ch/kongressberichte/id-2024/ebmt-eha-6th-european-car-t-cell-meetings-best-abstracts.html
ASCO Genitourinary Cancers Symposiumhttps://oncoletter.ch/kongressberichte/id-2024/ascogenitourinary-cancers-symposium.html
Rapid Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/id-2024/ascogenitourinary-cancers-symposium/rapid-abstract-sessions.html
Rapid Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/id-2024/ascogenitourinary-cancers-symposium/rapid-oral-abstract-session-a-prostate-cancer.html
Rapid Oral Abstract Session A: Prostate Cancerhttps://oncoletter.ch/kongressberichte/id-2024/ascogenitourinary-cancers-symposium/rapid-oral-abstract-session-a-prostate-cancer.html
Rapid Oral Abstract Session B: Urothelial Carcinomahttps://oncoletter.ch/kongressberichte/id-2024/ascogenitourinary-cancers-symposium/rapid-oral-abstract-session-b-urothelial-carcinoma.html
Rapid Oral Abstract Session C: Renal Cell, Adrenal, and Testicular Cancershttps://oncoletter.ch/kongressberichte/id-2024/ascogenitourinary-cancers-symposium/rapid-oral-abstract-session-c-renal-cell-adrenal-and-testicular-cancers.html
Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/id-2024/ascogenitourinary-cancers-symposium/oral-abstract-sessions.html
Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/id-2024/ascogenitourinary-cancers-symposium/oral-abstract-sessions/oral-abstract-sessions.html
Oral Abstract Session A: Prostate Cancerhttps://oncoletter.ch/kongressberichte/id-2024/ascogenitourinary-cancers-symposium/oral-abstract-session-a-prostate-cancer.html
Oral Abstract Session B: Urothelial Carcinomahttps://oncoletter.ch/kongressberichte/id-2024/ascogenitourinary-cancers-symposium/oral-abstract-session-b-urothelial-carcinoma.html
Oral Abstract Session C: Renal Cell Cancerhttps://oncoletter.ch/kongressberichte/id-2024/ascogenitourinary-cancers-symposium/oral-abstract-session-c-renal-cell-cancer.html
Trials in Progress Poster Sessionshttps://oncoletter.ch/kongressberichte/id-2024/ascogenitourinary-cancers-symposium/trials-in-progress-poster-sessions.html
Trials in Progress Poster Sessionshttps://oncoletter.ch/kongressberichte/id-2024/ascogenitourinary-cancers-symposium/trials-in-progress-poster-sessions/trials-in-progress-poster-sessions/trials-in-progress-poster-session-a-prostate-cancer.html
Trials in Progress Poster Session A: Prostate Cancerhttps://oncoletter.ch/kongressberichte/id-2024/ascogenitourinary-cancers-symposium/trials-in-progress-poster-sessions/trials-in-progress-poster-sessions/trials-in-progress-poster-session-a-prostate-cancer.html
Trials in Progress Poster Session B: Urothelial Carcinomahttps://oncoletter.ch/kongressberichte/id-2024/ascogenitourinary-cancers-symposium/trials-in-progress-poster-sessions/trials-in-progress-poster-sessions/trials-in-progress-poster-session-b-urothelial-carcinoma.html
Trials in Progress Poster Session C: Renal Cell, Adrenal, and Testicular Cancershttps://oncoletter.ch/kongressberichte/id-2024/ascogenitourinary-cancers-symposium/trials-in-progress-poster-sessions/trials-in-progress-poster-sessions/trials-in-progress-poster-session-c-renal-cell-adrenal-and-testicular-cancers.html
ASCO 2024 Gastrointestinal (GI) Cancers Symposiumhttps://oncoletter.ch/kongressberichte/id-2024/asco2024-gastrointestinal-gi-cancers-symposium.html
Rapid Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/id-2024/asco2024-gastrointestinal-gi-cancers-symposium/rapid-abstract-sessions.html
Rapid Abstract Sessionshttps://oncoletter.ch/kongressberichte/id-2024/asco2024-gastrointestinal-gi-cancers-symposium/rapid-oral-abstract-session-a-cancers-of-the-esophagus-and-stomach.html
Rapid Oral Abstract Session A: Cancers of the Esophagus and Stomachhttps://oncoletter.ch/kongressberichte/id-2024/asco2024-gastrointestinal-gi-cancers-symposium/rapid-oral-abstract-session-a-cancers-of-the-esophagus-and-stomach.html
Rapid Oral Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tracthttps://oncoletter.ch/kongressberichte/id-2024/asco2024-gastrointestinal-gi-cancers-symposium/rapid-oral-abstract-session-b-cancers-of-the-pancreas-small-bowel-and-hepatobiliary-tract.html
Rapid Oral Abstract Session C: Cancers of the Colon, Rectum, and Anushttps://oncoletter.ch/kongressberichte/id-2024/asco2024-gastrointestinal-gi-cancers-symposium/rapid-oral-abstract-session-c-cancers-of-the-colon-rectum-and-anus.html
Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/id-2024/asco2024-gastrointestinal-gi-cancers-symposium/oral-abstract-sessions.html
Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/id-2024/asco2024-gastrointestinal-gi-cancers-symposium/oral-abstract-session-a-cancers-of-the-esophagus-and-stomach.html
Oral Abstract Session A: Cancers of the Esophagus and Stomachhttps://oncoletter.ch/kongressberichte/id-2024/asco2024-gastrointestinal-gi-cancers-symposium/oral-abstract-session-a-cancers-of-the-esophagus-and-stomach.html
Oral Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tracthttps://oncoletter.ch/kongressberichte/id-2024/asco2024-gastrointestinal-gi-cancers-symposium/oral-abstract-session-b-cancers-of-the-pancreas-small-bowel-and-hepatobiliary-tract.html
Oral Abstract Session C: Cancers of the Colon, Rectum, and Anushttps://oncoletter.ch/kongressberichte/id-2024/asco2024-gastrointestinal-gi-cancers-symposium/oral-abstract-session-c-cancers-of-the-colon-rectum-and-anus.html
Trials in Progress Poster Sessionshttps://oncoletter.ch/kongressberichte/id-2024/asco2024-gastrointestinal-gi-cancers-symposium/trials-in-progress-poster-sessions.html
Trials in Progress Poster Sessionshttps://oncoletter.ch/kongressberichte/id-2024/asco2024-gastrointestinal-gi-cancers-symposium/trials-in-progress-poster-session-a-cancers-of-the-esophagus-and-stomach-and-other-gastrointestinal-cancers.html
Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancershttps://oncoletter.ch/kongressberichte/id-2024/asco2024-gastrointestinal-gi-cancers-symposium/trials-in-progress-poster-session-a-cancers-of-the-esophagus-and-stomach-and-other-gastrointestinal-cancers.html
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tracthttps://oncoletter.ch/kongressberichte/id-2024/asco2024-gastrointestinal-gi-cancers-symposium/trials-in-progress-poster-session-b-cancers-of-the-pancreas-small-bowel-and-hepatobiliary-tract.html
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anushttps://oncoletter.ch/kongressberichte/id-2024/asco2024-gastrointestinal-gi-cancers-symposium/trials-in-progress-poster-session-c-cancers-of-the-colon-rectum-and-anus.html
2023https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023.html
65th ASH Annual Meeting and Exposition - December 09-12, 2023https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023.html
ASH Press Briefings on Late Breaking and other important Abstractshttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/ash-press-briefings-on-late-breaking-and-other-important-abstracts.html
ASH Press Briefingshttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/acute-lymphoblastic-leukemias/all-clinical-and-epidemiological-studies/coming-soon.html
ASH Press Briefing 1, Saturday December 9, 2023https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/late-breaking-abstracts-session/tuesday-december-12-2023.html
ASH Press Briefing 2, Saturday December 9, 2023https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/ash-press-briefings-on-late-breaking-and-other-important-abstracts/ash-press-briefings/ash-press-briefing-2-saturday-december-9-2023-kopie.html
ASH Press Briefing 3, Sunday December 10, 2023https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/ash-press-briefings-on-late-breaking-and-other-important-abstracts/ash-press-briefings/ash-press-briefing-3-sunday-december-10-2023.html
ASH Press Briefing 4, Monday December 11, 2023 Late Breaking Abstractshttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/ash-press-briefings-on-late-breaking-and-other-important-abstracts/ash-press-briefings/ash-press-briefing-4-monday-december-11-2023-late-breaking-abstracts.html
Late-Breaking Abstracts Sessionhttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/late-breaking-abstracts-session.html
Acute Lymphoblastic Leukemiashttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/acute-lymphoblastic-leukemias.html
ALL: Clinical and Epidemiological studieshttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/late-breaking-abstracts-session/tuesday-december-12-2023.html
Progress Through Collaboration: Impactful Cooperative Efforts to Optimize Care for ALL - Sunday, December 10, 2023: 12:00 PM-1:30 PM Grand Hall B (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/acute-lymphoblastic-leukemias/all-clinical-and-epidemiological-studies/coming-soon.html
ALL: Therapies, Excluding Transplantation and Cellular Immunotherapieshttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/acute-lymphoblastic-leukemias/all-therapies-excluding-transplantation-and-cellular-immunotherapies/.html
Therapies, Excluding Transplantation and Cellular Immunotherapies: Optimal Frontline Treatment for ALL - Monday, December 11, 2023: 2:45 PM-4:15 PM Grand Hall C (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/acute-lymphoblastic-leukemias/all-therapies-excluding-transplantation-and-cellular-immunotherapies/.html
Therapies, Excluding Transplantation and Cellular Immunotherapies: Novel Therapies for ALL - Monday, December 11, 2023: 4:30 PM-6:00 PM Grand Hall D (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/all-therapies-excluding-transplantation-and-cellular-immunotherapies/novel-therapies-for-all.html
Acute Myeloid Leukemiashttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/acute-myeloid-leukemias.html
AML: Clinical and Epidemiological studieshttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/acute-myeloid-leukemias/aml-clinical-and-epidemiological-studies/real-world-outcomes-and-treatment-approaches-sunday-december-10-2023-4-30-pm-6-00-pm-pacific-ballroom-salon.html
Clinical and Epidemiological: Real World Outcomes and Treatment Approaches - Sunday, December 10, 2023: 4:30 PM-6:00 PM Pacific Ballroom Salons 24-26 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/acute-myeloid-leukemias/aml-clinical-and-epidemiological-studies/real-world-outcomes-and-treatment-approaches-sunday-december-10-2023-4-30-pm-6-00-pm-pacific-ballroom-salon.html
Clinical and Epidemiological: Innovations in Prognostication - Monday, December 11, 2023: 10:30 AM-12:00 PM Room 6B (San Diego Convention Center)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/acute-myeloid-leukemias/clinical-and-epidemiological-innovations-in-prognostication-monday-december-11-2023-10-30-am-12-00-pm-room-6b-san-diego-convention-cente.html
Clinical and Epidemiological: AML: De Novo and Myelodysplasia-Related - Monday, December 11, 2023: 2:45 PM-4:15 PM Pacific Ballroom Salons 24-26 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/acute-myeloid-leukemias/aml-clinical-and-epidemiological-studies/de-novo-and-myelodysplasia-related-monday-december-11-2023-2-45-pm-4-15-pm-pacific-ballroom-salons-24.html
Clinical and Epidemiological: AML Molecular Targets, Ethnicity, and AI - Monday, December 11, 2023: 4:30 PM-6:00 PM Pacific Ballroom Salons 24-26 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/acute-myeloid-leukemias/clinical-and-epidemiological-aml-molecular-targets-ethnicity-and-ai-monday-december-11-2023-4-30-pm-6-00-pm-pacific-ballroom-salons-24-2.html
AML: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapieshttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/acute-myeloid-leukemias/commercially-available-therapies-excluding-transplantation-and-cellular-immunotherapi.html
Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Long-Term Outcomes for Children and Adults Diagnosed With AML/APL - Monday, December 11, 2023: 10:30 AM-12:00 PM Room 6A (San Diego Convention Center)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/acute-myeloid-leukemias/commercially-available-therapies-excluding-transplantation-and-cellular-immunotherapi.html
Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Refining Chemotherapy Regimens Plus/Minus MRD Evaluation to Optimize Outcomes in AML - Mon, Dec11, 23: 2:45PM-4:15PM San Diego Ballroom AB Marriott Marquis SD Marinahttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/aml/commercially-available-therapies-excluding-transplantation-and-cellular-immunotherapi.html
Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Improving Intensive Chemotherapy Regimens for Treatment of AML - Mon, Dec 11, 2023: 4:30PM-6:00PM San Diego Ballroom AB (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/aml/available-therapies-excluding-transplantation-and-cellular-immunotherapi.html
AML: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapieshttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/acute-myeloid-leukemias/investigational-therapies-excluding-transplantation-cellular-immunotherapies-upcoming.html
Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Upcoming Therapies in Newly Diagnosed and Relapsed/Refractory AML - Sat, Dec 9, 2023: 9:30 AM-11:00 AM Pacific Ballroom Salons 21-22 (Marriott Marquis San Diego Mhttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/acute-myeloid-leukemias/investigational-therapies-excluding-transplantation-cellular-immunotherapies-upcoming.html
Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Novel Uses of Approved Therapeutic Agents - Saturday, December 9, 2023: 2:00 PM-3:30 PM Room 6A (San Diego Convention Center)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/acute-myeloid-leukemias/investigational-therapies-excluding-transplantation-and-cellular-immunotherapies-novel-uses.html
AML: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosishttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/acute-myeloid-leukemias/biomarkers-molecular-markers-and-minimal-residual-disease-in-diagnosis-and-prognosis-ris.html
Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Risk Refinement and Therapy Response - Saturday, December 9, 2023: 9:30 AM-11:00 AM Pacific Ballroom Salons 24-26 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/acute-myeloid-leukemias/biomarkers-molecular-markers-and-minimal-residual-disease-in-diagnosis-and-prognosis-ris.html
Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Biomarkers and Therapeutics - Saturday, December 9, 2023: 2:00 PM-3:30 PM Pacific Ballroom Salons 24-26 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/acute-myeloid-leukemias/biomarkers-molecular-markers-and-minimal-residual-disease-in-diagnosis-and-prognosis-bio.html
Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Minimal Residual Disease and Therapy Response - Sunday, December 10, 2023: 9:30 AM-11:00 AM Marriott Grand Ballroom 8-9 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/acute-myeloid-leukemias/biomarkers-molecular-markers-and-minimal-residual-disease-in-diagnosis-and-prognosis-therapy-response.html
Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Immunologic and Metabolic Biomarkers of Disease Control - Saturday, December 9, 2023: 4:00 PM-5:30 PM Room 6CF (San Diego Convention Center)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/acute-myeloid-leukemias/biomarkers-molecular-markers-and-minimal-residual-disease-in-diagnosis-and-prognosis-Immunologic-Metabolic-Biomarkers-Disease-Control.html
Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Deciphering Risk by Genetic and Epigenetic Features - Mon, Dec 11, 2023: 2:45 PM-4:15 PM Pacific Ballroom Salons 15-17 Marriott Marquis San Diego Marinahttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/acute-myeloid-leukemias/biomarkers-molecular-markers-and-minimal-residual-disease-in-diagnosis-and-prognosis.html
Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Response Predictors to Targeted Therapies and Transplant - Mon, Dec 11, 2023: 4:30 PM-6:00 PM Pacific Ballroom Salons 15-17 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/acute-myeloid-leukemias/biomarkers-molecular-markers-and-minimal-residual-disease-in-diagnosis-and-prognosis-res.html
Chronic Myeloid Leukemiahttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/chronic-myeloid-leukemia.html
CML: Clinical and Epidemiological studieshttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/chronic-myeloid-leukemia/cml-clinical-and-epidemiological-treatment-free-remission-and-prognostication-sunday.html
CML: Clinical and Epidemiological: Treatment-Free Remission and Prognostication - Sunday, December 10, 2023: 9:30 AM-11:00 AM Pacific Ballroom Salons 21-22 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/chronic-myeloid-leukemia/cml-clinical-and-epidemiological-treatment-free-remission-and-prognostication-sunday.html
CML: Clinical and Epidemiological: Novel Therapeutic Approaches - Monday, December 11, 2023: 2:45 PM-4:15 PM Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/chronic-myeloid-leukemia/cml-clinical-and-epidemiological-novel-therapeutic-approaches-monday-december-11.html
Myeloproliferative Syndromes and Chronic Myeloid Leukemiahttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/myeloproliferative-syndromes-and-chronic-myeloid-leukemia.html
MPS and CML: Basic and Translationalhttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/mps-and-cml-basic-and-translational-lineage-tracing-and-novel-target-discovery.html
MPS and CML: Basic and Translational: Lineage Tracing and Novel Target Discovery - Monday, December 11, 2023: 2:45 PM-4:15 PM Pacific Ballroom Salons 21-22 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/mps-and-cml-basic-and-translational-lineage-tracing-and-novel-target-discovery.html
MPS and CML: Basic and Translational: Oncogenic Drivers and Genetic Models - Monday, December 11, 2023: 4:30 PM-6:00 PM Pacific Ballroom Salons 21-22 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/mps-and-cml-basic-and-translational-oncogenic-drivers-and-genetic-models.html
MPS and CML: Basic and Translational: Oncogenic Drivers and Genetic Models - Monday, December 11, 2023: 4:30 PM-6:00 PM Pacific Ballroom Salons 21-22 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/mps-cml-basic-and-translational-oncogenic-drivers-and-genetic-models.html
MPS: Clinical and Epidemiologicalhttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/mps-clinical-and-epidemiological-rare-myeloproliferative-neoplasms-unveiling-promising-pathways-and-novel-therapies.html
MPS: Clinical and Epidemiological: Rare Myeloproliferative Neoplasms: Unveiling Promising Pathways and Novel Therapies - Saturday, December 9, 2023: 9:30 AM-11:00 AM Ballroom 20AB (San Diego Convention Center)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/mps-clinical-and-epidemiological-rare-myeloproliferative-neoplasms-unveiling-promising-pathways-and-novel-therapies.html
MPS: Clinical and Epidemiological: Charting The Future Of MPN Therapies - Sunday, December 10, 2023: 4:30 PM-6:00 PM Ballroom 20CD (San Diego Convention Center)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/mps-clinical-and-epidemiological-charting-the-future-of-mpn-therapies.html
MPS: Clinical and Epidemiological: Myelofibrosis: New Therapeutic Frontiers - Sunday, December 10, 2023: 4:30 PM-6:00 PM Pacific Ballroom Salons 21-22 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/mps-clinical-and-epidemiological-myelofibrosis-new-therapeutic-frontiers.html
MPS: Clinical and Epidemiological: Treatment and Outcomes in MPNs - Monday, December 11, 2023: 10:30 AM-12:00 PM Ballroom 20CD (San Diego Convention Center)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/mps-clinical-and-epidemiological-treatment-and-outcomes-in-mpns.html
Lymphomashttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/lymphomas.html
Lymphomas: Translationalhttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/lymphomas-translational-molecular-and-genetic-microenvironment-and-methylome-in-lymphoma-and-misc-saturday.html
Lymphomas: Translational – Molecular and Genetic: Microenvironment and Methylome in Lymphoma and Misc - Saturday, December 9, 2023: 2:00 PM-3:30 PM Ballroom 20AB (San Diego Convention Center)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/lymphomas-translational-molecular-and-genetic-microenvironment-and-methylome-in-lymphoma-and-misc-saturday.html
Lymphomas: Translational – Molecular and Genetic: Signaling Pathways and MRD in Lymphoma - Sunday, December 10, 2023: 12:00 PM-1:30 PM Harbor Ballroom (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/lymphomas-translational-molecular-and-genetic-signaling-pathways-and-mrd-in-lymphoma-sunday.html
Lymphomas: Translational – Molecular and Genetic: Insights into Lymphoma: Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics - Monday, December 11, 2023: 2:45 PM-4:15 PM Room 6DE (San Diego Convention Center)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/lymphomas-translational-molecular-and-genetic-insights-into-lymphoma-unraveling-the-molecular-complexity-for-precision-diagnostics-and-therapeutics.html
Lymphomas: Translational – Non-Genetic: Illuminating the Tumor Microenvironment and Immune Landscape in Lymphoma - Saturday, December 9, 2023: 2:00 PM-3:30 PM Seaport Ballroom ABCD (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/lymphomas-translational-non-genetic-illuminating-the-tumor-microenvironment-and-immune-landscape-in-lymphoma.html
Lymphomas: Translational – Non-Genetic: Elucidating Biomarkers and Mechanisms of Therapy in Lymphoma - Sunday, December 10, 2023: 9:30 AM-11:00 AM Grand Hall C (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/lymphomas-translational-non-genetic-elucidating-biomarkers-and-mechanisms-of-therapy-in-lymphoma.html
Mantle Cell, Follicular, and Other Indolent B Cell Lymphomashttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/mantle-cell-follicular-and-other-indolent-b-cell-lymphomas-clinical-and-epidemiological-immunotherapy.html
Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Immunotherapy - Sunday, December 10, 2023: 4:30 PM-6:00 PM Grand Hall C (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/mantle-cell-follicular-and-other-indolent-b-cell-lymphomas-clinical-and-epidemiological-immunotherapy.html
Mantle Cell, Follicular and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Prospective Clinical Trials in Mantle Cell Lymphoma Incorporating Novel Agents - Monday, December 11: 10:30 AM-12 PM Grand Hall B (Manchester Grand Hyatt Shttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/mantle-cell-follicular-and-other-indolent-b-cell-lymphomas-clinical-and-epidemiological-prospective-clinical-trials-in-mantle-cell-lymphoma-in.html
Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Targeted Therapy - Monday, December 11, 2023: 4:30 PM-6:00 PM Grand Hall C (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/mantle-cell-follicular-and-other-indolent-b-cell-lymphomas-clinical-and-epidemiological-targeted-therapy.html
Hodgkin Lymphomas and T/NK cell Lymphomashttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/hodgkin-lymphomas-and-t-nk-cell-lymphomas-clinical-and-epidemiological-topics-in-t-cell-szary-and-hodgkin-lymphomas.html
Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological: Topics in T Cell, Szary and Hodgkin Lymphomas - Saturday, December 9, 2023: 2:00 PM-3:30 PM Grand Hall B (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/hodgkin-lymphomas-and-t-nk-cell-lymphomas-clinical-and-epidemiological-topics-in-t-cell-szary-and-hodgkin-lymphomas.html
Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological: Advances in Treating T Cell Lymphomas - Saturday, December 9, 2023: 4:00 PM-5:30 PM Grand Hall B (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/hodgkin-lymphomas-and-t-nk-cell-lymphomas-clinical-and-epidemiological-advances-in-treating-t-cell-lymphomas.html
Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological: Advances in the Treatment of Hodgkin Lymphoma - Sunday, December 10, 2023: 4:30 PM-6:00 PM Grand Hall B (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/hodgkin-lymphomas-and-t-nk-cell-lymphomas-clinical-and-epidemiological-advances-in-the-treatment-of-hodgkin-lymphoma-sunday-december-10-2023-4-30-pm-6-00-pm-gr.html
Aggressive Lymphomashttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/aggressive-lymphomas-prospective-therapeutic-trials-novel-therapies-for-relapsed-refractory-aggressive-lymphoma.html
Aggressive Lymphomas: Prospective Therapeutic Trials: Novel Therapies For Relapsed/Refractory Aggressive Lymphoma - Sunday, December 10, 2023: 9:30 AM-11:00 AM Seaport Ballroom ABCD (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/aggressive-lymphomas-prospective-therapeutic-trials-novel-therapies-for-relapsed-refractory-aggressive-lymphoma.html
Aggressive Lymphomas: Prospective Therapeutic Trials: Initial treatment strategies in aggressive B Cell lymphomas - Monday, December 11, 2023: 2:45 PM-4:15 PM Seaport Ballroom ABCD (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/aggressive-lymphomas-prospective-therapeutic-trials-initial-treatment-strategies-in-aggressive-b-cell-lymphomas.html
Aggressive Lymphomas: Clinical and Epidemiological: Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL - Saturday, December 9, 2023: 9:30 AM-11:00 AM Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/aggressive-lymphomas-clinical-and-epidemiological-real-world-data-on-outcomes-and-treatment-related-toxicity-in-b-cell-nhl.html
Aggressive Lymphomas: Clinical and Epidemiological: Diagnostic and Prognostic Implications in the Care of Patients With Aggressive Lymphomas - Saturday, December 9, 2023: 2:00 PM-3:30 PM Grand Hall C (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/aggressive-lymphomas-clinical-and-epidemiological-diagnostic-and-prognostic-implications-in-the-care-of-patients-with-aggressive-lymphomas.html
Aggressive Lymphomas: Clinical and Epidemiological: Outcomes of Relapsed/Refractory DLBCL Treated with Immunochemotherapy, CAR-T Cell and Novel Agents - Saturday, December 9, 2023: 4:00 PM-5:30 PM Grand Hall C (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/aggressive-lymphomas-clinical-and-epidemiological-outcomes-of-relapsed-refractory-dlbcl-treated-with-immunochemotherapy-car-t-cell-and-novel-agents.html
Aggressive Lymphomas: Clinical and Epidemiological: Treatment to Best Outcomes: Find the Right Therapy for the Right Patient - Sunday, December 10, 2023: 9:30 AM-11:00 AM Grand Hall D (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/aggressive-lymphomas-clinical-and-epidemiological-treatment-to-best-outcomes-find-the-right-therapy-for-the-right-patient.html
Aggressive Lymphomas: Clinical and Epidemiological: Aiming for the Right Target: Using CAR-T and Bispecifics in Aggressive Lymphomas - Sunday, December 10, 2023: 4:30 PM-6:00 PM Ballroom 20AB (San Diego Convention Center)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/aggressive-lymphomas-clinical-and-epidemiological-aiming-for-the-right-target-using-car-t-and-bispecifics-in-aggressive-lymphomas.html
Aggressive Lymphomas: Clinical and Epidemiological: Uncommon Aggressive NHL - Monday, December 11, 2023: 4:30 PM-6:00 PM Harbor Ballroom (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/aggressive-lymphomas-clinical-and-epidemiological-uncommon-aggressive-nhl.html
Chronic Lymphocytic Leukemiashttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/chronic-lymphocytic-leukemias.html
CLLhttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/cll/chronic-lymphocytic-leukemias-basic-and-translational-molecular-determinants-of-cll-and-richter-transformation.html
Chronic Lymphocytic Leukemias: Basic and Translational: Molecular Determinants of CLL and Richter Transformation - Saturday, December 9, 2023: 9:30 AM-11:00 AM Grand Hall B (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/cll/chronic-lymphocytic-leukemias-basic-and-translational-molecular-determinants-of-cll-and-richter-transformation.html
Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Analysis and Treatment of High Risk and Treatment of Relapsed CLL or Richter Transformation - Saturday, December 9, 2023: 2:00 PM-3:30 PM Grand Hall D (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/cll/chronic-lymphocytic-leukemia-clinical-and-epidemiological-analysis-and-treatment-of-high-risk-and-treatment-of-relapsed-cll-or-richter-transformation-saturday-december.html
Chronic Lymphocytic Leukemia: Clinical and Epidemiological: New Inhibitors and Cellular Therapies for Treatment of Relapsed CLL - Saturday, December 9, 2023: 4:00 PM-5:30 PM Grand Hall D (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/cll/chronic-lymphocytic-leukemia-clinical-and-epidemiological-new-inhibitors-and-cellular-therapies-for-treatment-of-relapsed-cll.html
Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia - Sunday, December 10, 2023: 4:30 PM-6:00 PM Seaport Ballroom ABCD (Manchester Grand Hyatt)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/cll/chronic-lymphocytic-leukemia-clinical-and-epidemiological-frontline-treatment-with-targeted-agents-in-patients-with-chronic-lymphocytic-leukemia-sunday-december-10-202.html
Myelodysplastic Syndromeshttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/myelodysplastic-syndromes.html
MDShttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/mps-and-cml-basic-and-translational-lineage-tracing-and-novel-target-discovery.html
Myelodysplastic Syndromes – Basic and Translational: Molecular Drivers and Therapeutic Implications - Saturday, December 9, 2023: 4:00 PM-5:30 PM Pacific Ballroom Salons 21-22 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/mds/myelodysplastic-syndromes-basic-and-translational-molecular-drivers-and-therapeutic-implications.html
Myelodysplastic Syndromes – Clinical and Epidemiological: Treatment Options and Decision Making in Low Risk MDS - Saturday, December 9, 2023: 2:00 PM-3:30 PM Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/mds/myelodysplastic-syndromes-clinical-and-epidemiological-treatment-options-and-decision-making-in-low-risk-mds-saturday-december-9-2023-2-00-pm-3-30-pm-pacific-ballroom-salo.html
Myelodysplastic Syndromes – Clinical and Epidemiological: Treatments and Outcome Predictions in High Risk MDS - Saturday, December 9, 2023: 4:00 PM-5:30 PM Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/mds/myelodysplastic-syndromes-clinical-and-epidemiological-treatments-and-outcome-predictions-in-high-risk-mds.html
Myelodysplastic Syndromes – Clinical and Epidemiological: Genomic Classification and Prognostication of MDS - Monday, December 11, 2023: 4:30 PM-6:00 PM Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/mds/myelodysplastic-syndromes-clinical-and-epidemiological-genomic-classification-and-prognostication-of-mds.html
Multiple Myeloma and Plasma Cell Dyscrasiashttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/multiple-myeloma-and-plasma-cell-dyscrasias.html
Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translationalhttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/multiple-myeloma-and-plasma-cell-dyscrasias-basic-and-translational-spatial-dissection-and-multiomics-analysis-of-the-multiple-myelom-Microenvironment.html
Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Spatial Dissection and Multiomics Analysis of the Multiple Myeloma Tumor and Immune Microenvironment - Saturday, Dec 9: 9:30 AM-11AM Harbor Ballroom (Manchester Grand Hyahttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/multiple-myeloma-and-plasma-cell-dyscrasias-basic-and-translational-spatial-dissection-and-multiomics-analysis-of-the-multiple-myelom-Microenvironment.html
Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Characterization of the MM and the Tumor Microenvironment - Saturday, December 9, 2023: 4:00 PM-5:30 PM Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/multiple-myeloma-and-plasma-cell-dyscrasias-basic-and-translational-characterization-of-the-mm-and-the-tumor-microenvironment-saturda.html
Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Characterizing Response and Resistance to CAR-T and TCEs - Sunday, December 10, 2023: 9:30 AM-11:00 AM Harbor Ballroom (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/multiple-myeloma-and-plasma-cell-dyscrasias-basic-and-translational-characterizing-response-and-resistance-to-car-t-and-tces-sunday-d.html
Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Molecular Characterization of MM and Precursor Disease States - Sunday, December 10, 2023: 4:30 PM-6:00 PM Harbor Ballroom (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/multiple-myeloma-and-plasma-cell-dyscrasias-basic-and-translational-molecular-characterization-of-mm-and-precursor-disease-states-sun.html
Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Advancing Therapies in Multiple Myeloma and Waldenström's Macroglobulinemia - Monday, December 11, 2023: 10:30 AM-12:00 PM Harbor Ballroom (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/multiple-myeloma-and-plasma-cell-dyscrasias-basic-and-translational-advancing-therapies-in-multiple-myeloma-and-waldenstroem-s-macrog.html
Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Multiple Myleoma Circulating Tumor Cells, Novel Mechanisms, and Immune Interactions - Monday, December 11, 2023: 2:45 PM-4:15 PM Harbor Ballroom (Manchester Grand Hyatt)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/multiple-myeloma-and-plasma-cell-dyscrasias-basic-and-translational-multiple-myleoma-circulating-tumor-cells-novel-mechanisms-and-imm.html
Multiple Myeloma: Clinical and Epidemiologicalhttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/multiple-myeloma-clinical-and-epidemiological-t-cell-redirecting-therapy-outcomes-and-associated-complications.html
Multiple Myeloma: Clinical and Epidemiological: T Cell Redirecting Therapy Outcomes and Associated Complications - Saturday, December 9, 2023: 9:30 AM-11:00 AM Seaport Ballroom ABCD (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/multiple-myeloma-clinical-and-epidemiological-t-cell-redirecting-therapy-outcomes-and-associated-complications.html
Multiple Myeloma: Clinical and Epidemiological: Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics - Saturday, December 9, 2023: 4:00 PM-5:30 PM Harbor Ballroom (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/multiple-myeloma-clinical-and-epidemiological-minimal-residual-disease-and-alternative-non-invasive-bio-marker-evaluations-in-myeloma-therapeutics-saturday.html
Multiple Myeloma: Clinical and Epidemiological: Monoclonal Gammopathies of Determined Significance - Novel Insights on the Relevance of Gammopathies and Misc - Sun, Dec 10: 12 PM-1:30 PM Grand Hall C (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/multiple-myeloma-clinical-and-epidemiological-monoclonal-gammopathies-of-determined-significance-novel-insights-on-the-relevance-of-gammopathies-and-misc.html
Multiple Myeloma: Clinical and Epidemiological: Novel Biomarkers for Treatment Guidance in Multiple Myeloma - Sunday, December 10, 2023: 4:30 PM-6:00 PM Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/multiple-myeloma-clinical-and-epidemiological-novel-biomarkers-for-treatment-guidance-in-multiple-myeloma.html
Multiple Myeloma: Clinical and Epidemiological: Immunological Effects of Sustained Responses in Multiple Myeloma - Monday, December 11, 2023: 10:30 AM-12:00 PM Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/multiple-myeloma-clinical-and-epidemiological-immunological-effects-of-sustained-responses-in-multiple-myeloma.html
Multiple Myeloma: Clinical and Epidemiological: Molecular and Biological Signatures and Predictors of Outcomes - Monday, December 11, 2023: 2:45 PM-4:15 PM Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/multiple-myeloma-clinical-and-epidemiological-molecular-and-biological-signatures-and-predictors-of-outcomes-monday-december-11-2023-2-45-pm-4-15-pm-seapor.html
Multiple Myeloma: Clinical and Epidemiological: Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma - Monday, December 11, 2023: 4:30 PM-6:00 PM Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/multiple-myeloma-clinical-and-epidemiological-predicting-outcome-and-side-effects-of-novel-immunotherapies-in-multiple-myeloma-monday-december-11-2023-4-30.html
Multiple Myeloma: Prospective Therapeutic Trialshttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/multiple-myeloma-prospective-therapeutic-trials-smoldering-and-newly-diagnosed-myeloma-saturday-december-9-2023.html
Multiple Myeloma: Prospective Therapeutic Trials: Smoldering and Newly Diagnosed Myeloma - Saturday, December 9, 2023: 2:00 PM-3:30 PM Harbor Ballroom (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/multiple-myeloma-prospective-therapeutic-trials-smoldering-and-newly-diagnosed-myeloma-saturday-december-9-2023.html
Multiple Myeloma: Prospective Therapeutic Trials: Relapsed and Refractory Myeloma - Monday, December 11, 2023: 4:30 PM-6:00 PM Seaport Ballroom ABCD (Manchester Grand Hyatt San Diego)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/multiple-myeloma-prospective-therapeutic-trials-relapsed-and-refractory-myeloma-monday-december-11-2023-4-30-pm-6-00-pm-seaport-ballroom-abcd-manchester-.html
MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasiashttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/mgus-amyloidosis-other-non-myeloma-plasma-cell-dyscrasias-clinical-epidemiological-screening-to-vaccines-spectrum-of-plasma-cell-disorders.html
MGUS, Amyloidosis & Other Non-Myeloma Plasma Cell Dyscrasias: Clinical & Epidemiological: Screening to Vaccines Spectrum of Plasma Cell Disorders - Sat, Dec 9: 2 PM-3:30 PM Seaport Ballroom EFGH (Manchester Grand Hyatt)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/mgus-amyloidosis-other-non-myeloma-plasma-cell-dyscrasias-clinical-epidemiological-screening-to-vaccines-spectrum-of-plasma-cell-disorders.html
MGUS, Amyloidosis & Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: From Light Chain to Fibril–Novel Diagnostics to Treatments for Amyloidosis - Sun, Dec 10: 12 PM-1:30 PM Seaport Ballroom EFGH (Manchester Grandhttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/mgus-amyloidosis-other-non-myeloma-plasma-cell-dyscrasias-clinical-and-epidemiological-from-light-chain-to-fibril-novel-diagnostics-to-trea.html
Cellular Immunotherapieshttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/cellular-immunotherapies.html
Cellular Immunotherapies: Late Phase and Commercially Available Therapieshttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/cellular-immunotherapie-late-phase-and-commercially-available-therapies/cellular-therapy-for-b-cell-lymphomas-prospective-clinical-trials-and-real-world-data.html
Cellular Therapy for B Cell Lymphomas: Prospective Clinical Trials and Real World Data - Saturday, December 9, 2023: 9:30 AM-11:00 AM Room 6A (San Diego Convention Center)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/cellular-immunotherapie-late-phase-and-commercially-available-therapies/cellular-therapy-for-b-cell-lymphomas-prospective-clinical-trials-and-real-world-data.html
Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Translational Data and Prognostic Factors - Saturday, December 9, 2023: 2:00 PM-3:30 PM Room 6CF (San Diego Convention Center)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/cellular-immunotherapie-late-phase-and-commercially-available-therapies/translational-data-and-prognostic-factors.html
Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Prediction and Management of CAR-T Cell Related Toxicity - Saturday, December 9, 2023: 4:00 PM-5:30 PM Room 6B (San Diego Convention Center)https://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/cellular-immunotherapies-late-phase-and-commercially-available-therapies-prediction-and-management-of-car-t-cell-related-toxicity.html
Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas: Clinical Trial and Real World Evidence - Monday, December 11, 2023: 4:30 PM-6:00 PMhttps://oncoletter.ch/kongressberichte/id-2023/65th-ash-annual-meeting-2023/cellular-immunotherapies-late-phase-and-commercially-available-therapies-cellular-therapy-for-multiple-myeloma-b-cell-ALL.html
46th SAN ANTONIO BREAST CANCER SYMPOSIUM - December 5 - 9, 2023, San Antonio Texashttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium.html
Studies presented at the SABCS 2023 Press Briefinghttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/studies-presented-at-the-sabcs-2023-press-briefing.html
Interviews von Renate Haidinger, Brustkrebs Deutschland e.V.https://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/interviews-von-renate-haidinger-brustkrebs-deutschland-e-v.html
Kurze Videos mit Expert:innen zu ausgewählten Highlights aus Sitzungen und Vorträgen sowie speziellen Schwerpunktthemenhttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/kurze-videos-mit-expert-innen-zu-ausgewaehlten-highlights-aus-sitzungen-und-vortraegen-sowie-speziellen-schwerpunktthemen.html
General Sessions 1-3https://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/general-sessions-1-3.html
General Sessionshttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium-2023/general-session-1.html
GENERAL SESSION 1 | WEDNESDAY, DECEMBER 6 | 9:00AM-12:00PM CThttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium-2023/general-session-1.html
GENERAL SESSION 2 | THURSDAY, DECEMBER 7 | 8:15AM-11:15AM CThttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/general-sessions-2.html
GENERAL SESSION 3 | FRIDAY, DECEMBER 8 | 8:15AM-11:15AM CThttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/general-session-3.html
Rapid Fire Sessions 1&2https://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/rapid-fire-sessions-1-2.html
Rapid Fire Sessions 1&2https://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/rapid-fire-session-1.html
Rapid Fire Session 1 | WEDNESDAY, DECEMBER 6 | 12:15-1:00PM CThttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/rapid-fire-session-1.html
Rapid Fire Session 2 | THURSDAY, DECEMBER 7 | 12:00-12:45PM CThttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/rapid-fire-session-2.html
Late Breaking Abstracts Oral Sessionhttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/late-breaking-abstracts-oral-session.html
Late Breaking Abstracts Oral Sessionhttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/late-breaking-abstracts-oral-session/late-breaking-abstracts-oral-session-friday-december-8.html
Late Breaking Abstracts Oral Session| FRIDAY, DECEMBER 8 | 12:00- 12:45PM CThttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/late-breaking-abstracts-oral-session/late-breaking-abstracts-oral-session-friday-december-8.html
POSTER SPOTLIGHT SESSIONS 1-18https://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/poster-spotlight-sessions-1-18.html
POSTER SPOTLIGHT SESSIONShttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/poster-spotlight-sessions-1-less-is-more-minimizing-surgical-treatment-in-patients-with-early-stage-breast-cancer.html
Poster Spotlight Session 1: Less is More: Minimizing Surgical Treatment in Patients with Early Stage Breast Cancerhttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/poster-spotlight-sessions-1-less-is-more-minimizing-surgical-treatment-in-patients-with-early-stage-breast-cancer.html
Poster Spotlight Session 2: Improving QOL and Care Delivery for the Breast Cancer Patienthttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/poster-spotlight-sessions-2-improving-qol-and-care-delivery-for-the-breast-cancer-patient.html
Poster Spotlight Session 3: Insights from Single Cell, Spatial, and Artificial Intelligence Approacheshttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/poster-spotlight-sessions-3-insights-from-single-cell-spatial-and-artificial-intelligence-approaches.html
Poster Spotlight Session 4: Gaps in the Timing, Treatment Selection, and Supportive Services for Cancer Carehttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/poster-spotlight-sessions-4-gaps-in-the-timing-treatment-selection-and-supportive-services-for-cancer-care.html
Poster Spotlight Session 5: Shining a New Light on Breast Cancer: Novel Molecular and Functional Imaging Approaches to Detect and Characterize Breast Cancerhttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/poster-spotlight-sessions-5-shining-a-new-light-on-breast-cancer-novel-molecular-and-functional-imaging-approaches-to-detect-and-char.html
Poster Spotlight Session 6: Prognostic and Predictive Uses of Cell Free DNAhttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/poster-spotlight-sessions-6-prognostic-and-predictive-uses-of-cell-free-dna.html
Poster Spotlight Session 7: Preventionhttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/poster-spotlight-sessions-7-prevention.html
Poster Spotlight Session 8: Antibody Drug Conjugates: Where are We Headed?https://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/poster-spotlight-sessions-8-antibody-drug-conjugates-where-are-we-headed.html
Poster Spotlight Session 9: Exploiting Tumor Biology in HER2-positive Breast Cancer to Escalate or De-escalate Neoadjuvant Therapyhttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/poster-spotlight-sessions-9-exploiting-tumor-biology-in-her2-positive-breast-cancer-to-escalate-or-de-escalate-neoadjuvant-therapy.html
Poster Spotlight Session 10: Refining Prediction of Cancer Risk and Outcomeshttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/poster-spotlight-sessions-10-refining-prediction-of-cancer-risk-and-outcomes.html
Poster Spotlight Session 11: CNS Disease in Breast Cancer: Where are We Now and Can We do Better?https://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/poster-spotlight-sessions-11-cns-disease-in-breast-cancer-where-are-we-now-and-can-we-do-better.html
Poster Spotlight Session 12: Putting Brakes on the Cell Cycle: Understanding Mechanisms Governing CDK 4/6 Inhibitor Resistance and Role for Novel Therapeutic Strategieshttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/poster-spotlight-sessions-12-putting-brakes-on-the-cell-cycle-understanding-mechanisms-governing-cdk-4-6-inhibitor-resistance-and-rol.html
Poster Spotlight Session 13: Special Populations: Pregnancy, Male and Geriatric Patientshttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/poster-spotlight-sessions-13-special-populations-pregnancy-male-and-geriatric-patients.html
Poster Spotlight Session 14: Setting Expectations for Toxicities Related to I/O Therapyhttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/poster-spotlight-sessions-14-setting-expectations-for-toxicities-related-to-i-o-therapy.html
Poster Spotlight Session 15: Novel Nuclear Receptor Targeting Therapieshttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/poster-spotlight-sessions-15-novel-nuclear-receptor-targeting-therapies.html
Poster Spotlight Session 16: Enhancing Immunotherapy for Triple Negative Breast Cancer: Novel therapies and Biomarkershttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/poster-spotlight-sessions-16-enhancing-immunotherapy-for-triple-negative-breast-cancer-novel-therapies-and-biomarkers.html
Poster Spotlight Session 17: Biomarkers of Response and/or Resistance to Endocrine Based Therapies: Implications for Treatment Approacheshttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/poster-spotlight-sessions-17-biomarkers-of-response-and-or-resistance-to-endocrine-based-therapies-implications-for-treatment-approac.html
Poster Spotlight Session 18: Disparate Care Calls for Desperate Measures: Understanding Gaps in Quality of Care and Opportunities to Improve ithttps://oncoletter.ch/kongressberichte/id-2023/46th-san-antonio-breast-cancer-symposium/poster-spotlight-sessions-18-disparate-care-calls-for-desperate-measures-understanding-gaps-in-quality-of-care-and-opportunities-to-i.html
ESMO Congress 2023 - 20. - 24. OKTOBER - MADRID, SPANIENhttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien.html
ESMO23 - Presidential Symposia I-IIIhttps://oncoletter.ch/kongressberichte/id-2023/presidential-symposia-i-iii.html
ESMO23 - Presidential Symposia I-IIIhttps://oncoletter.ch/kongressberichte/id-2023/presidential-symposium-i-sat-21-10-2023-16-30-18-15.html
Presidential Symposium I - Sat, 21.10.2023; 16:30 - 18:15https://oncoletter.ch/kongressberichte/id-2023/presidential-symposium-i-sat-21-10-2023-16-30-18-15.html
Presidential Symposium II - Sun, 22.10.2023; 16:30 - 18:15https://oncoletter.ch/kongressberichte/presidential-symposium-ii-sun-22-10-2023-16-30-18-15.html
Presidential Symposium III - Mon, 23.10.2023; 16:30 - 18:15https://oncoletter.ch/kongressberichte/id-2023/presidential-symposium-iii-mon-23-10-2023-16-30-18-15.html
BREAST CANCERhttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/esmo-23-breast-cancer.html
Interviewshttps://oncoletter.ch/kongressberichte/id-2023/interviews-von-renate-haidinger-brustkrebs-deutschland-e-v.html
Interviews von Renate Haidinger, Brustkrebs Deutschland e.V.https://oncoletter.ch/kongressberichte/id-2023/interviews-von-renate-haidinger-brustkrebs-deutschland-e-v.html
Breast cancer, early stagehttps://oncoletter.ch/kongressberichte/id-2023/breast-cancer/breast-cancer-early-stage/proffered-paper-session-breast-cancer-early-stage.html
Proffered Paper session: Breast cancer, early stage - Fri, 20.10.2023; 14:00 - 15:40https://oncoletter.ch/kongressberichte/id-2023/breast-cancer/breast-cancer-early-stage/proffered-paper-session-breast-cancer-early-stage.html
Mini Oral session: Breast cancer, early stage - Mon, 23.10.2023; 16:30 - 18:00https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/mini-oral-session-breast-cancer-early-stage-mon-23-10-2023-16-30-18-00.html
Breast cancer, metastatic.https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/proffered-paper-session-breast-cancer-metastatic.html
Proffered Paper session: Breast cancer, metastatic - Sat, 21.10.2023; 10:15 - 11:35https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/proffered-paper-session-breast-cancer-metastatic.html
Mini Oral session: Breast cancer, metastatic - Sun, 22.10.2023; 08:30 - 09:55https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/mini-oral-session-breast-cancer-metastatic-sun-22-10-2023-08-30-09-55.html
LUNG CANCER & OTHER THORACIC MALIGNANCIEShttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/lung-cancer-other-thoracic-malignancies.html
Statement ESMO Highlights Lungenkrebs Prof. Dr. med. Alessandra Curioni-Fontecedro, Fribourghttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/lung-cancer-other-thoracic-malignancies/statement-esmo-highlights-lungenkrebs-prof-dr-med-alessandra-curioni-fontecedro-fribourg/statement.html
Statementhttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/lung-cancer-other-thoracic-malignancies/statement-esmo-highlights-lungenkrebs-prof-dr-med-alessandra-curioni-fontecedro-fribourg/statement.html
Non-metastatic NSCLC and other thoracic malignancieshttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/lung-cancer-other-thoracic-malignancies/proffered-paper-session-non-metastatic-nsclc-and-other-thoracic-malignancies.html
Proffered Paper session: Non-metastatic NSCLC and other thoracic malignancies - Fri, 20.10.2023; 14:00 - 15:45https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/lung-cancer-other-thoracic-malignancies/proffered-paper-session-non-metastatic-nsclc-and-other-thoracic-malignancies.html
Mini Oral session 1: Non-metastatic NSCLC and other thoracic malignancies - Sat, 21.10.2023; 14:45 - 16:15https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/mini-oral-session-1-non-metastatic-nsclc-and-other-thoracic-malignancies-sat-21-10-2023-1.html
Mini Oral session 2: Non-metastatic NSCLC and other thoracic malignancies - Mon, 23.10.2023; 14:45 - 15:55https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/mini-oral-session-2-non-metastatic-nsclc-and-other-thoracic-malignancies-mon-23-10-2023-1.html
NSCLC, metastatichttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/lung-cancer-other-thoracic-malignancies/nsclc-metastatic/proffered-paper-session-nsclc-metastatic.html
Proffered Paper session: NSCLC, metastatic - Fri, 20.10.2023; 16:00 - 17:30https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/lung-cancer-other-thoracic-malignancies/nsclc-metastatic/proffered-paper-session-nsclc-metastatic.html
Mini Oral session 1: NSCLC, metastatic - Sat, 21.10.2023; 08:30 - 10:00https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/mini-oral-session-1-nsclc-metastatic-sat-21-10-2023-08-30-10-00.html
Mini Oral session 2: NSCLC, metastatic - Sun, 22.10.2023; 08:30 - 10:00https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/mini-oral-session-2-nsclc-metastatic-sun-22-10-2023-08-30-10-00.html
HEAD & NECK CANCERhttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/head-neck-cancer.html
Statement Highlights Head and Neck Cancer - Assoz.-Prof. Priv.-Doz. Dr. Thorsten Füreder, Wienhttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/head-neck-cancer/statement-highlights-head-and-neck-cancer-assoz-prof-priv-doz-dr-thorsten-fuereder-wien-coming-soon.html
Head & Neck Sessionshttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/proffered-paper-session-head-neck-cancer.html
Proffered Paper session: Head & neck cancer - Mon, 23.10.2023; 08:30 - 09:55https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/proffered-paper-session-head-neck-cancer.html
Mini Oral session: Head & neck cancer - Sat, 21.10.2023; 10:15 - 11:15https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/mini-oral-session-head-neck-cancer-sat-21-10-2023-10-15-11-15.html
GYNAECOLOGICAL CANCERShttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/gynaecological-cancers.html
Interviews von Renate Haidinger, Brustkrebs Deutschland e.V. mit Prof. Dr. med. Sven Mahner - Highlights Gynäkologische Tumorenhttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/gynaecological-cancers/interviews-kopie/interviews-von-renate-haidinger-brustkrebs-deutschland-e-v-mit-prof-dr-med-sven-mahner.html
Interviewshttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/gynaecological-cancers/interviews-kopie/interviews-von-renate-haidinger-brustkrebs-deutschland-e-v-mit-prof-dr-med-sven-mahner.html
Gynaecological Sessionshttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/proffered-paper-session-1-gynaecological-cancers-fri-20-10-2023-16-00-17-30.html
Proffered Paper session 1: Gynaecological cancers - Fri, 20.10.2023; 16:00 - 17:30https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/proffered-paper-session-1-gynaecological-cancers-fri-20-10-2023-16-00-17-30.html
Proffered Paper session 2: Gynaecological cancers - Sat, 21.10.2023: 08:45 - 10:00https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/proffered-paper-session-2-gynaecological-cancers-sat-21-10-2023-08-45-10-00.html
Mini Oral session: Gynaecological cancers - Sun, 22.10.2023; 10:15 - 11:55https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/mini-oral-session-gynaecological-cancers-sun-22-10-2023-10-15-11-55.html
CNS TUMOURS & SARCOMAhttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/cns-tumours-sarcoma.html
CNS & SARCOMA Sessionshttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/proffered-paper-session-cns-tumours-fri-20-10-2023-16-00-17-30.html
Proffered Paper session: CNS tumours - Fri, 20.10.2023: 16:00 - 17:30https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/proffered-paper-session-cns-tumours-fri-20-10-2023-16-00-17-30.html
Proffered Paper session: Sarcoma - Sun, 22.10.2023; 08:30 - 10:00https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/proffered-paper-session-sarcoma-sun-22-10-2023-08-30-10-00.html
Mini Oral session: CNS tumours - Sat, 21.10.2023; 10:15 - 11:45https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/mini-oral-session-cns-tumours-sat-21-10-2023-10-15-11-45.html
Mini Oral session: Sarcoma - Sat, 21.10.2023; 10:15 - 11:45https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/mini-oral-session-sarcoma-sat-21-10-2023-10-15-11-45.html
GENITOURINARY TUMOURShttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/genitourinary-tumours.html
GU tumours, non-prostate.https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/proffered-paper-sessions-1-gu-tumours-non-prostate-sat-21-10-2023-08-30-09-50.html
Proffered Paper sessions 1: GU tumours, non-prostate - Sat, 21.10.2023; 08:30 - 09:50https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/proffered-paper-sessions-1-gu-tumours-non-prostate-sat-21-10-2023-08-30-09-50.html
Proffered Paper session 2: GU tumours, non-prostate - Sat, 21.10.2023; 14:45 - 16:10https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/proffered-paper-session-2-gu-tumours-non-prostate-sat-21-10-2023-14-45-16-10.html
Mini Oral session: GU tumours, non-prostate - Sun, 22.10.2023; 10:15 - 11:45https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/mini-oral-session-gu-tumours-non-prostate-sun-22-10-2023-10-15-11-45.html
GU tumours, prostatehttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/gu-tumours-prostate/proffered-paper-session-gu-tumours-prostate-fri-20-10-2023-16-00-17-20.html
Proffered Paper session: GU tumours, prostate - Fri, 20.10.2023; 16:00 - 17:20https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/gu-tumours-prostate/proffered-paper-session-gu-tumours-prostate-fri-20-10-2023-16-00-17-20.html
Mini Oral session: GU tumours, prostate - Sun, 22.10.2023; 08:30 - 09:35https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/mini-oral-session-gu-tumours-prostate-sun-22-10-2023-08-30-09-35.html
GASTROINTESTINAL TUMOURShttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/gastrointestinal-tumours.html
GI, upper digestivehttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/gi-upper-digestive/proffered-paper-sessions-1-gi-upper-digestive-fri-20-10-2023-14-00-15-40.html
Proffered Paper sessions 1: GI, upper digestive - Fri, 20.10.2023; 14:00 - 15:40https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/gi-upper-digestive/proffered-paper-sessions-1-gi-upper-digestive-fri-20-10-2023-14-00-15-40.html
Proffered Paper sessions 2: GI, upper digestive - Sun, 22.10.2023; 10:15 - 11:45https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/proffered-paper-sessions-2-gi-upper-digestive-sun-22-10-2023-10-15-11-45.html
Mini Oral session: GI, upper digestive - Sat, 21.10.2023; 16:30 - 18:10https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/mini-oral-session-gi-upper-digestive-sat-21-10-2023-16-30-18-10.html
GI, lower digestivehttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/gastrointestinal-tumours/proffered-paper-session-gi-lower-digestive-mon-23-10-2023-08-30-10-00.html
Proffered Paper session: GI, lower digestive - Mon, 23.10.2023; 08:30 - 10:00https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/gastrointestinal-tumours/proffered-paper-session-gi-lower-digestive-mon-23-10-2023-08-30-10-00.html
Mini Oral session: GI, lower digestive - Sun, 22.10.2023; 14:45 - 16:20https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/mini-oral-session-gi-lower-digestive-sun-22-10-2023-14-45-16-20.html
NETs and endocrine tumourshttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/nets-and-endocrine-tumours.html
NETs and endocrine tumours Sessionshttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/proffered-paper-session-nets-and-endocrine-tumours-sun-22-10-2023-08-30-10-00.html
Proffered Paper session: NETs and endocrine tumours - Sun, 22.10.2023; 08:30 - 10:00https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/proffered-paper-session-nets-and-endocrine-tumours-sun-22-10-2023-08-30-10-00.html
Mini Oral session: NETs and endocrine tumours - Sun, 22.10.2023; 16:30 - 18:00https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/mini-oral-session-nets-and-endocrine-tumours-sun-22-10-2023-16-30-18-00.html
HAEMATOLOGICAL MALIGNANCIEShttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/haematological-malignancies.html
Haematological malignancies Sessionshttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/proffered-paper-session-haematological-malignancies-sun-22-10-2023-16-30-18-00.html
Proffered paper session: Haematological malignancies - Sun, 22.10.2023; 16:30 - 18:00https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/proffered-paper-session-haematological-malignancies-sun-22-10-2023-16-30-18-00.html
MELANOMA AND OTHER SKIN TUMOURShttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/melanoma-and-other-skin-tumours.html
Melanoma Sessionshttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/proffered-paper-session-melanoma-and-other-skin-tumours-mon-23-10-2023-08-30-10-00.html
Proffered Paper session: Melanoma and other skin tumours - Mon, 23.10.2023; 08:30 - 10:00https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/proffered-paper-session-melanoma-and-other-skin-tumours-mon-23-10-2023-08-30-10-00.html
Mini Oral session: Melanoma and other skin tumours - Sat, 21.10.2023; 14:45 - 16:10https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/mini-oral-session-melanoma-and-other-skin-tumours-sat-21-10-2023-14-45-16-10.html
INVESTIGATIONAL IMMUNOTHERAPYhttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/investigational-immunotherapy.html
INVESTIGATIONAL IMMUNOTHERAPYhttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/proffered-paper-session-investigational-immunotherapy-mon-23-10-2023-10-15-11-40.html
Proffered Paper session: Investigational immunotherapy - Mon, 23.10.2023; 10:15 - 11:40https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/proffered-paper-session-investigational-immunotherapy-mon-23-10-2023-10-15-11-40.html
Mini Oral session: Investigational immunotherapy - Sat, 21.10.2023; 16:30 - 17:50https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/mini-oral-session-investigational-immunotherapy-sat-21-10-2023-16-30-17-50.html
BASIC SCIENCE & TRANSLATIONAL RESEARCH & DEVELOPMENTAL THERAPEUTICS (Kopie)https://oncoletter.ch/3186.html
Basic science & translational research sessions & developmental therapeuticshttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/proffered-paper-session-1-basic-science-translational-research-sat-21-10-2023-10-15-11-45.html
Proffered Paper session 1: Basic science & translational research - Sat, 21.10.2023; 10:15 - 11:45https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/proffered-paper-session-1-basic-science-translational-research-sat-21-10-2023-10-15-11-45.html
Proffered Paper session 2: Basic science & translational research - Sat, 21.10.2023; 14:45 - 16:15https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/proffered-paper-session-2-basic-science-translational-research-sat-21-10-2023-14-45-16-15.html
Proffered Paper session: Developmental therapeutics - Sun, 22.10.2023; 08:30 - 10:00https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/proffered-paper-session-developmental-therapeutics-sun-22-10-2023-08-30-10-00.html
Mini Oral session: Developmental therapeutics - Mon, 23.10.2023; 16:30 - 18:00https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/mini-oral-session-developmental-therapeutics-mon-23-10-2023-16-30-18-00.html
Mini Oral session: Basic science & translational research - Sun, 22.10.2023; 08:30 - 10:00https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/mini-oral-session-basic-science-translational-research-sun-22-10-2023-08-30-10-00.html
SUPPORTIVE AND PALLIATIVE CAREhttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/supportive-and-palliative-care.html
Supportive and palliative care sessionshttps://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/supportive-and-palliative-care/proffered-paper-session-supportive-and-palliative-care-fri-20-10-2023-16-00-17-20.html
Proffered Paper session: Supportive and palliative care - Fri, 20.10.2023; 16:00 - 17:20https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/supportive-and-palliative-care/proffered-paper-session-supportive-and-palliative-care-fri-20-10-2023-16-00-17-20.html
Mini Oral session: Supportive and palliative care - Sat, 21.10.2023; 14:45 - 16:15https://oncoletter.ch/kongressberichte/id-2023/esmo-congress-2023-20-24-oktober-madrid-spanien/mini-oral-session-supportive-and-palliative-care-sat-21-10-2023-14-45-16-15.html
 IASLC 2023 World Conference on Lung Cancerhttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer.html
IASLC World Conference on Lung Cancer Press Briefing Recordingshttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/iaslc-world-conference-on-lung-cancer-press-briefing-recordings.html
Oral Session: Advancing Immunotherapy in ES-SCLChttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/oral-session-advancing-immunotherapy-in-es-sclc.html
Oral Session: Evolving Landscape in Mesotheliomahttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/oral-session-evolving-landscape-in-mesothelioma.html
Oral Session: Newer Generation Treatments for EGFR, ALK and ROS1https://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/oral-session-newer-generation-treatments-for-egfr-alk-and-ros1.html
Oral Session: Antibody Drug Conjugates: The Next Tsunamihttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/oral-session-antibody-drug-conjugates-the-next-tsunami.html
Oral Session: Immunotherapy for Advanced NSCLChttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/oral-session-immunotherapy-for-advanced-nsclc.html
Oral Session: Pushing the Boundaries: Adjuvant & Neoadjuvant Approaches in Early NSCLChttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/oral-session-pushing-the-boundaries-adjuvant-and-neoadjuvant-approaches-in-early-stage-non-small-cell-lung-cancer.html
Oral Session: Immune Checkpoint Therapy: Long Term Follow Uphttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/oral-session-immune-checkpoint-therapy-long-term-follow-up.html
Oral Session: MET Matters in NSCLChttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/oral-session-met-matters-in-nsclc.html
Oral Session: Integration of Local Therapies with Modern Immune Checkpoint Inhibitors and Targeted Therapies in Metastatic NSCLC: When and How?https://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/oral-session-integration-of-local-therapies-with-modern-immune-checkpoint-inhibitors-and-targeted-therapies-in-metastatic-nsclc-when-and-how.html
Oral Session: Next Steps in Locally Advanced NSCLC: Optimizing Techniques & Choosing Populations That Benefithttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/oral-session-next-steps-in-locally-advanced-nsclc-optimizing-techniques-choosing-populations-that-benefit.html
More Links to Oral Sessionshttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/more-links-to-oral-sessions.html
Mini Oral Session: Targeted Therapy: KRAS and Beyondhttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/mini-oral-session-targeted-therapy-kras-and-beyond.html
Mini Oral Session: Mediastinal Lumps and Bumpshttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/mini-oral-session-mediastinal-lumps-and-bumps.html
Mini Oral Session: New Technology and Innovations in Early Stage Lung Cancerhttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/mini-oral-session-new-technology-and-innovations-in-early-stage-lung-cancer.html
Mini Oral Session: Targeted Therapy: EGFR and HER2https://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/mini-oral-session-targeted-therapy-egfr-and-her2.html
Mini Oral Session: Bringing New Discoveries into Early Phase Clinical Trialshttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/mini-oral-session-bringing-new-discoveries-into-early-phase-clinical-trials.html
Mini Oral Session: Innovations in the Treatment of Stage III NSCLChttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/mini-oral-session-innovations-in-the-treatment-of-stage-iii-nsclc.html
Mini Oral Session: Current Standards and Future Directions in Mesotheliomahttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/mini-oral-session-current-standards-and-future-directions-in-mesothelioma.html
Mini Oral Session: Refining Practice and Redefining Standards in SCLChttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/mini-oral-session-refining-practice-and-redefining-standards-in-sclc.html
More Links to Mini Oral Sessionshttps://oncoletter.ch/kongressberichte/id-2023/iaslc-2023-world-conference-on-lung-cancer/more-links-to-mini-oral-sessions.html
ESMO World Congress on Gastrointestinal Cancer (ESMO World GI 2023)https://oncoletter.ch/kongressberichte/id-2023/esmo-world-congress-on-gastrointestinal-cancer-2023.html
Session II: Cancer of the Pancreashttps://oncoletter.ch/kongressberichte/id-2023/esmo-world-congress-on-gastrointestinal-cancer-2023/session-ii-cancer-of-the-pancreas.html
Session III: Cancer of the Biliary Tracthttps://oncoletter.ch/kongressberichte/id-2023/esmo-world-congress-on-gastrointestinal-cancer-2023/session-iii-cancer-of-the-biliary-tract-2.html
Session V: Presentation of Selected Abstracts – Biliary Tract and Pancreatic Cancerhttps://oncoletter.ch/kongressberichte/id-2023/esmo-world-congress-on-gastrointestinal-cancer-2023/session-v-presentation-of-selected-abstracts-biliary-tract-and-pancreatic-cancer.html
Session VI: Presentation of Selected Abstracts - Esophageal and Stomach Cancershttps://oncoletter.ch/kongressberichte/id-2023/esmo-world-congress-on-gastrointestinal-cancer-2023/session-vi-presentation-of-selected-abstracts-esophageal-and-stomach-cancers.html
Session VIII: Esophageal and Gastric Cancershttps://oncoletter.ch/kongressberichte/id-2023/esmo-world-congress-on-gastrointestinal-cancer-2023/session-viii-esophageal-and-gastric-cancers.html
Session IX: Hepatocellular Cancerhttps://oncoletter.ch/kongressberichte/id-2023/esmo-world-congress-on-gastrointestinal-cancer-2023/session-ix-hepatocellular-cancer.html
Session XI: Presentation of Selected Abstracts: Colorectal Cancerhttps://oncoletter.ch/kongressberichte/id-2023/esmo-world-congress-on-gastrointestinal-cancer-2023/session-xi-presentation-of-selected-abstracts-colorectal-cancer.html
Session XVIII: Immune Mechanisms and Microbiome in GI Tumorshttps://oncoletter.ch/kongressberichte/id-2023/esmo-world-congress-on-gastrointestinal-cancer-2023/session-xviii-immune-mechanisms-and-microbiome-in-gi-tumors.html
Session XIX: Predicting and Managing Rare Toxicities in Patients With GI Cancershttps://oncoletter.ch/kongressberichte/id-2023/esmo-world-congress-on-gastrointestinal-cancer-2023/session-xix-predicting-and-managing-rare-toxicities-in-patients-with-gi-cancers.html
Session XX: Presentation of Selected Abstracts: Metastatic Colorectal Cancerhttps://oncoletter.ch/kongressberichte/id-2023/esmo-world-congress-on-gastrointestinal-cancer-2023/session-xx-presentation-of-selected-abstracts-metastatic-colorectal-cancer.html
Session XXIII: Colorectal Cancer: Metastatic Diseasehttps://oncoletter.ch/kongressberichte/id-2023/esmo-world-congress-on-gastrointestinal-cancer-2023/session-xxiii-colorectal-cancer-metastatic-disease.html
EHA2023 Congresshttps://oncoletter.ch/kongressberichte/id-2023/eha2023-congress.html
Plenary Sessionhttps://oncoletter.ch/kongressberichte/id-2023/eha2023-congress/plenary-session.html
EHA 2023 Press Briefing, Friday, June 9https://oncoletter.ch/kongressberichte/id-2023/eha2023-congress/eha-2023-press-briefing-friday-june-9.html
Late Breaking Abstracts Sessionhttps://oncoletter.ch/kongressberichte/id-2023/late-breaking-abstracts-session.html
Acute lymphoblastic leukemiahttps://oncoletter.ch/kongressberichte/id-2023/eha2023-congress/acute-lymphoblastic-leukemia.html
Acute myeloid leukemiahttps://oncoletter.ch/kongressberichte/id-2023/eha2023-congress/acute-myeloid-leukemia.html
Aggressive Non-Hodgkin lymphomahttps://oncoletter.ch/kongressberichte/id-2023/eha2023-congress/aggressive-non-hodgkin-lymphoma.html
Chronic lymphocytic leukemiahttps://oncoletter.ch/kongressberichte/id-2023/eha2023-congress/chronic-lymphocytic-leukemia.html
Chronic myeloid leukemiahttps://oncoletter.ch/kongressberichte/id-2023/eha2023-congress/chronic-myeloid-leukemia.html
Myeloma and other monoclonal gammopathies - Clinicalhttps://oncoletter.ch/kongressberichte/id-2023/eha2023-congress/myeloma-and-other-monoclonal-gammopathies-clinical.html
Gene therapy, cellular immunotherapy and vaccinationhttps://oncoletter.ch/kongressberichte/id-2023/eha2023-congress/gene-therapy-cellular-immunotherapy-and-vaccination.html
Hodgkin lymphomahttps://oncoletter.ch/kongressberichte/id-2023/eha2023-congress/hodgkin-lymphoma.html
Indolent and mantle-cell non-Hodgkin lymphoma/Waldenströmhttps://oncoletter.ch/kongressberichte/id-2023/eha2023-congress/indolent-and-mantle-cell-non-hodgkin-lymphoma-waldenstroem.html
Myelodysplastic syndromeshttps://oncoletter.ch/kongressberichte/id-2023/eha2023-congress/myelodysplastic-syndromes.html
Myeloproliferative neoplasmshttps://oncoletter.ch/kongressberichte/id-2023/eha2023-congress/myeloproliferative-neoplasms.html
Stem cell transplantationhttps://oncoletter.ch/kongressberichte/id-2023/eha2023-congress/stem-cell-transplantation.html
ASCO Annual Meeting, June 2-6, 2023 - McCormick Place, Chicagohttps://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023.html
Late-Breaking Abstract -, Plenary - & Highlights of the Day Sessionshttps://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023/late-breaking-abstract-plenary-highlights-of-the-day-sessions.html
Interviews in Kooperation mit info@ONCO-SUISSE, moderiert von Prof. Roger von Moos: Schweizer Experten fassen die ASCO Ergebnisse zusammenhttps://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023/interviews-in-kooperation-mit-info-onco-suisse-moderiert-von-prof-roger-von-moos-schweizer-experten-fassen-die-asco-ergebnisse-zusammen.html
Round Table und Interviews von Renate Haidinger, Brustkrebs Deutschland e.V.https://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023/round-table-und-interviews-von-renate-haidinger-brustkrebs-deutschland-e-v.html
Saturday, June 3 & Sunday June 4, On-Site Press Briefingshttps://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023/asco-2023-press-briefing-late-breaking-abstracts/saturday-june-3-on-site-briefing.html
Lung Cancer: Oral & Poster Discussion Sessionshttps://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023/lung-cancer-oral-poster-discussion-sessions.html
Head and Neck Cancer: Oral & Poster Discussion Sessionshttps://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023/head-and-neck-cancer-oral-poster-discussion-sessions.html
Breast Cancer: Oral & Poster Discussion Sessionshttps://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023/breast-cancer-oral-poster-discussion-sessions.html
Gynecologic Cancer: Oral & Poster Discussion Sessionshttps://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023/gynecologic-cancer-oral-poster-discussion-sessions-kopie.html
Gastrointestinal Cancer: Oral & Poster Discussion Sessionshttps://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023/gastrointestinal-cancer-oral-poster-discussion-sessions.html
Sarcoma Cancer: Oral & Poster Discussion Sessions.https://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023/sarcoma-cancer-oral-poster-discussion-sessions.html
Melanoma/Skin Cancers: Oral & Poster Discussion Sessions.https://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023/melanoma-skin-cancers-oral-poster-discussion-sessions.html
Central Nervous System Tumors: Oral & Poster Discussion Sessions.https://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023/central-nervous-system-tumors-oral-poster-discussion-sessions.html
Genitourinary Cancer: Oral & Poster Discussion Sessionshttps://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023/genitourinary-cancer-oral-poster-discussion-sessions.html
Hematologic Malignancies: Oral & Poster Discussion Sessionshttps://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023/hematologic-malignancies-oral-poster-discussion-sessions.html
Developmental Therapeutics: Oral & Poster Discussion Sessionshttps://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023/developmental-therapeutics-oral-poster-discussion-sessions.html
Pediatric Oncology: Oral & Poster Discussion Sessionshttps://oncoletter.ch/kongressberichte/id-2023/ascoannual-meeting-june-2-6-2023/pediatric-oncology-oral-poster-discussion-sessions.html
Comprehensive Cancer Center Zürich: Patientenakademie – Brustkrebshttps://oncoletter.ch/kongressberichte/patientenakademie-brustkrebs.html
Neuigkeiten in der Behandlung und Nachsorge bei Brustkrebshttps://oncoletter.ch/kongressberichte/patientenakademie-brustkrebs/neuigkeiten-in-der-behandlung-und-nachsorge-bei-brustkrebs.html
18th St.Gallen International Breast Cancer Conference 2023 (SGBCC)https://oncoletter.ch/kongressberichte/id-2023/sgbcc-18th-st-gallen-international-breast-cancer-conference-2023.html
Interviews von Renate Haidinger, Brustkrebs Deutschland e.V. mit:https://oncoletter.ch/kongressberichte/id-2023/sgbcc-18th-st-gallen-international-breast-cancer-conference-2023/interviews-von-renate-haidinger-brustkrebs-deutschland-e-v-mit-kopie.html
ASCO Genitourinary Cancers Symposium 2023https://oncoletter.ch/kongressberichte/id-2023/ascogenitourinary-cancers-symposium-2023.html
General Sessionshttps://oncoletter.ch/kongressberichte/id-2023/ascogenitourinary-cancers-symposium-2023/general-sessions.html
Rapid Abstract Sessionshttps://oncoletter.ch/kongressberichte/id-2023/ascogenitourinary-cancers-symposium-2023/rapid-abstract-sessions.html
Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/id-2023/ascogenitourinary-cancers-symposium-2023/oral-abstract-sessions.html
Statements zu den Highlights des ASCO-GUhttps://oncoletter.ch/kongressberichte/id-2023/ascogenitourinary-cancers-symposium-2023/statements-zu-den-highlights-des-asco-gu.html
ASCO 2023 Gastrointestinal (GI) Cancers Symposiumhttps://oncoletter.ch/kongressberichte/id-2023/asco2023-gastrointestinal-gi-cancers-symposium.html
Rapid Abstract Sessionshttps://oncoletter.ch/kongressberichte/id-2023/asco2023-gastrointestinal-gi-cancers-symposium/rapid-abstract-sessions.html
Oral Abstract Sessionshttps://oncoletter.ch/kongressberichte/id-2023/asco2023-gastrointestinal-gi-cancers-symposium/oral-abstract-sessions.html
Links to more Abstractshttps://oncoletter.ch/kongressberichte/id-2023/asco2023-gastrointestinal-gi-cancers-symposium/links-to-more-abstracts.html
2021https://oncoletter.ch/Kongressberichte/2021/63rd-ASH-Annual-Meeting-and-Exposition_December-11-14-2021.html
63rd ASH Annual Meeting and Exposition - December 11-14, 2021https://oncoletter.ch/Kongressberichte/2021/63rd-ASH-Annual-Meeting-and-Exposition_December-11-14-2021.html
Late-Breaking Abstracts Sessionhttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/Late-Breaking-Abstracts-Session_63rd-ASH.html
Press Briefinghttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/press-briefing.html
ALLhttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/ALL.html
AMLhttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/aml/acute-myeloid-leukemia-clinical-and-epidemiological.html
Acute Myeloid Leukemia: Clinical and Epidemiologicalhttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/aml/acute-myeloid-leukemia-clinical-and-epidemiological.html
Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapieshttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/aml/acute-myeloid-leukemias-commercially-available-therapies-excluding-transplantation-and-cellular-immunotherapies.html
Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapieshttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/aml/acute-myeloid-leukemias-investigational-therapies-excluding-transplantation-and-cellular-immunotherapies.html
Lymphomahttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/cml/mantle-cell-follicular-and-other-b-cell-lymphomas.html
Mantle Cell, Follicular, and Other B-Cell Lymphomashttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/cml/mantle-cell-follicular-and-other-b-cell-lymphomas.html
Hodgkin Lymphomas and T/NK cell Lymphomashttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/lymphoma/hodgkin-lymphomas-and-t-nk-cell-lymphomas.html
Aggressive Lymphomas Prospective Therapeutic Trialshttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/lymphoma/aggressive-lymphomas-prospective-therapeutic-trials.html
Aggressive Lymphomas: Clinical and Epidemiologicalhttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/lymphoma/aggressive-lymphomas-clinical-and-epidemiological.html
CMLhttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/cml.html
Myeloproliferative Syndromeshttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/myeloproliferative-syndromes.html
MDShttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/mds.html
CLLhttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/cll.html
Multiple Myelomahttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/multiple-myeloma/multiple-myeloma-and-plasma-cell-dyscrasias-clinical-and-epidemiological.html
Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiologicalhttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/multiple-myeloma/multiple-myeloma-and-plasma-cell-dyscrasias-clinical-and-epidemiological.html
Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trialshttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/multiple-myeloma/myeloma-and-plasma-cell-dyscrasias-clinical-prospective-therapeutic-trials.html
Cellular Therapieshttps://oncoletter.ch/Kongressberichte-2021/63rd-ASH/cellular-therapies.html
SAN ANTONIO BREAST CANCER SYMPOSIUM - December 7 - 11, 2021, San Antonio Texashttps://oncoletter.ch/Kongressberichte/2021/san-antonio-breast-cancer-symposium-december-7-11-2021-san-antonio-texas.html
Interviews von Renate Haidinger, Brustkrebs Deutschland e.V. mit:https://oncoletter.ch/kongressberichte-2021/sabcs/interviews.html
General Sessions 1-4https://oncoletter.ch/kongressberichte-2021/san-antonio-breast-cancer-symposium-december-7-11-2021-san-antonio-texas/general-sessions-1-4.html
9. Interdisziplinäres Prostatakarzinom-Symposium, St. Gallen, 2. Dezember 2021https://oncoletter.ch/Kongressberichte/2021/9-interdisziplinaeres-prostatakarzinom-symposium-st-gallen-2-dezember-2021.html
Vorträge Block I: Aktuelle Trends in Diagnose und Therapie des Prostatakarzinomshttps://oncoletter.ch/id-2021/9-interdisziplinaeres-prostatakarzinom-symposium-st-gallen-2-dezember-2021/vortraege-block-i-aktuelle-trends-in-diagnose-und-therapie-des-prostatakarzinoms.html
Vorträge Block II: Indikationsstellung in der Therapie des Prostatakarzinoms und Aspekte der Lebensqualitäthttps://oncoletter.ch/id-2021/9-interdisziplinaeres-prostatakarzinom-symposium-st-gallen-2-dezember-2021/vortraege-block-ii-indikationsstellung-in-der-therapie-des-prostatakarzinoms-und-aspekte-der-lebensqualitaet.html
Kongressberichte Archiv 2021https://archiv.oncoletter.ch/kongressberichte-2020.html
Kongressberichte Archiv 2020https://archiv.oncoletter.ch/kongressberichte-2020.html
Kongressberichte Archiv 2019https://archiv.oncoletter.ch/kongressberichte-2019.html
Kongressberichte Archiv 2018https://archiv.oncoletter.ch/kongressberichte-2018.html
Kongressberichte Archiv 2017https://archiv.oncoletter.ch/kongressberichte-2017.html
Kalenderhttps://oncoletter.ch/kalender.html
Organisationenhttps://oncoletter.ch/Netzwerke.html
Netzwerkehttps://oncoletter.ch/Netzwerke.html
Fachgesellschaftenhttps://oncoletter.ch/Fachgesellschaften.html
Info für PatientINNenhttps://oncoletter.ch/Organisationen/info-fuer-patientinnen-patienten-angehoerige.html
Science Boardhttps://oncoletter.ch/science-board.html

Viewport: height=device-height, width=device-width, initial-scale=1.0, minimum-scale=1.0, target-densitydpi=device-dpi

Robots: index,follow


URLs of crawlers that visited me.